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INVESTIGATIONS INTO THE FUNCTION OF ELP3 IN TOXOPLASMA GONDII 
 
The parasite Toxoplasma gondii causes life-threatening infection in 
immunocompromised individuals. Our lab has determined that Toxoplasma 
Elongator protein-3 (TgElp3) is required for parasite viability. While catalytic 
domains are conserved, TgElp3 is the only component of the six-subunit 
Elongator complex present in Toxoplasma; moreover, TgElp3 localizes to the 
outer mitochondria membrane (OMM). These unusual features suggest that 
TgElp3 may have unique roles in parasite biology that could be useful in drug 
targeting. The goals of this thesis were to determine the function of TgElp3 and 
how the protein traffics to the OMM. 
In other species, Elp3 mediates lysine acetylation of histones and alpha-
tubulin, and its radical S-adenosyl methionine (rSAM) domain is important for the 
formation of tRNA modifications, which enhance translation efficiency and fidelity. 
Given its location, histones would not be an expected substrate, and we further 
determined that tubulin acetylation in Toxoplasma is mediated by a different 
enzyme, TgATAT. We found that overexpression of TgElp3 at the parasite’s 
mitochondrion results in a significant replication defect, but overexpression of 
TgElp3 lacking the transmembrane domain (TMD) or with a mutant rSAM domain 
is tolerated. We identified one such modification, 5-methoxycarbonylmethyl-2-
thiouridine (mcm5S2U) that is likely mediated by TgElp3. These findings signify 
the importance of TgElp3’s rSAM domain for protein function, and confirms 
TgElp3 activity at the OMM is essential for Toxoplasma viability as previously 
reported. 
To determine how TgElp3 traffics to the OMM, we performed a 
bioinformatics survey that discovered over 50 additional “tail-anchored” proteins 
present in Toxoplasma. Mutational analyses found that targeting of these TA 
proteins to specific parasite organelles was strongly influenced by the TMD 
sequence, including charge of the flanking C-terminal sequence. 
  Gustavo Arrizabalaga, Ph.D., Chair  
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CHAPTER 1: Introduction 
1.1 Toxoplasma gondii, a protozoan parasite 
Toxoplasma gondii is an obligate intracellular protozoan parasite that was 
first identified in 1908 by two independent investigators (1, 2). The parasite’s 
name originates from the Greek word toxon meaning bow-like and gundi, the 
African rodent from which Toxoplasma was first identified (2). As one of the most 
widely distributed parasites, Toxoplasma is capable of infecting virtually any 
nucleated cell in warm-blooded animals (3, 4). It is estimated that one-third of the 
world’s population, including 60 million people in the United States, is 
seropositive for Toxoplasma infection (5). Toxoplasma must be within a host cell 
to replicate (Figure 1). The phylum Apicomplexa consists of Toxoplasma as well 
as other notorious threats to global health such as Plasmodium spp. and 
Cryptosporidium spp. Malaria which is caused by Plasmodium kills over half a 
million people a year (6) while Cryptosporidium infections are a major cause of 
waterborne illnesses throughout the world (7–9). Across the globe, these 
pathogens are responsible for significant morbidity and mortality in humans and 
livestock. Toxoplasma and its close relatives cause widespread disease 
throughout the world and thus warrant research to identify therapeutics to 
eradicate these pathogens.  
 
Figure 1. A human foreskin fibroblast cell infected with Toxoplasma gondii.  
An image of two parasite vacuoles within a human foreskin fibroblast cell in 
relation to the host cell nucleus. One parasite vacuole contains 2 parasites and 
the second vacuole contains 4 parasites. Scale bar= 5 µm. 
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There are multiple Toxoplasma strains responsible for human infection. 
The three main clonal lineages are referred to as type I, II and III (10). While the 
type I strain is the most virulent, infections with type II and III strains are more 
common in people and animals (10). Outside of these three clonal lineages, 
there are other strains that appear to be more genetically diverse, particularly 
those identified in South America (11). These parasite strains are defined by 
several important differences including virulence, growth rate and cyst formation. 
In contrast to type I strains (e.g. RH and GT1), type II and III strains are less 
virulent, replicate slower, and readily form tissue cysts (12, 13). Since type II 
strains (e.g. ME49 and Pru) more readily form tissue cysts, they are used to 
study tachyzoite and bradyzoite differentiation (13). Interestingly, these three 
distinct clonal parasite lines genetically differ by only 1% (10). 
 Toxoplasma is an early-branching eukaryote it contains all of the 
traditional eukaryotic organelles including a nucleus, Golgi apparatus, 
endoplasmic reticulum and a single tubular mitochondrion (Figure 2). This single 
mitochondrion appears to have a reduced genome compared to higher 
eukaryotes. However, due to complications with purification techniques and 
nuclear pseudogenes, complete characterization of the Toxoplasma 
mitochondrial genome remains incomplete (14). To date, within the Toxoplasma 
mitochondrial genome there is evidence of fragmented rRNA genes along with 
three protein encoding genes: cytochrome c oxidase I (cox1), cytochrome c 
oxidase III (cox3), and cytochrome b (cob) (14–16).  Of note, there is no 
evidence of mitochondrial encoded tRNA genes, indicating these tRNAs must be 
imported into the organelle for translation (17).  
Parasite specific organelles in Toxoplasma include dense granules, 
rhoptries and micronemes which secrete proteins that coordinate invasion into 
the host cell and establishment of a parasitophorous vacuole (Figure 2). In 
addition to the nucleus and mitochondrion, the apicoplast also contains DNA. 
This apicoplast is derived from a secondary endosymbiotic event, a prokaryotic 
cyanobacterium was incorporated into a unicellular eukaryote which was 
subsequently engulfed by Toxoplasma (Figure 2) (18–20). The Toxoplasma 
3 
apicoplast is an essential organelle responsible for the biosynthesis of fatty acids 
and isoprenoids (19). The apicoplast is positioned in close proximity to the single 
mitochondrion and it is thought these organelles shuttle essential metabolic 
components to one another (18).  
 
Figure 2. Illustration of Toxoplasma gondii cellular structure. 
Eukaryotic organelles present in Toxoplasma are the nucleus, endoplasmic 
reticulum, Golgi apparatus and a single mitochondrion. Parasite specific 
organelles include dense granules, rhoptries, micronemes and the apicoplast. 
Each immunofluorescence assay (IFA) image shows four intracellular 
parasites within a single vacuole stained with anti-HA to detect the designated 
tagged organellar protein. 
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1.2 Life cycle of Toxoplasma 
As an intracellular pathogen, Toxoplasma gondii spends the majority of its 
life cycle within a host. Toxoplasma has a complex life cycle that can be 
subdivided into sexual and asexual phases, and throughout these phases the 
parasites can differentiate into three different infectious forms: sporozoite, 
bradyzoite and tachyzoite (21). Cats are the definitive host, meaning Toxoplasma 
can only sexually reproduce in the epithelium of the feline’s small intestine 
(Figure 3). Parasites typically reach the cat intesting after the feline consumes 
oocycsts (sporozoites) from the environment or tissue cysts (bradyzoites) from 
an infected animal. Once ingested by the cat, the parasites can differentiated into 
male and female gametocytes which leads to the formation of oocysts (21). 
These highly infectious sporozoite-containing oocysts are shed into the 
environment where they can be directly ingested or inhaled by intermediate hosts 
(22). Common sources of oocysts are contaminated water, fruits, or vegetables 
(23). Once within the intermediate host, which can be any warm-blooded 
vertebrate, the sporozoites are released from the oocysts and the parasites 
differentiate into tachyzoites, which have a doubling time of 6-8 hours (21). 
5 
As depicted in Figure 4, there are four main parts of the lytic cycle: 
attachment, invasion, replication and egress (24). Parasite attachment is 
mediated by recognition of host cell specific factors like surface glycoproteins 
(24–26). Following attachment, the parasite actively invades the host cell which 
causes invagination of the host cell membrane (27). This process continues until 
the parasite is fully internalized within a parasitophorous vacuole. Once inside 
the host cell, parasite replication can occur through a process termed 
endodyogeny (24). In endodyogeny, division begins with the parasite Golgi 
apparatus followed by the formation of two nascent daughters within the mother 
parasite. The first signs of the developing progeny are depicted as two dome-
shaped structures which are made up of the inner membrane complex and 
subpellicular microtubules. As these daughter cells develop, the mother parasite 
  
Figure 3. Diagram of the Toxoplasma life cycle. 
Cats are the definitive host of Toxoplasma where the parasites can sexually 
reproduce. During infection cats shed oocysts into the environment, which are 
then ingested by animals including humans through contaminated water and 
food sources. Once inside the intermediate host, the sporozoite-containing 
oocysts differentiate into tachyzoites. Upon immune pressure, tachyzoites 
differentiate into the slower replicating or dormant bradyzoites. Bradyzoites 
within tissue cysts can be transmitted through predation. When the cat ingests 
oocysts from the environment or bradyzoites from infected prey, the life cycle is 
considered complete. Pregnant women who become infected for the first time 
can transmit tachyzoites to the fetus via the placenta.  
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nucleus separates into the dome-shaped structures taking on a horseshoe like 
appearance. Expansion of the inner membrane complex and subpellicular 
microtubules of each daughter cell eventually surrounds one half of the mother 
nucleus, which eventually partitions into two separate nuclei. The progeny 
continue to grow until the mother parasite inner membrane complex disappears 
and the outer membrane becomes the plasma membrane for each daughter cell.  
Tachyzoites continue to divide by endodyogeny and after repeated rounds of 
replication the parasitophorous vacuole fills with parasites, overtaking the host 
cell. To continue to propagate, these tachyzoites must depart from their current 
host cell through a process called egress. Parasite egress can be initiated by 
several different factors including mechanical disruption of the host cell, the host 
immune response or through parasite specific mechanisms (28). Freshly 
egressed parasites then invade new host cells and continue to proliferate through 
repeating the lytic cycle.  
The most serious consequences of Toxoplasma infection result from the 
lysis of host cells due to parasite egress. In healthy individuals, Toxoplasma is 
quickly controlled by the immune response (13). Upon exposure to interferon 
gamma and potentially other unidentified mechanisms, tachyzoites differentiate 
into the more slowly replicating bradyzoites (29, 30). These bradyzoites are 
encompassed within a cyst wall converted from the parasitophorous vacuole, and 
this cyst wall appears impervious to clearance by the immune system and current 
drug treatments (13, 31). Consequently, life-threatening opportunistic disease 
can arise due to reactivated infection during immune suppression (32).  
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1.3 Toxoplasma infection 
Toxoplasma gondii infection can be separated into acute and latent 
phases. Acute toxoplasmosis occurs during the initial or reactivated infection of 
the host. If the host is healthy, Toxoplasma infection may be asymptomatic or 
present with swollen lymph nodes and/or mild flu-like symptoms (32). These 
symptoms are typically a result of the host’s immune response which readily 
clears the actively replicating tachyzoites (32). Some of these tachyzoites may 
escape the immune system by converting to the bradyzoite-containing cyst, 
where it will likely persist throughout the rest of the host’s life (3, 32).  
The latent stage of infection was originally thought to be benign. Although, 
recent studies have identified an association between latent Toxoplasma 
infection and some neurological diseases including depression, obsessive-
 
Figure 4. Cartoon of the Toxoplasma lytic cycle. 
Parasites (blue) first attach and then actively invade a host cell (light green) and 
form a parasitophorus vacuole (dark green). Once inside the host cell, the 
parasites replicate. Synchronous replication continues filling the host cell with 
parasites. Once full, a series of signals tell the parasites to actively egress which 
ruptures the host cell. These parasites attach to new host cells and the cycle 
continues. On average, the lytic cycle takes 30-40 hr for the RHΔhx strain.  
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compulsive disorder, schizophrenia, Parkinson’s disease and epilepsy (33–37). 
Interestingly, when rodents are infected with Toxoplasma they lose their aversion 
to cats and become attracted to cat urine, making them more susceptible to 
predation (38). Ingestion of a Toxoplasma infected rodent by a cat facilitates 
completion of the parasite life cycle (39). More studies are needed to determine if 
the latent infection causes adverse effects on the human host.  
While the latent infection is controlled by the host immune system, serious 
problems can occur when the individual becomes immunocompromised. 
Particularly patients with AIDs, undergoing organ transplant or chemotherapy are 
at a high risk for reactivated acute infection (3, 32). This reactivated acute 
infection occurs when an infected individual’s immune system becomes 
depressed (21). Loss of immune pressure triggers the latent bradyzoites to 
reconvert into the fast replicating tachyzoites (21) . If not controlled, replicating 
tachyzoites can cause massive tissue destruction and even death. 
Consequences of acute toxoplasmosis include neurological symptoms, 
myocarditis, ocular lesions, and encephalitis (40–42).  
Another serious disease caused by acute Toxoplasma infection is 
congenital toxoplasmosis which occurs when a pregnant woman becomes 
infected for the first-time and the tachyzoites are vertically transmitted to the fetus 
(43). Infection of the unborn fetus can cause spontaneous miscarriage or birth 
defects (43, 44). Congenitally infected infants may suffer from cognitive 
disorders, hydrocephalus, and vision or hearing impairments, and are prone to 
recurring bouts of reactivated infection throughout their lives (32).   
 
1.4 Treatment of toxoplasmosis 
Currently, there are no cures for toxoplasma infection, but there are drugs 
to treat acute toxoplasmosis. The primary drug regimen consists of a 
combination of sulfadiazine and pyrimethamine to target the folic acid synthesis 
pathway (45, 46). Sulfadiazine inhibits the dihydropteroate synthase (DHPS) to 
prevent formation of dihydrofolic acid and pyrimethamine inhibits dihydrofolate 
reductase (DHFR) to prevent the formation of tetrahydrofolic acid (45). The 
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combination therapy inhibits the synthesis of nucleic acid precursors resulting in 
death of the parasites (47).  
Unfortunately, there are significant adverse side-effects associated with 
the anti-folate regimen. A number of individuals have sulfa allergies, in these 
cases clindamycin can be administered instead of sulfadiazine (48, 49). 
Clindamycin is an antibiotic that targets translation in the apicoplast organelle, 
but is not as effective at killing the parasite as sulfadiazine (50). A second 
problem lies with the toxicity of pyrimethamine. Despite having a higher affinity 
for the Toxoplasma DHFR enzyme, pyrimethamine can also target the human 
DHFR enzyme which can cause adverse side-effects including bone marrow 
suppression (51). To reduce these pyrimethamine induced side-effects, 
treatments are supplemented with folinic acid (52).  
In the case of pregnant women who become infected for the first time, 
treatment with pyrimethamine is not advised in the first trimester. Since 
pyrimethamine can cross the placenta and is teratogenic, an alternative drug 
spiramycin is typically used (44). Spiramycin is unable to cross the placenta and 
is considered safe in pregnant women, fetus and newborn (53). This non-toxic 
macrolide will reduce transmission of Toxoplasma from the pregnant woman to 
the fetus; however, it will not affect the severity of disease in an already infected 
fetus (54). Depending on the severity of fetal infection, pyrimethamine is 
sometimes used.  
Current therapies to treat toxoplasmosis are problematic since they cause 
many adverse side-effects and are unable to completely cure Toxoplasma 
infections. As the bradyzoite-containing cysts are impervious to current 
treatments, these cysts will remain embedded within host tissues and can 
reactivate to cause recurrent infection. A better understanding of Toxoplasma 
biology is needed to develop new drugs to combat this infectious pathogen.  
 
1.5 Lysine acetylation as a drug target 
  Lysine acetylation is an essential post-translational modification (PTM) in 
Toxoplasma. Lysine acetyltransferases transfer the acetyl group from acetyl 
10 
coenzyme A onto the epsilon-amino group of a lysine. Lysine deacetylases 
remove this PTM, making the modification reversible. Lysine acetylation is 
associated with many different biological processes including transcription, 
translation and metabolism. In Toxoplasma, over 400 acetylation sites are 
present on a variety of proteins in all subcellular compartments, including some 
parasite specific proteins (55).   
Recent studies in protozoan parasites have established lysine acetylation 
as a valid drug target (56, 57). For example, inhibition of lysine deacetylases by 
inhibitors such as apicidin and FR235222 result in parasite death (58, 59). In 
conjunction, our laboratory identified garcinol as an inhibitor of the lysine 
acetyltransferase TgGCN5b, which may explain its potent activity against 
Toxoplasma and Plasmodium (60). Inhibition of TgGCN5b disrupts gene 
expression and stalls parasite replication (60). Interfering with lysine acetylation 
pathways in Toxoplasma reduces parasite viability (61). Therefore, examining 
these pathways in greater detail is a promising approach to identify novel 
therapeutics for toxoplasmosis.   
 
1.6 History of Elp3 
 In 1999, two independent studies in Saccharomyces cerevisiae 
established that Elongator protein 3 (Elp3) is the lysine acetyltransferase (KAT) 
component of the Elongator complex (62, 63). The Elongator complex was 
originally detected through purification of hyperphosphorylated RNA polymerase 
II (RNAPII) and implicated in chromatin remodeling during transcription 
elongation; hence, the Elongator complex was named (62). Further 
characterization of the Elongator complex identified a total of six individual 
subunits (Elp1-6) that form two sub complexes; these sub complexes are thought 
to dimerize and associate with RNAPII to mediate transcriptional elongation (64–
66). 
Given the high degree of sequence similarity between ScElp3 and 
members of the GCN5-related N-acetyltransferase (GNAT) superfamily, it was 
postulated that ScElp3 may possesses KAT activity. An in vitro lysine 
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acetyltransferase assay revealed that recombinant Elp3 is capable of acetylating 
all four histones on their amino-terminal tails (63, 67). Since Elp3 associates with 
RNAPII and has KAT activity, it was theorized that Elp3 is the component of the 
Elongator complex responsible for acetylating histones to promote transcriptional 
elongation. In support of this model, Elp3 mutational studies identified two 
conserved tyrosine residues required for binding acetyl coenzyme A (acetyl coA), 
the cofactor required for Elp3 KAT activity (68).  
 In an independent forward genetics approach, yeast subjected to a toxic 
zymocin treatment developed resistant mutations in Elongator complex proteins, 
which were independently named as putative toxin target genes: TOT1, TOT2, 
and TOT3 (isoallelic with Elp1, Elp2 and Elp3) (69, 70). Zymocin is a 
heterotrimeric (αβγ) toxin produced by the Kluyveromyces lactis yeast strain that 
causes irreversible growth arrest of sensitive yeast strains, including 
Saccharomyces cerevisiae (69). The zymocin α and β subunits act at the cell 
exterior to facilitate import of the γ-toxin (71). In agreement with previous 
findings, examination of yeast Elp3 mutants determined that zymocin resistance 
occurs through a RNAPII dependent mechanism (70, 72–75). 
Characterization of the Elongator complex in humans was reported in 
2002 (76). Consistent with studies in yeast, the human Elongator complex 
associates with RNAPII and recombinant human Elp3 acetylates histone H3 and 
histone H4 in vitro (76). In HeLa cells, under normal cell culture conditions Elp3 
was found to predominantly localize to the cell nucleus, however some proteins 
were also detected in the cytoplasm (76). Not surprisingly, studies in Arabidopsis 
thaliana also identified homologues to all six components of the Elongator 
complex and interaction studies confirmed RNAPII association, suggesting 
Elongator is evolutionarily conserved in structure and function (77).  
Preliminary work performed in multiple species has established Elp3 as 
the lysine acetyltransferase component of the Elongator complex. Nevertheless, 
the biological function of Elp3 is not well defined. Phenotypes associated with the 
loss of Elp3 range from regulation of neuronal migration and axon development 
in Drosophila to alterations in microtubule dynamics in humans and worms (78–
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81). Disruption of Elp3 in mice causes impaired zygotic paternal genome 
demethylation (82). In Arabidopsis thaliana, an amino acid substitution (D to N) 
conserved in all Elp3 homologues causes reduced cell proliferation and 
malformed leaf structure (76). In Saccharomyces cerevisiae, Elp3 knockouts are 
viable but display a slow growth phenotype under stress conditions (63). Given 
the role of Elp3 in transcriptional elongation, disruption is likely to modify the 
expression of many genes, which might explain the pleiotropic phenotypes 
observed.  
Recent evidence suggests that Elp3 may possess a second enzymatic 
activity as a tRNA modification enzyme. The formation of tRNA modifications is 
dependent on the radical S-adenosyl-L-methionine (rSAM) domain found in all 
Elp3 homologues (83). In Toxoplasma the rSAM domain contains a canonical 
CX3CX2C motif required for iron sulfur cluster formation while most other Elp3 
homologues contain a non-canonical CX4CX9CX2C motif (83). Mutations in this 
cysteine motif result in loss of tRNA modifications in vitro (84).  Interestingly, 
several studies demonstrated that overexpression of select tRNAs can suppress 
Elongator mutant phenotypes in yeast (63, 85). The Elongator complex is 
required for the synthesis of 5-methoxycarbonymethyl (mcm5) and 5-
carbamoylmethyl (ncm5) modifications present on uridines at the tRNA wobble 
position (86, 87). The effect of these wobble uridine tRNA modifications is 
thought to promote translation fidelity and efficiency, but the exact mechanisms 
are not well understood (88).  
Future work is needed to determine if protein acetylation is the only 
biochemical activity of Elp3 or if it also functions as a tRNA modification enzyme. 
In either instance, the gene name Elongator protein 3 is relevant as it may be 
involved with transcriptional elongation through histone acetylation or 
translational elongation through tRNA modifications and disruption of either 
function would affect a broad range of cellular processes resulting in a multitude 
of different phenotypes.   
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1.7 Elp3 and human disease 
 Mutations in Elp3 are associated with several diseases in humans. 
Familial dysautonomia (FD) affects the sensory and autonomic nervous system 
causing defects in neuronal development. Mutations in Elp1 and Elp3 have been 
reported in FD patients (89, 90). Experimental studies using FD fibroblasts show 
a decrease in histone H3 acetylation and RNAPII density on select cell motility 
genes, indicating dysregulation of gene expression (91). Furthermore, alterations 
in tubulin acetylation and microtubule-based protein trafficking observed in 
Elongator mutants is suggested to be a contributing factor in FD disease (89). A 
second neurologic disease, amyotrophic lateral sclerosis (ALS), was found to be 
associated with Elp3 allelic variations in a genome-wide association study of 
almost 1500 individuals from three different populations (92). These neurological 
disease findings suggest Elp3 may have a critical role in neuron biology (93).   
Elp3 is upregulated in human colon adenocarcinoma and breast cancer 
(94, 95). Studies identified that Wnt signaling induces Elp3 expression which in 
turn promotes translation of Sox9, a transcription factor implicated in 
tumorigenicity (94); through this mechanism Elp3 is crucial for maintaining a 
subpopulation of cells needed to trigger tumor initiation in the intestine. In an 
independent study, increased Elp3 expression was associated with an increased 
risk of breast cancer metastasis (95). Moreover, genetic ablation of Elp3 in a 
breast cancer mouse model strongly impaired invasion and metastasis formation 
(95). These findings suggest that Elp3 may play a role in cancer progression.  
 
1.8 Identification of an Elp3 homologue in Toxoplasma 
 In 2013, our laboratory identified a homologue of Elp3 in Toxoplasma (83). 
Initial characterization of Toxoplasma Elp3 (TgElp3) unveiled several unusual 
features. In the phylum Apicomplexa, Elp3 is the only conserved component of 
the Elongator complex as no clear homologues of the other five Elongator 
subunits can be detected in genome sequences (Figure 5) (83).  
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Figure 5. Elp3 is the only component of the Elongator complex found in 
Toxoplasma. 
The Elongator complex consists of 6 core subunits (Elp1-Elp6) that dimerize 
and associated with RNAPII. Elp3 is the only subunit that contains known 
enzymatic domains and is responsible for acetylating histone tails to open up 
chromatin and facilitate transcriptional elongation. Ac=acetylated lysine. 
 
Protein sequence alignments between Toxoplasma and other species 
determined that the catalytic KAT and rSAM domains are highly conserved and 
using an in vitro KAT assay, TgElp3 demonstrated acetyltransferase activity on 
histone H3 (83). Despite apparent enzymatic conservation, Elp3 homologues in 
Toxoplasma and other apicomplexans have some unique protein features. 
Specifically, there is an N-terminal protein extension and most strikingly, a C-
terminal transmembrane domain (TMD) (83). Our laboratory found that the TMD 
is required for TgElp3 localization to the parasite’s OMM (Figure 6) (83). Our 
laboratory also found that TgElp3 is a tail-anchored protein positioned with its 
catalytic domains protruding into the cytosol, representing the first tail-anchored 
lysine acetyltransferase reported in any species (83). Since localization of TgElp3 
to the OMM is essential for Toxoplasma viability, examination of this protein and 
how it localizes to the parasite mitochondrion will provide insight into its 
evolutionary importance and may also identify novel therapeutic targets. 
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Figure 6. Comparison of Elp3 protein structure.  
Depiction of the conserved enzymatic domains from Homo sapiens (HsElp3), 
Saccharomyces cerevisiae (ScElp3), Toxoplasma gondii (TgElp3), and 
Plasmodium falciparum (PfElp3). The transmembrane domain is only present 
in the phylum Apicomplexa. Amino acids (aa); S-adenosylmethionine (SAM); 
lysine acetyltransferase (KAT); transmembrane (TM).  
 
1.9 Summary and hypotheses 
Toxoplasma is a prevalent pathogen that causes both acute and chronic 
infection. Current treatments only target the acute infection and are unable to 
completely clear the pathogen. Available drugs are problematic as they have 
serious side effects and/or cause allergic reactions. Identification of novel drug 
targets is needed to develop better therapies to treat Toxoplasma infection.   
Disruption of protein acetylation in Toxoplasma is a viable approach to 
developing novel therapeutics. Our lab and others have shown that inhibition of 
lysine acetyltransferases and deacetylases is lethal to the parasite (61). 
However, the exact mechanisms of how these drugs work and/or what pathways 
they target is not fully understood. To increase our understanding of lysine 
acetylation in Toxoplasma, our lab has characterized several different lysine 
acetyltransferases including TgElp3. Examination of TgElp3 led to the 
identification of several unique features including the presence of a C-terminal 
transmembrane domain and localization to the OMM. Attempts to knockout the 
TgElp3 gene failed, suggesting that TgElp3 is essential for parasite viability. 
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Furthermore, using an in vitro lysine acetylation assay, our lab confirmed that 
TgElp3 has acetyltransferase activity on histone H3.  
Given that TgElp3 possesses lysine acetyltransferase activity in vitro, 
localizes to the OMM and appears essential for Toxoplasma survival, we 
hypothesize that TgElp3 lysine acetyltransferase activity at the outer 
mitochondrion is required for parasite viability. Our hypothesis was 
examined by performing the following aims: 1) identify substrates of TgElp3, and 
2) determine how TgElp3 is trafficked to the outer mitochondrial membrane. After 
performing several overexpression and mutational studies we identified that the 
rSAM domain is required for TgElp3 function. In other species, the rSAM domain 
is important for the formation of tRNA modifications. Therefore, we 
subsequently hypothesized that overexpression of TgElp3 causes hyper-
modification of tRNA resulting in altered translation. To test this hypothesis 
we explored the following aims: 1) determine if the Elp3 associated tRNA 
modification is present in Toxoplasma, and 2) assess protein synthesis in TgElp3 
mutant parasite strains.  
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CHAPTER 2: Characterization of TgElp3  
2.1 Introduction 
 In other species, Elp3 has been implicated in a diverse array of enzymatic 
functions (96). Early studies in yeast and human cells identified Elp3 as a lysine 
acetyltransferase (62, 63, 67). In vitro studies determined histone H3 as a 
primary substrate of Elp3 and inactivation of the Elongator complex showed 
decreased acetylation in vivo (63, 67). With these studies, a working model 
emerged that Elp3 is the lysine acetyltransferase component of the Elongator 
complex, which promotes transcription through histone acetylation. Based on this 
model, Elp3 should primarily localize within the nucleus and associate with 
chromatin. In 2002, a pivotal study in yeast challenged this model as the 
Elongator complex was identified to mostly localize to the cytoplasm and could 
not be co-immunoprecipitated with chromatin (97). Furthermore, a subsequent 
study identified Elongator to associate with pre-mRNA and in vitro studies 
confirmed Elongator binds to RNA at a much higher affinity than DNA (98). In 
2005, the first report of Elp3 as a tRNA modification enzyme showed that the 
Elongator complex is required for the synthesis of the 5-methoxycarbonylmethyl 
(mcm5) wobble uridine tRNA modification and that Elp3 co-immunoprecipitates 
with tRNAGlu in yeast (86). Given the diverse biological processes associated with 
Elp3, it is likely that Elp3 possesses multiple enzymatic functions, perhaps 
depending on the species, cell type, or subcellular localization.   
 We recently identified an unusual homologue of Elp3 in Toxoplasma 
gondii (TgElp3) that localizes to the outer mitochondrial membrane such that its 
catalytic domains face the cytosol (83). While the catalytic domains are 
conserved, TgElp3 is the only component of the six-subunit Elongator complex 
present (83). Using a lysine acetyltransferase assay, we have shown that TgElp3 
can acetylate histone H3 in vitro (83). However, given the unique mitochondrial 
localization, histone H3 is an unlikely substrate for TgElp3 in vivo. Therefore, the 
biological role of TgElp3 remains unresolved; this chapter describes attempts to 
define the function of TgElp3.  
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2.2 Materials and Methods 
2.2.1 Plasmid DNA construction 
 For all constructs, the In-Fusion HD cloning kit was used to insert DNA 
fragments into plasmid backbones (Clontech #011614). This directional cloning 
approach uses the In-Fusion Enzyme which efficiently fuses amplified DNA 
fragments containing 15 bp overlapping ends which match the destined 
backbone plasmid. Primers for each of the constructs are listed in Appendix A. 
The Phusion High Fidelity DNA Polymerase (Thermo Scientific #F530L) was 
used for all PCR amplification reactions. Details specific to each plasmid are 
below. 
 
2.2.1.1 BioID 
 Toxoplasma HA-tagged Elp3 cDNA was amplified using primers F1 and 
R1 from the previously published construct:  TubHX- HATgElp3 (83) and inserted 
into the HindIII restriction site of the pcDNA3.1mycBioID vector creating the 
mycBirA- HATgElp3 fusion protein. Using primers F2 and R2 the fusion mycBirA- 
HATgElp3 DNA sequence was amplified and inserted into the TubHX vector (99)  
digested with restriction enzymes EcorV and Bglll. The construct design was 
confirmed through sequencing using primers F3 and R3.  
 
2.2.1.2 Endogenous Replacement  
 The upstream promoter region (~1500bp) of TgElp3 was amplified from 
RHΔhxΔku80 genomic DNA using primers F4/R4, and HATgElp3 was amplified 
using primers F5/R5 from the previously published construct: TubHX- HATgElp3   
(83). These two PCR products were combined and used as template for a 
“stitching PCR” reaction using primers F4/R5. This reaction created the 
TgElp3prom+ HATgElp3cDNA PCR product. Next, the downstream region 
(~1500bp) of TgElp3 was amplified from RHΔhxΔku80 genomic DNA using 
primers F6 and R6. The TgElp3 downstream region amplicon was inserted into 
the HindIII restriction site of the pDHFR-TS plasmid (pDHFR-TS-dsElp3) (99, 
100). This plasmid (pDHFR-TS-dsElp3) was then digested using DraIII and the 
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TgElp3prom+ HATgElp3cDNA PCR amplicon was inserted to create the HATgElp3 
endogenous replacement construct. 
 The QuickChange II XL Site-Directed Mutagenesis kit (Agilent 
Technologies. #200521) was used to generate the mutant constructs: HATgElp3-
rSAMmut(C284A) and HATgElp3-KATmut(Y715/716A), using primers F7/R7 and 
F8/R8, respectively. Constructs were sequenced using primers F9 and R9. Prior 
to transfection, plasmids were linearized using the restriction enzyme SpeI. 
Parasites were screened for correct genomic integration using primers F10/R10 
and F11/R11. 
 
2.2.1.3 Destabilization Domain 
 The TubHX-DD-HATgElp3 was previously created by Krista Stilger. To 
generate the mutant TubHX-DD-HATgElp3 constructs, the QuickChange II XL 
Site-Directed Mutagenesis kit (Agilent Technologies. #200521) was used. 
Primers F7/R7 were used to create the TubHX-DD-HATgElp3-rSAMmut(C284A) 
plasmid and primers F8/R8 were used to create the TubHX-DD-HATgElp3-
KATmut(Y715/716A) plasmid. Prior to transfection, plasmids were linearized 
using the NotI restriction digest enzyme.  
 
2.2.1.4 Ectopic Overexpression 
 To generate the wild-type HATgElp3OE construct, the open reading frame 
was amplified from RHΔhx cDNA and inserted at the BglII restriction site within 
TubHX cloning vector (99). This vector uses the constitutively active Toxoplasma 
Tubulin promoter and contains an HXGPRT section marker. The QuickChange II 
XL Site-Directed Mutagenesis kit (Agilent Technologies. #200521) was used to 
generate the following mutant constructs: rSAM(C284A/C287A)OE, ΔTMDOE, 
KAT(Y715/716A)OE, KAT(Y716A)OE, KAT(Y715F/Y716F)OE, 
rSAM(C284A/C287A)/KAT(Y716A)OE and 
rSAM(C284A/C287A)/KAT(Y715F/Y716F)OE. Primers used for site-directed 
mutagenesis are listed in Appendix B. Site-Directed mutagenesis was performed 
multiple times using different primers to generate both cysteine mutations in the 
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rSAM domain and for the KAT+rSAM mutants. Prior to transfection each plasmid 
was linearized using the NotI restriction enzyme.  
 To overexpress TgElp3 in the type II ME49 parasite strain, wild-type 
TgElp3 was amplified from the HATgElp3OE construct and inserted into the HindIII 
restriction site of the pDHFR plasmid using primers F12/R12.  
 
2.2.1.5 Recombinant TgElp3 expression vectors 
 The TubHXHATgElp3OE plasmid was used for all PCR reactions and full 
length TgElp3 without its TMD was amplified for all constructs unless otherwise 
stated. The F17/R17 primers were used to amplify TgElp3 which was inserted 
into the NdeI restriction site of the pET-19b plasmid (Novagen #69677) to 
generate the pET19b-10xHIS-EnzymaticElp3ΔTMD plasmid. The F18/R18 
primers were used to amplify TgElp3 which was inserted into the NotI and NdeI 
restriction sites of the pET-30a (+) DNA plasmid (Novagen #69909) to generate 
the pET30a-EnzymaticElp3ΔTMD construct. Next, to generate the pGEX-4T-1-
GST-EnzymaticElp3ΔTMD construct, the F19/R19 primers were used and the 
TgElp3 amplicon was inserted into the SmaI restriction site of the pGEX-4T-1 
plasmid (GE Healthcare #28-9545-49).  
 Three 6xHIS-SUMO-Elp3 plasmids were generated with varying N-
terminal extensions with full length 6HIS-SUMO-Elp3ΔTMD (primers F20/R20), 
partially truncated 6HIS-SUMO-Elp3ΔTMDshort1 (primers F20/R20.1), and 
removal of the N-terminus of TgElp3 just upstream of the rSAM domain, SUMO-
Elp3ΔTMDshort2 (primers F20/R20.2). Each of these PCR amplicons was 
inserted into the SspI restriction site of the His6-Sumo-TEV (N terminal on 
backbone) vector (Addgene Plasmid #29659).  
 For the BacPAKTM (Clontech #631402) recombinant protein expression 
system, we used the BacPAK9 vector. We generated two constructs, a GST-tag 
and one with no tag.  Primers F21 and R21 were used to amplify TgElp3 and this 
amplicon was inserted into the SmaI restriction site of the BacPAK9 plasmid. 
Primers F22 and R22 were used to amplify GST-Elp3 from the previously 
generated pGEX-4T-1-GSTconstruct; this amplicon was inserted into the SmaI 
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restriction site of BacPAK9. Construct designs were confirmed using sequencing 
primers F23/R23.  
 
2.2.2 Parasite culture  
 Since Toxoplasma is an intracellular pathogen, a host cell is required for 
parasite maintenance. For all experiments Toxoplasma was cultured in human 
foreskin fibroblasts (HFFs). HFFs were cultured with Dulbecco’s Modified Eagle’ 
Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS) at 37ºC and 5% CO2. The HFF medium was changed to DMEM 
supplemented with 1% FBS prior to parasite inoculation. Parasites were passed 
to a new confluent HFF flask once the host cell monolayer was completely lysed. 
 There are several common lab strains of Toxoplasma that were used 
throughout these studies. The RHΔhx parasite strain is a hypervirulent type I 
strain that reproduces asexually by means of endodyogeny. This strain was 
originally isolated from a patient with the initials R.H. and has had the 
hypoxanthine-xanthine-guanine phosphoribosyl transferase (HXGPRT) gene 
knocked out (Δhx) for drug selection purposes (101). This RHΔhx parasite strain 
was used for the BioID (section 2.3.1), inducible dominant-negative (section 
2.3.3) and overexpression experiments (section 2.3.4). To facilitate double 
homologous recombination, the ku80 gene was disrupted in the RHΔhx parasite 
strain to generate RHΔhxΔku80 (102, 103). This parasite strain was used for the 
endogenous replacement studies (section 2.3.2). A third parasite strain used in 
section 2.3.4 is the type II ME49 strain. This parasite strain has a lower 
replication rate and exhibits a higher efficiency of tissue cyst formation in vitro 
and in vivo (104).   
 
2.2.3 Generation of transgenic parasites   
 To express various plasmids ectopically or to modify the endogenous 
locus, freshly egressed Toxoplasma tachyzoites were transfected. Prior to 
transfection, 25-75 µg of DNA plasmid was linearized by restriction enzyme 
digest overnight to facilitate recombination (105). Following digestion, 
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Phenol:Chloroform:Isoamyl Alcohol  was used to purify DNA. The precipitated 
DNA pellet was re-suspended in cytomix (120 mM KCl, 0.15 mM CaCl2, 10 mM 
K2HPO4/KH2PO4 pH 7.6, 25 mM HEPES pH 7.6, 2 mM EDTA, 5 mM MgCl2, 1.2 
mg/ml ATP, and 1.44 mg/ml glutathione), a buffer that mimics intracellular 
conditions and shown to increase parasite survival following electroporation 
(106).  
 For each transfection, approximately half of a freshly lysed T-25 cm2 flask 
of parasites (~3 x 107 parasites) were washed and re-suspended in cytomix. 
Parasites were mixed with the re-suspended DNA and added to a 2 mm gap 
electroporation cuvette (Fisher #BTX620). For transfection, a BTX ECM 630 
electroporator was used and the parasites were pulsed with 1.5 kV, 25 ohms and 
25 µF (100, 107). Following transfection, parasites were split evenly between 
multiple flasks containing confluent HFF monolayers to isolate independent 
clones.  
 Drugs used for selection were added 24 hours post-transfection and 
parasites were maintained under selection for a minimum of three passages prior 
to isolation of individual clones. For plasmids containing the HXGPRT gene, 25 
µg/mL of mycophenolic acid (MPA) and 50 µg/mL of xanthine (XAN) was used 
for selection (101). Parasites that do not possess a functional HXGPRT gene 
require inosine-monophosphate dehydrogenase (IMPDH) to synthesize guanine-
based nucleotides (101). IMPDH is inhibited by MPA, resulting in death of 
parasites that have not integrated the exogenous plasmid containing the 
HXGPRT cassette. Parasites that have integrated the HXGPRT cassette with the 
addition of a guanine nucleotide precursor (XAN) can bypass the IMPDH 
pathway. A second selection cassette used in these studies contains the mutated 
dihydrofolate-thymidylate synthase (DHFR-TS) gene. DHFR-TS is required for de 
novo synthesis of purines and is inhibited by 1 µM pyrimethamine (100). 
Parasites that have integrated the mutated DHFR-TS gene are resistant to 
treatment with pyrimethamine.   
 Limiting dilution was used to isolate individual clones from populations of 
transfected parasites. Freshly egressed parasites were counted using a 
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hemocytometer and were diluted to 2.5 parasites/mL. Parasites were split into 
96-well plates containing confluent HFFs and were left undisturbed for 5-7 days. 
The 96-well plates were screened for wells containing a single plaque, an 
indication of inoculation with a single parasite clone. Individual clones were 
transferred from the 96-well plate into two 24-well plates containing confluent 
HFFs. One plate was used for culturing until positive clones were identified and 
the second plate was used for screening. Endogenous replacement parasite 
clones were first screened by PCR and positive clones were confirmed by IFA 
and Western blot. Ectopic overexpressing parasite clones were first screened by 
IFA and positive clones were confirmed using Western blot. At least two 
positively identified clones from individual populations were further confirmed by 
sequencing.  
 Immediately following confirmation of correct transgene integration, 
positive clones were frozen down to create stocks for future use. A fifty percent 
lysed T-25 cm2 flask of parasites was scraped and spun down. The resulting 
pellet was re-suspended in a 1:1 ratio of ice cold parasite medium to freezing mix 
(DMEM, 1% FBS and 25% DMSO) and then transferred into sterile cryogenic 
vials (Cole-Parmer #368632). The tubes were placed at -80ºC in Styrofoam box 
for 24 hours before being moved to long term storage in liquid nitrogen.  
 
2.2.4 Affinity purification of biotinylated proteins 
 Parasites were cultured in growth medium containing 50 µM biotin for 24 
hours. Freshly egressed parasites were washed with phosphate buffered saline 
(PBS) and lysed with radio immunoprecipitation assay buffer (RIPA) buffer (20 
mM Tris-HCL (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 
1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate, 1 mM Na3VO4) supplemented with cOmpleteTM, Mini, EDTA-
free protease inhibitor (Roche #11836170001) and sonicated twice for 30 
seconds each time with a microtip sonicator. Lysate was incubated with magnetic 
Dynabeads MyOneTM Streptavidin C1 beads (Invitrogen # 65001) at 4ºC for 12 
hours on a rotator. Beads were washed twice with wash buffer 1 (2% SDS), once 
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with wash buffer 2 (0.1% deoxycholate, 1% Triton-X-100, 500 mM NaCl, 1 mM 
EDTA and 50 mM HEPES, pH 7.5), once with wash buffer 3 (250 mM LiCl, 0.5% 
NP-40, 0.5% deoxycholate, 1 mM EDTA and 10 mM Tris pH 8.1), twice with 
wash buffer 4 (50 mM Tris, pH 7.4 and 50 mM NaCl) and twice with PBS.  
 
2.2.5 Mass spectrometry analysis 
A Thermo-Fisher Scientific LTQ Orbitrap Velos Pro mass spectrometer 
(Thermo-Fisher Scientific, Waltham, MA) interfaced with a Waters Acquity UPLC 
system (Waters, Milford, MA) was used for analysis. Samples were reduced with 
10 mM DTT in 10 mM ammonium bicarbonate and then alkylated with 55 mM 
iodoacetamide. Alkylated samples (on bead) were digested by trypsin (Promega, 
Madison, WI) overnight at 37ºC. Digested peptides were injected onto a C18 
trapping column (NanoAcquity UPLC Trap column 180 µM x 20 mm, 5 µm, 
Symmetry C18) and subsequently onto an analytical column (NanoAcquity UPLC 
column 100 µm x 100 mm, 1.7 µm BEH130 C18). Peptides were eluted with a 
linear gradient from 3 to 40% acetonitrile in water with 0.1% formic acid 
developed over 90 minutes at room temperature at a flow rate of 500 nL/min, and 
the effluent was electro-sprayed into the LTQ Oribitrap mass spectrometer. 
Blanks were run prior to the sample to make sure there were no significant 
background signals from solvents or columns. SEQUEST(Thermo-Fisher 
Scientific) was used to search against ToxoDB (v10.0) to identify biotinylated 
proteins.  
 
2.2.6 Antibodies 
The following primary antibodies were used at the dilutions indicated: rat 
anti-HA (1:2000, Roche #11867423001), rabbit anti-HA (1:2000, Cell Signaling 
Technology #3724), rabbit anti-TgElp3 (1:2000), mouse anti-SAG1 (1:2000, 
Genway #MA1-83499), mouse anti-TgF1B-ATPase (1:4000) (108, 109), and 
mouse anti-puromycin clone 12D10 (1:2000, Sigma Aldrich #MABE343). 
Secondary HRP-linked antibodies for Western blot analysis included donkey anti-
rabbit (1:2000, GE Healthcare #NA934), sheep anti-mouse (1:5000, GE 
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Healthcare #NA931) and goat-anti rat (1:2000, GE Healthcare #NA935). For IFA 
analyses, a 1:5000 dilution was used for secondary antibodies conjugated to a 
fluorophore (Alexa Fluor; Thermo Fisher #A11005, #A11006, #A11007 and 
#A11034). 
 
2.2.7 Immunoblotting 
 Infected HFFs containing intracellular parasites were scraped, syringe 
lysed with a 25-gauge needle and passed through a 3 µm filter to remove host 
cell debris. Parasites were lysed in RIPA buffer supplemented with cOmpleteTM, 
Mini, EDTA-free protease inhibitor (Roche #11836170001) and sonicated three 
times on ice for 10 seconds with a microtip sonicator. Insoluble material was 
removed by centrifugation at 21,000 x g for 10 min at 4ºC and cleared lysate was 
quantified using a detergent compatible (DCTM) protein assay kit (Bio-Rad 
#5000111).  
For each sample, equal amounts of protein were mixed with Laemmli 
sample buffer supplemented with 5% beta-mercaptoethanol and heated at 95ºC 
for 10 min. Samples were centrifuged at 21,000 x g for 3 min and subjected to 
SDS-PAGE with precast 4 to 20% Mini-PROTEAN TGX gels (Bio-Rad 
#4568094). The Transblot SD semidry transfer system was used to transfer 
proteins to a nitrocellulose membrane (Bio-Rad #1703940). Blots were subjected 
to Ponceau S staining to ensure relatively equal protein loading and transfer. 
Membranes were then washed with Tris buffered saline-Tween 20 (TBST) and 
blocked with 5% milk-TBST for 30 min. Membranes were incubated with primary 
antibodies (see section 2.2.6) for 1.5 hr at room temperature or at 4ºC overnight 
and then washed 3 x 10 min each time in TBST. Following the wash steps, 
membranes were incubated with secondary antibodies for 1 hr at room 
temperature and washed again for 3 x 10 min. Proteins were detected with 
SuperSignalTM West Femto Maximum Sensitivity Substrate (Thermofisher 
#34094) or PierceTM ECL Plus Western Blotting Substrate (Thermofisher #32134) 
and imaged on a FluorChem R imager (Bio-Techne). 
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2.2.8 Immunofluorescence assays 
 Freshly lysed parasites were inoculated onto confluent HFF monolayers 
grown on coverslips in a 24-well plate. Plates were fixed with 4% 
paraformaldehyde in PBS and blocked for 30 min in 3% BSA + PBS. Cells were 
permeabilized with 0.2% Triton X-100 in BSA-PBS for 10 min. Primary antibodies 
(see section 2.2.6) diluted in 3% BSA-PBS were applied overnight at 4ºC. 
Coverslips were washed 3 x 10 min with PBS. Secondary antibodies diluted in 
3% BSA-PBS were applied for 1 hr at room temperature and then washed for 3 x 
10 min with PBS. The nucleic acid stain 4’,6-diamidino-2-phenylindole 
dihydrochloride (DAPI, Life Technologies #D1306) diluted 1:1000 in PBS was 
applied for 10 min at room temperature and then washed 3 x 10 min at room 
temperature. Coverslips were mounted using Vectashield antifade mounting 
medium (Vector Labs #H-1000).  
  
2.2.9 Toxoplasma growth assays 
2.2.9.1 Plaque Assay 
 Plaque assays were used to assess parasite growth (110, 111). 
Intracellular parasites were harvested from the host cell monolayer by scraping, 
syringe lysing (25-guage needle) and filtering through a 3.0 µm polycarbonate 
filter (Whatman). Parasites were counted using a hemocytometer and 500 
parasites were inoculated into a single well of a 12-well plate containing confluent 
HFFs. For each assay, an individual parasite line was plated in triplicate. Four 
hours after inoculation, uninvaded parasites were removed and fresh medium 
was replaced. The cultures were incubated undisturbed for 6 days and then fixed 
with 100% ice-cold methanol. To visualize plaques, plates were stained with 
crystal violet. Pictures of individual plaques were taken at random using a Leica 
inverted DM16000B microscope (40x dry objective). The mean area of 30 
plaques was measured using ImageJ for each of three independent experiments. 
For the RHΔhx overexpression studies the plaque area was analyzed using two-
way analysis of variance (ANOVA). For the ME49 overexpression studies, the 
plaque area was analyzed using the two-tailed student’s t-test. 
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2.2.9.2 Doubling Assay 
Doubling assays were used to assess parasite replication (112, 113). 
Intracellular parasites were harvested as described above in section 2.2.9.1; 
150,000 parasites were used to inoculate a HFF monolayer in a 6-well plate. The 
medium was changed after 4 hours to remove any uninvaded parasites. Plates 
were fixed at 18, 24, and 30 hours post inoculation using ice-cold methanol. To 
enhance visualization of the number of parasites within each vacuole, cells were 
stained using Diff Quick Stain Kit (Andwin Scientific). The number of parasites in 
100 random vacuoles was counted for each parasite strain and the average 
number of parasites per vacuole was calculated; this assay was repeated three 
times. For the RHΔhx overexpression studies, the average number of parasites 
per vacuole for each parasite line was analyzed using two-way ANOVA. For the 
ME49 overexpression studies, the average number of parasites per vacuole for 
each parasite line was analyzed using the two-tailed student’s t-test. 
  
2.2.10 γ-toxin modification assay tRNA  
2.2.10.1 RNA isolation 
 Total RNA was extracted from both extracellular and intracellular 
parasites. For intracellular parasites two T-175 cm2 flasks were scraped, syringe 
lysed using a 25-guage needle and passed through a 3.0 µm polycarbonate filter 
(Whatman) to remove host cell debris and washed three times in PBS. After the 
final wash, parasites were resuspended in 250 µL of PBS and 750 µL of TRIzolTM 
LS Reagent (Invitrogen) and RNA was isolated according to the manufacturer’s 
protocol. For the extracellular parasite sample, two T-175 cm2 flasks of freshly 
egressed parasites were filtered and further processed the same as the 
intracellular samples. The final RNA pellet was resuspended in 30 µL of DEPC 
treated water and the RNA concentration was quantified using a Nanodrop. The 
absorbance of the RNA sample is measured at 260 and 280 nm. To check the 
quality of the total RNA and amount of host cell contamination, 3 µg of RNA was 
run on a 0.8% agarose gel.  
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2.2.10.2 Characterization of tRNAs treated with γ-toxin in vitro 
For each sample, 5 µg of total RNA was mixed with γ-toxin protein in 10 
mM Tris-HCl, 10 mM MgCl2, 50 mM NaCl and 1mM dithiothreitol (pH 7.5) and 
incubated for 10 min at 30ºC. The samples were separated on a 10% 
polyacrylamide, 8 M urea gel, and transferred to a Zeta-Probe membrane (Bio-
Rad). Oligonucleotides used to detect tRNAs were 5’- 
GTATCCTAACCACCTAGACTACATGGGA-3’ (Tg-tRNAGlu), 5’- 
TCTCCTTAACCACTCGGACACA-3’ (Tg-tRNASer), 5’-
CCAGGAATCCTAACCGCTAGACCATATGGGA-3’ (Hs-tRNAGlu) and 5’- 
GCCTTAACCACTCGGCCATCACAGC-3’ (Hs-tRNASer). Oligonucleotides were 
labeled by using adenosine [γ32P]-triphosphate (6000 Ci/mmol, Amersham 
Biosciences) and polynucleotide kinase (Roche Applied Science). Northern blots 
were visualized by autoradiography. These assays were performed in 
collaboration with Jenna Lentini and Dragony Fu at the University of Rochester. 
 
2.2.11 Recombinant protein expression and purification 
To produce recombinant TgElp3 protein, bacteria (RosettaTM 2(DE3) 
pLysS  or ArticExpressTM competent cells) were grown to an OD600 of 0.6 in 500 
ml of Luria broth containing ampicillin (or kanamycin) then induced with 0.5-1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3-4 hrs at 37°C, or 1-3 hrs to 
overnight at 13°C. The Qiagen Ni-NTA Spin Kit (Qiagen # K950-01) under native 
conditions was used per the manufactures instructions. Briefly, the bacteria was 
pelleted at 3700 RPM for 30 min at 4°C. The pellet was re-suspended in lysis 
buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) supplemented 
with cOmpleteTM, Mini, EDTA-free protease inhibitor (Roche #11836170001), 
lysozyme (Roche #37059) and Benzonase Endonuclease (Novagen #706643). 
Lysates were incubated on ice for 30 mins and then centrifuged at 4°C for 20 
mins and the insoluble pellet discarded. GST-tagged TgElp3 antigen was purified 
over glutathione resin (Clontech cat# 635607) for at 3700 RPM 4 hrs at 4°C. The 
Ni-NTA column was equilibrated with lysis buffer and then loaded with cleared 
lysate containing His-Tagged-Elp3 and centrifuged at 1600 RPM for 10 mins at 
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4°C. The column was washed twice with wash buffer (50 mM NaH2PO4, 300 mM 
NaCl, 20 mM imidazole, pH 8.0). Elution buffer (50 mM NaH2PO4, 300 mM NaCl, 
500 mM imidazole, pH 8.0) was added to the column to elute TgElp3 protein. 
Eluted protein was immediately stored in 20% glycerol. Protein was analyzed by 
Western blot, coomassie brilliant blue staining and/or silver staining.  
For the GST-tagged proteins, a similar protocol was used except 
glutathione resin and different buffers were used. Briefly, the bacteria were 
pelleted and resuspended in GST buffer (125 mM Tris-HCl pH 8.0 and 150 mM 
NaCl) supplemented with cOmpleteTM, Mini, EDTA-free protease inhibitor 
(Roche #11836170001), lysozyme (Roche #37059), and Benzonase 
Endonuclease (Novagen #706643) and incubated on ice for 30 mins. Lysates 
were then centrifuged at 4°C for 20 mins and the insoluble pellet discarded. GST-
tagged TgElp3 was purified over glutathione resin (Clontech cat# 635607) for 4 
hrs at 4°C. GST-bound resin was washed 3 times with GST buffer followed by 
elution of GST-TgElp3 by incubating the resin in GST elution buffer (50 mM Tris-
HCl pH 8.0 and 10 mM reduced Lglutathione) for 5 min at 4°C and collecting the 
supernatant. 
The SF21 cell line derived from the fall army worm, Spodoptera frugiperda 
is used to propagate baculovirus. For these studies, we used Clontech’s 
BacPAKTM expression according to the manufacturer’s directions. Briefly, SF21 
cells were maintained in Grace’s Basic Medium (Clontech #631404) 
supplemented with yeastolate, lactalbumin hydrolysate, L-glutamine and 10% 
FBS at 27°C.Prior to transfection, plasmid DNA was purified using the Endotoxin-
Free—NucleoBond Xtra Midi Plus EF kit (Clontech #740422.10). The BacPAK9-
TgElp3 vector DNA was transfected using Bacfectin into the SF21 cells along 
with Bsu36I-digested BacPAK6 Viral DNA. In vivo homologous recombination 
between the plasmid and viral DNA rescues the viral DNA, and transfers the 
TgElp3 gene to the viral genome. Five days after the addition of the Bacfectin-
DNA mixture, the medium full of viruses was collected and stored at 4°C. The 
cells were collected and assessed for TgElp3 protein expression via Western 
blot, coomassie brilliant blue staining and/or silver staining. The collected virus 
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was propagated and used under various conditions as suggested in the 
manufacture’s protocol. 
 
2.2.12 Analysis of protein synthesis 
2.2.12.1 Polyribosome profiling 
 For polyribosome analysis, two T-175 cm2 flasks of intracellular parasites 
were treated with 50 µg/mL of cycloheximide for 10 min (114, 115). Infected 
monolayers were scraped, syringe lysed using a 25-guage needle and passed 
through a 3.0 µm polycarbonate filter (Whatman) to remove host cell debris and 
washed twice in ice-cold PBS containing 50 µg/mL of cycloheximide. Parasites 
were pelleted by centrifugation at 1000 x g for 10 min at 4ºC and re-suspended in 
500 µL of lysis buffer (20 mM Tris-HCL (pH 7.9), 150 mM NaCl, 10 mM MgCl2, 
0.1% Triton, 50 µg/mL cycloheximide, and 0.04 U/µL RNaseOUTTM Recombinant 
Ribonuclease Inhibitor (Thermofisher #10777019)). Parasites were passed 
through a 25-guage needle several times to facilitate parasite lysis followed by a 
10 min incubation on ice. Insoluble proteins were cleared by centrifugation at 
21,000 x g for 10 min at 4ºC and 400 µL of lysate was layered onto 10 to 50% 
sucrose gradients prepared in lysis buffer without Triton or RNaseOUTTM 
Recombinant Ribonuclease Inhibitor. Polyribosome complexes were resolved by 
centrifugation using a Beckman Coulter SW41Ti rotor at 40,000 rpm at 4ºC for 2 
hr. Gradients were fractionated by a BioComp Instruments gradient station and 
the absorbance was measured using an ISCO UA-6 absorbance monitor set at 
254 nm.  
 
2.2.12.2 Surface Sensing of Translation (SUnSET) 
  To determine if the Surface of Sensing of Translation (SUnSET) 
technique could be used to assess protein synthesis in Toxoplasma, we 
assessed the incorporation of puromycin in freshly egressed RHΔhx parasites. 
Approximately 2.5 x 106 parasites were incubated with 10 µg/mL puromycin 
(SIGMA #P8833) for 15 min before or after incubation with 100 µg/mL 
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cycloheximide for 10 min. Cells were pelleted and processed for Western blot 
analysis the same as referenced above in section 2.2.7.  
To visually assess puromycin incorporation by IFA, confluent HFF 
monolayers grown on coverslips in a 24-well plate were inoculated with RHΔhx 
parasites. To limit the amount of puromycin incorporation into the host cell and 
reduce host cell background, HFF cells were at least two weeks old before 
inoculation with parasites (116). Twelve hours post infection, 10 µg/mL 
puromycin was added for 15 min before or after incubation with 50 µg/mL 
cycloheximide (SIGMA #C7698) for 1 hr. Coverslips were fixed and processed 
for IFA analysis as referenced above in section 2.2.8. 
 To assess protein synthesis in parental RHΔhx and HATgElp3OE strains, 
the same procedure referenced above was followed except incubation times 
without or with 10 µg/mL puromycin were for 10, 20 and 30 min. For intracellular 
parasites, 2 x T175 cm2 flasks were each inoculated with 3.5 x 106 parasites. 
Puromycin was added (10 µg/mL) 42 hr post infection. Following treatment, 
parasites were harvested at 10, 20 and 30 min. To remove host cell debris, flasks 
were scraped, syringe lysed (25-guage needle) and passed through a 3.0 µM 
polycarbonate filter. Samples were washed twice with ice-cold PBS and 
processed for Western blot analysis (section 2.2.7).  
 Since active translation is occurring in the HFF monolayer, the 
background signal can be high. High background can confound interpretation of 
puromycin signals. To circumvent this problem, we used a co-culture approach in 
which 3 x 105 parasites of each parasite line (RHΔhx and HATgElp3OE) were 
inoculated onto a single coverslip containing a confluent HFF monolayer. 
Medium was changed 4 hr post-infection to remove uninvaded parasites and 
puromycin (10 µg/mL) was added 30 hr post-infection for 10, 20, and 30 mins. 
Coverslips were immediately fixed and processed for IFA analysis as referenced 
in section 2.2.8.  
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2.3 Results and Discussion 
2.3.1 Attempt to identify TgElp3 interacting proteins using BioID  
 To identify TgElp3 substrates in Toxoplasma we performed the recently 
developed proximity dependent identification (BioID) assay (117, 118). BioID is 
an in vivo technique that allows for the identification of nearby proteins and 
potential interacting partners within a native biological environment (117). The 
BioID approach utilizes the fusion of a promiscuous biotin protein ligase from 
Escherichia coli to a target protein (e.g. TgElp3); expression of this fusion protein 
in the presence of biotin results in proximity-dependent biotinylation of proteins 
within 10-20 nm to the fusion protein (117) (Figure 7).  
 
 
Figure 7. BioID experimental workflow.  
Expression of a promiscuous biotin-ligase fused to TgElp3 (BL-HATgElp3) in 
live parasites and incubation with biotin for 24 hrs leads to the selective 
biotinylation of proteins proximal to TgElp3. Biotinylation of proteins is 
confirmed by IFA and Western blot analysis. For protein identification, cells are 
lysed and biotinylated proteins are affinity purified and subjected to mass 
spectrometry.  
 
 To identify TgElp3 substrates we used the RHΔhx parasite line to 
ectopically overexpress a BiotinLigase-HATgElp3 (BL-HATgElp3) fusion protein. 
Mitochondrial localization was confirmed by immunofluorescence assay (IFA) 
(Figure 8). To assess biotinylation, BL-HATgElp3 parasites were incubated with 
vehicle (negative control) or 50 µM biotin for 24 hours and biotinylation was 
assessed by IFA and Western blot (Figure 8). As expected, we observed 
mitochondrial enrichment of biotinylated proteins with the biotin signal 
predominantly co-localizing with BL- HATgElp3; additionally, increased 
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biotinylation was observed in the biotin treated samples compared to vehicle by 
Western blot (Figure 8), indicating the biotin ligase fused to TgElp3 is functional.  
    To identify TgElp3 proximal proteins, BL-HATgElp3 and parental RHΔhx 
parasites (negative control) were incubated with 50µM biotin for 24 hours. 
Parasites were lysed in RIPA buffer and brief sonication was performed to 
ensure complete lysis. Total lysate was subjected to affinity purification with 
streptavidin conjugated magnetic beads and captured biotinylated proteins were 
assessed by Western blot (Figure 8). Biotinylated proteins were observed in both 
the parental RHΔhx and BL-HATgElp3 parasite strains, however, as expected 
there were significantly more biotinylated proteins detected in the BL-HATgElp3 
parasite sample.  
34 
 
 
Figure 8. Identification of proximal TgElp3 proteins. 
A. Immunofluorescence assay of BLHA-TgElp3 parasites at 24hrs treated with 
vehicle or 50 μM biotin. α-Streptavidin (red) detecting biotinylated proteins, α-
HA (green) detecting BirAHATgElp3 merged with the DNA stain DAPI (blue). B. 
Total protein isolated from BLHA-TgElp3 expressing parasites treated with 
vehicle or 50 μM biotin, probed with anti-Streptavidin; affinity purification of 
biotinylated proteins using α-streptavidin beads from parental RH∆hx and 
BLHA-TgElp3 treated with 50μM biotin for 24hrs. Protein eluted from beads and 
probed with anti-Streptavidin.  
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Since the amount of precipitated proteins was greater in the BL-HATgElp3 
sample, and many of the bands appeared unique, we hypothesized that these 
were likely potential substrates of TgElp3. Therefore we scaled up the affinity 
purification of biotinylated proteins and submitted the samples to the Indiana 
University School of Medicine mass spectrometry core facility for analysis. This 
analysis identified eight proteins unique to the BL-HATgElp3 sample including 
TgElp3 (Table 1). To confirm specificity of these proteins, we repeated the affinity 
purification and mass spectrometry analysis for a total of three independent trials. 
Our second and third analyses identified eleven and fifteen proteins unique to the 
BL-HATgElp3 sample (Table 1). TgElp3 was detected in all three BL-HATgElp3 
samples indicating the BioID assay worked. However, aside from TgElp3 no 
other proteins were consistently detected in all three trials. Therefore, we 
concluded that this approach was not reliably identifying potential TgElp3 
substrates.  
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Table 1. Proteins uniquely biotinylated in BL-HATgElp3 expressing parasites. 
Proteins identified in each experiment (Exp.) are listed with the number (No.) of 
peptides detected in order by accession number. Elp3 (bold) was the only protein 
detected in all three trials. 
 
Exp. 
Accession 
Number Description 
No. of 
Peptides 
3 TGME49_002760 hypothetical protein 1 
3 TGME49_005470 translation elongation factor 2 family protein, 
putative  
2 
3 TGME49_005580 hypothetical protein  1 
1 TGME49_023940 hypothetical protein 3 
3 TGME49_028630 hypothetical protein  1 
2 TGME49_059630 hypothetical protein, conserved  1 
3 TGME49_066640A acetyl-coenzyme A synthetase, putative 2 
2 TGME49_115610 hypothetical protein  1 
2 TGME49_204020  60S ribosomal protein L8, putative  2 
1 TGME49_216000 IMC3 2 
2 TGME49_218260  histone H3.3 variant  2 
2 TGME49_218520 microneme protein MIC6 1 
3 TGME49_219140 EF-1 guanine nucleotide exchange domain-
containing protein 
1 
3 TGME49_219630 flavodoxin domain-containing protein  1 
3 TGME49_226410 EF-1 guanine nucleotide exchange domain-
containing protein  
2 
1 TGME49_230940  hypothetical protein  3 
3 TGME49_232940 heat shock protein HSP20  1 
1 TGME49_235470 myosin-A  2 
3 TGME49_267390 DNA-directed RNA polymerases I and III subunit 
RPAC1, putative 
1 
2 TGME49_282055 protein phosphatase PP2C-hn  1 
1 TGME49_286420  elongation factor 1-alpha, putative 3 
2 TGME49_288720 60S ribosomal protein L10, putative 1 
1 TGME49_290660 RNA recognition motif-containing protein  2 
3 TGME49_294670 translation initiation factor 3 subunit 2 
2 TGME49_294800  putative elongation factor 1-alpha (EF-1-ALPHA)  1 
2 TGME49_300200  histone H2AZ  1 
3 TGME49_300200  histone H2AZ 1 
1 TGME49_305480 elongator complex protein ELP3 6 
2 TGME49_305480  elongator complex protein ELP3 5 
3 TGME49_305480  elongator complex protein ELP3  10 
3 TGME49_311230 hypothetical protein 2 
2 TGME49_316400 alpha tubulin TUBA1, partial  2 
3 TGME49_324600  heat shock protein  2 
1 TGME49_411760  actin 2 
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2.3.2 Endogenous replacement of TgElp3  
Considering that previous attempts to knockout TgElp3 have failed and 
localization at the mitochondrion is essential for parasite viability, we sought to 
characterize the molecular function of TgElp3 (83, 119). Since TgElp3 possesses 
two highly conserved enzymatic domains (radical S-adenosylmethionine (rSAM) 
and lysine acetyltransferase (KAT) domain) (83), we decided to take a targeted 
mutational approach to determine which domain(s) is required for TgElp3 
function. As a control, we replaced the endogenous locus with hemagglutinin 
(HA)-tagged wild-type cDNA (HATgElp3) in RHΔhx∆ku80 parasites; 
recombination frequency was ~50%. Correct integration was confirmed by PCR 
and protein expression was assessed by Western blot and IFA analyses using 
the anti-TgElp3 and anti-HA antibodies (Figure 9). To determine if parasites 
could survive when either the radical SAM or KAT domains were mutated, we 
generated two more HATgElp3 allelic replacement constructs: rSAM mutant 
(C284A) and KAT mutant (Y715A/Y716A); in other species, these rSAM and KAT 
mutations are critical for Elp3 function (68, 82, 84, 120). Despite several 
attempts, we were unable to generate rSAM or KAT mutants at the endogenous 
TgElp3 locus. Since the endogenous replacement of TgElp3 with wild-type 
recombinant HATgElp3 was obtained, we conclude that both enzymatic domains 
are likely required for TgElp3 function.  
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Figure 9. Endogenous tagging of TgElp3. 
A. Diagram of the construct used to replace the endogenous TgElp3 locus by 
double homologous recombination. Arrows indicate location of PCR primers. For 
PCR1, the forward primer is located upstream of the recombination site and the 
reverse primer is located in the HA-tag. The PCR2 primers are intron spanning. 
B. Correct integration of HATgElp3 at the endogenous locus is confirmed by PCR 
analysis. C. For each sample, 100 µg of protein was used for Western blot 
analysis of parental RHΔhx∆ku80 and HATgElp3 parasites. The blot was probed 
with anti-TgELP3, anti-HA and anti-SAG1 antibodies as a loading control. D. 
IFAs stained for anti-HA (green) and the mitochondrial maker anti-TgF1B-ATPase 
(red). Images merged with the DNA stain DAPI (blue). Scale bar, 3μm.  
 
2.3.3 Expression of catalytically inactive TgElp3 using an inducible 
destabilization domain  
As an alternative strategy to assess if both KAT and rSAM domains are 
required for TgElp3 function we used an inducible dominant-negative strategy. 
For this approach, we fused a destabilization domain (dd) onto TgElp3 which 
directs proteins to the proteasome for degradation; however, in the presence of 
the ligand Shield-1, the fusion protein is stabilized (121, 122). The constitutively 
active tubulin promoter was used to ectopically express dd fused to the N-
terminus of HATgElp3. Using the same wild-type and mutation sequences 
referenced above, we generated three clonal parasite strains in the RHΔhx 
background: ddHATgElp3, ddHATgElp3-KATmut and ddHATgElp3-rSAMmut. Initial 
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experiments to assess proteasomal rescue by Shield-1 were performed by IFA.  
With increased concentrations of Shield-1 (0-500nM), we observed an increase 
of ddHATgElp3 protein expression; however, removing Shield-1 for 24 hours did 
not result in the loss of ddHATgElp3 (Figure 10). Furthermore, ddHATgElp3 protein 
expression showed variability between parasite vacuoles (Figure 10). Since 
regulation of protein expression is dependent on degradation by the proteasome 
and TgElp3 traffics to the mitochondrion, we hypothesize that some ddHATgElp3 
protein likely bypasses proteasome degradation by insertion into the 
mitochondrion via its TMD. Once anchored to the OMM, ddHATgElp3 protein is 
stabilized independent of Shield-1 concentrations. Considering elucidation of 
TgElp3 function requires tight regulation of protein expression and our 
preliminary experiments show inconsistent ddHATgElp3 protein control by Shield-
1, we did not feel that this approach would be reliable for elucidating TgElp3 
function.   
 
 
Figure 10. ddHATgElp3 protein regulation by Shield-1. 
Clonal ddHATgElp3 were maintained in 100nM shield. Freshly egressed 
parasites were inoculated onto coverslips containing a HFF monolayer. Medium 
was replaced with fresh medium with or without Shield-1 at various 
concentrations 2 hr post-infection. Plates were fixed at 24 hr and stained for 
anti-HA (green). ddHATgElp3 protein expression was still present without shield 
and variation of ddHATgElp3 expression was observed between vacuoles within 
the same treatment.  
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2.3.4 Overexpression of wild-type and mutant TgElp3 
Gene dosage is important for normal gene function and since we were 
unable to knockout, endogenously mutate or use an inducible dominant negative 
approach to study TgElp3, we sought to determine if overexpression of TgElp3 
would be tolerated. We engineered a construct to ectopically overexpress 
HATgElp3 driven by the constitutively active tubulin promoter. This construct was 
transfected into the RHΔhx parasite strain and several independent clones were 
obtained. Overexpression of TgElp3 was confirmed by Western blot using the 
anti-TgElp3 and anti-HA antibodies (Figure 11).  IFA analyses confirmed TgElp3 
localization to the parasite mitochondrion using the established mitochondrial 
marker F1B ATPase (108, 109) (Figure 11). 
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Figure 11. Overexpression of HATgElp3OE in Toxoplasma gondii. 
A. Schematic of the construct used to express HATgElp3OE and various mutant 
forms. The constitutive tubulin promoter (pTub) was used to express full length 
HA-tagged TgElp3 cDNA (cElp3). Letters in red represent mutated amino acids. 
B. Western blot analysis of protein (100 µg) isolated from parental RH∆hx, 
HATgElp3OE and mutant HATgElp3OE parasite strains using anti-TgElp3 and anti-
SAG1 as a loading control. C. IFA assay using anti-HA to detect TgElp3 
(green), anti-TgF1B ATPase a known mitochondrial marker (red) merged with 
the DNA stain DAPI (blue), scale bar 3µm.  
42 
Upon initial observation, HATgElp3 overexpressing parasites (HATgElp3OE) 
appeared to grow slowly in culture. A plaque assay quantitatively confirmed a 
growth defect in the HATgElp3OE parasites compared to the parental line (Figure 
12). To further investigate this growth defect, we performed a doubling assay to 
assess parasite replication. HATgElp3OE parasite replication rate was significantly 
slower at the 24 and 30 hour time points (Figure 12). This replication defect was 
observed in multiple independent clones and further confirmed in an independent 
type II HATgElp3OE parasite strain (ME49) (Figure 13).  
Interestingly, after passing the HATgElp3OE parasites for several weeks 
(approximately 115 replications), some of the parasites would adapt and resume 
a normal replication rate; these adapted parasites were no longer expressing the 
HATgElp3 ectopic copy as determined by IFA analysis. Loss of overexpression 
resulted in a mixed population of parasites and gradual restoration of growth. 
This occurred on multiple occasions and therefore the HATgElp3OE parasites were 
routinely checked by IFA to ensure each assay was performed with a clonal 
parasite line. With the observed replication defect and frequent adaptation, we 
conclude that overexpression of TgElp3 is not well tolerated and there is strong 
selective pressure in Toxoplasma to silence its expression.  
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Figure 12. Overexpression of TgElp3 causes a significant replication defect. 
A. Plaque assays were performed to assess proliferation. Plaque area was 
quantified using Image J. TgElp3OE, KAT(Y716A)OE and KAT(Y715/716F)OE 
parasites show a significant replication defect; mean area of 30 plaques + s.d. is 
depicted, *P<0.05 (two-way ANOVA). B. Doubling assays were performed at 24 
and 30 hours to assess parasite replication rate. The number of parasites in 100 
random vacuoles was quantified and the percentage of vacuoles containing the 
designated number of parasites is shown, *P<0.05 (two-way ANOVA) 
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To investigate why TgElp3 overexpression is not well tolerated, we 
considered two possibilities: (1) independent of TgElp3 function, increased levels 
of protein at the OMM may generally induce mitochondrial dysfunction, and (2) 
the replication defect is specific to the enzymatic activity of TgElp3 at the 
mitochondrion. To address these possibilities we generated several mutant 
HATgElp3OE constructs: rSAM(C284A/C287A)OE, KAT(Y715/716A)OE and a 
construct containing a premature stop codon to remove the transmembrane 
domain (ΔTMDOE). Since we cannot control for the number of ectopic gene 
copies or where they integrate within the genome, at least two independent 
clonal parasite lines with equal TgElp3 protein expression were acquired for each 
of the mutant constructs (Figure 11).  
Surprisingly, we were unable to obtain a KAT(Y715/716A)OE clone with 
TgElp3 protein expression comparable to the other overexpressing parasite 
strains. We hypothesized that the two tyrosine to alanine mutations may render 
the protein unstable. Therefore, we decided to generate two more versions of the 
KAT mutant overexpressing construct: (1) mutate a single tyrosine to alanine 
(Y761A), and (2) mutate both tyrosine residues to phenylalanine (Y715F/Y716F), 
a more physiologically relevant substitution. Using both of these KAT mutant 
constructs we easily obtained clonal parasites expressing TgElp3 protein 
comparable to the other overexpressing lines (Figure 11). In addition, we 
generated two double mutant parasite lines, each containing a rSAM and KAT 
mutation: (1) rSAM(C284A/C287A)/KAT(Y716A)OE, and (2) 
rSAM(C284A/C287A)/KAT(Y715F/Y716F)OE) (Figure 11). For all parasite strains, 
protein expression was assessed by Western blot and localization at the 
mitochondrion (except for ΔTMDOE) was confirmed by IFA using the anti-HA 
antibody (Figure 11).  
 Using the transgenic HATgElp3OE parasite lines, we performed a plaque 
assay to assess parasite growth. Interestingly, compared to parental parasites, 
the KAT(Y761A)OE and KAT(Y715F/Y716F)OE parasites as well as the previously 
characterized wild-type HATgElp3OE parasites all grew significantly slower (Figure 
12). In contrast, parasites expressing a rSAM mutation or mislocalized TgElp3 
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(ΔTMDOE) grew at the same rate as parental parasites (Figure 12). Doubling 
assays were performed to assess parasite replication. Consistent with the plaque 
assay growth defect results, a significant replication defect was detected in the 
wild-type HATgElp3OE, KAT(Y761A)OE and KAT(Y715F/Y716F)OE parasite lines at 
24 and 30 hour time points (Figure 12). Assuming these mutations ablate KAT 
activity, these data suggest that KAT activity is not associated with the slowed 
growth phenotype. 
 
Figure 13. Overexpression of TgElp3 in the ME49 parasite strain. 
A. Western blot analysis of parental ME49 and two independent HATgElp3OE 
clonal isolates (designated C1 and C2) using anti-HA and anti-aldolase as a 
loading control. B. Doubling assays were performed to assess parasite growth. 
The infected cultures were examined at 24 hr and 48 hr time points. Parasite 
replication was monitored by quantifying the number of parasites in 100 random 
vacuoles. The number of parasites per vacuole is shown *P<0.05 (two-tailed 
student’s t-test).  
 
Also consistent with the plaque assays, overexpression of TgElp3 
harboring a rSAM mutation or mislocalized HATgElp3OE (ΔTMDOE) did not alter 
parasite replication. Considering that all of the TgElp3 rSAM mutant 
overexpressing parasites grew the same as parental, we conclude that increased 
TgElp3 at the OMM does not physically interfere with mitochondrial function and 
that the rSAM domain is essential for TgElp3 function. Moreover, mislocalization 
of wild-type HATgElp3OE was also tolerated, suggesting the replication defect is 
specific to the enzymatic activity of TgElp3 at the mitochondrion. Since 
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overexpression of KAT mutants of TgElp3 still grew slowly, the rSAM domain 
appears to be more important than the KAT domain in producing the slowed 
growth phenotype. In summary, these results signify the importance of TgElp3’s 
rSAM domain for protein function, and confirm TgElp3 activity is dependent on 
localization to the OMM. 
 
2.3.5 The mcm5s2U tRNA modification is present in Toxoplasma 
 Our mutational approaches identified the rSAM domain as essential for 
TgElp3 function. In other species, rSAM domain of Elp3 is important for the 
formation of tRNA modifications, which enhance translation efficiency and fidelity 
(123–125). Specifically, Elp3 is required for the synthesis of 5-
methoxycarbonylmethyl (mcm5) and 5-carbamoylmethyl (ncm5) groups present 
on uridines at the wobble position in tRNA (86). Given the significant replication 
defect observed in the HATgElp3OE parasite strain, we hypothesized that 
overexpression of TgElp3 causes hyper-modification of tRNA resulting in altered 
translation (Figure 14). 
 
Figure 14. Overexpression of TgElp3 may cause hyper-modification of tRNAs 
resulting in altered translation rate and slowed parasite growth. 
A biological model of how dysregulation of tRNA modifications may alter 
translation rate and affect parasite growth. Red cloverleaf structures=tRNA, 
yellow stars=modified nucleosides.   
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In Saccharomyces cerevisiae, loss of Elp3 correlates with the loss of the 
mcm5 side-chain generating resistance to the Kluyveromyces lactis killer toxin (γ-
toxin) (69, 86, 126). The γ-toxin is a tRNA endonuclease that cleaves tRNA 3’ of 
the wobble nucleoside 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) (127) 
(Figure 15). The mcm5s2U tRNA modification identified in S. cerevisiae is only 
present in lysine, glutamic acid and glutamine tRNAs, and its formation requires 
two enzymes: (1) Elp3 for the formation of mcm5, and (2) cytosolic thiouridylase 
(Ctu1/Ctu2) for the formation of the 2-thio (s2) group (95, 125, 128–130).  Blast 
analyses of the Toxoplasma proteome using S. cerevisiae Ctu1/Ctu2 sequences 
identified two putative cytosolic thiouridylase proteins, TGME49_309020 and 
TGME49_294380, suggesting that the mcm5s2U tRNA modification likely exists in 
Toxoplasma. 
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Figure 15. Ctu1/Ctu2 and Elp3 are required for the mcm5s2 wobble uridine 
modification.  
A. Elp3 and Ctu1/Ctu2 pathways are required for the mcm5 and s2 modifications, 
respectively, at the wobble uridine position. B. Depiction of where the γ-toxin 
endonuclease cleaves the mcm5s2U tRNA modification. C. Structure of human 
(Hs-tRNAGlu) and Toxoplasma glutamic acid tRNA (Tg-tRNAGlu). 
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To determine if the mcm5s2U tRNA modification exists in Toxoplasma, we 
performed an in vitro enzymatic assay using recombinant γ-toxin in collaboration 
with Dragony Fu’s lab at the University of Rochester. Total RNA samples from 
parental RHΔhx, HATgElp3OE and rSAM(C284A/C287A)OE parasite lines along 
with an HFF control sample were incubated with recombinant γ-toxin or an empty 
vector control. To assess cleavage, we designed Northern blot probes specific to 
Toxoplasma glutamic acid tRNA (Tg-tRNAGlu) as well as a control probe for 
serine tRNA (Tg-tRNASer); since tRNASer is not known to possess the mcm5s2U 
tRNA modification, we do not expect to see cleavage. Considering Toxoplasma 
is an intracellular pathogen, host cell contamination is likely. To address this 
concern we used RNA extracted from both intracellular and extracellular 
parasites, and included Northern blot probes specific to human glutamic acid 
(Hs-tRNAGlu) and serine tRNAs (Hs-tRNASer). Interestingly, Tg-tRNAGlu contains 
an extra nucleotide in the D-loop making it 73 bp long compared to the Hs-
tRNAGlu composed of 72 bp. This extra base pair makes the Toxoplasma wobble 
uridine base pair 35, not 34 which is typically found (Figure 15).   
Upon treatment with γ-toxin the amount of full length Tg-tRNAGlu 
decreased, indicating the presence of the mcm5s2U tRNA modification in 
Toxoplasma (Figure 16). A similar pattern was observed in the HFF control 
sample when probed with anti-Hs-tRNAGlu (Figure 16). As expected, there was 
no decrease in full length Tg-tRNASer or Hs-tRNASer with treatment of γ-toxin, 
indicating an absence of the mcm5s2U tRNA modification. Of note, the Hs-
tRNASer probe appears to detect tRNA in the parasite sample; however, the Tg-
tRNASer seems specific to Toxoplasma.   
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Figure 16. Identification of the tRNAGlu mcm5s2 modification in Toxoplasma.  
Northern blot of 5 µg total RNA isolated from intracellular (A) and extracellular (B) 
RHΔhx, HATgElp3OE and rSAM(C284A/C287A)OE parasites and uninfected host 
cells (HFF) sample incubated without or with the γ-toxin endonuclease for 10 min 
at 30ºC. GluTTC and SerCGA probes specific to T. gondii and H. sapiens were 
used. The probe used for each blot is listed on the left.  
 
Unexpectedly, a doublet was observed in the Toxoplasma samples when 
using the Tg-tRNAGlu probe. Initially, we thought this may be due to host cell 
contamination, however, when using the Hs-tRNAGlu probe against the 
Toxoplasma samples, we did not detect Hs-tRNAGlu (Figure 16). Non-specific 
binding of the Tg-tRNAGlu probe to another Toxoplasma tRNA could explain the 
doublet. The Toxoplasma aspartic acid tRNA (Tg-tRNAAsp) shares the closest 
sequence homology, matching 17 of the 28 nucleotides in the Tg-tRNAGlu probe. 
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Despite some sequence similarity between the Tg-tRNAGlu and Tg-tRNAAsp 
sequences, there is only a one-third mismatch between Tg-tRNAGlu probe and 
the Tg-tRNAAsp sequence making it unlikely to be the cause of the doublet. 
Another possibility is that there may be a portion of Tg-tRNAGlu that has some 
unresolved secondary structure causing a band shift in the gel. Curiously, a 
doublet has also been observed in S. cerevisiae when probed for the glutamic 
acid tRNA (87), but an explanation remains unknown.  
There was no difference in levels of intact or cleaved Tg-tRNAGlu levels 
between the parental, TgElp3OE and rSAM(C284A/C287A)OE samples, indicating 
the TgElp3OE replication defect is not a result of hyper-mcm5s2U tRNAGlu 
modifications. Seeing that this assay does not directly test for all Elp3 tRNA 
modifications and a second enzyme is required for the mcm5s2U modification, 
this could explain why we observed no difference. In other species, Elp3 is 
known to modify 11 different tRNAs and this assay examines only tRNAGlu (86, 
87). In conclusion, we were able to identify the first tRNA modification (mcm5s2U) 
in Toxoplasma. However, we still do not know the cause of the TgElp3OE 
replication defect.  
 
2.3.6 Attempt to generate recombinant TgElp3 
 Recently, an in vitro tRNA modification assay was developed by Raven 
Huang (84). This assay used recombinant Elp3 from archaeal 
Methanocaldococcus infernus (MinElp3), a synthetic tRNAArg and [14C] acetyl-
CoA. In the presence of MinElp3, a covalent attachment of the [14C] acetyl group 
to the tRNA occurrs, demonstrating catalysis by MinElp3; catalysis does not 
occur when MinElp3’s rSAM or KAT domains are mutated, suggesting that both 
domains are required to modify tRNA (84). To test TgElp3 in this assay, a 
minimum of 1mg of purified protein is required. Using 5 x T-150s of freshly 
egressed parasites, we were able to purify only ~1µg of HATgElp3 protein. To 
generate enough TgElp3 protein to perform the in vitro tRNA modification assay, 
it was necessary to employ a heterologous recombinant protein expression 
system.  
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In attempts to generate sufficient recombinant TgElp3 protein, we 
engineered several TgElp3 expression constructs, each with the TMD removed 
(TgElp3ΔTMD). For expression, we used the Rosetta (DE3) pLysS competent 
cells which are designed to enhance the expression of eukaryotic proteins that 
contain codons rarely used in Escherichia coli. Despite trying several different N-
terminal epitope tags (10 x Histidine, GST, SUMO and no tag), we were unable 
to purify soluble TgElp3.  Next, we tried expressing TgElp3 in a second E. coli 
competent cell line specifically engineered to overcome the hurdle of protein 
insolubility, Artic Express Competent Cells. This cell line expresses several 
protein chaperones which aid in protein folding to increase protein solubility. 
Nevertheless, we were unable to purify soluble protein.  
We also attempted to use a heterologous eukaryotic system to express 
TgElp3. We chose the baculovirus gene expression system in Spodoptera 
frugiperda (SF21) cells to express TgElp3. We generated two TgElp3ΔTMD 
constructs (with or without a GST-tag) for use in Clontech’s BacPAKTM 
Baculovirus Expression System. Using the SF21 cells, we were able to express 
high amounts of TgElp3 protein but the majority was insoluble. 
The reason for TgElp3’s insolubility is likely due to its rSAM domain. The 
rSAM domain contains a canonical cysteine motif (CX3CX2C) that forms an iron-
sulfur cluster [4Fe-4S]. This iron-sulfur cluster is thought to reductively cleave S-
adenosyl-L-methionine (SAM) to generate a radical required for a methylation 
reaction (131). The iron-sulfur cluster relies on three iron atoms ligated to each of 
the three cysteines, while the fourth iron atom presumably binds the co-factor 
SAM (132, 133). As this cluster is only bound by three protein derived cysteine 
ligands rather than four, the [4Fe-4S] cluster tends to be extremely labile in the 
presence of oxygen, frequently degrading to other iron-sulfur cluster forms (134–
136). This has been observed with other rSAM domain containing proteins and 
consequently in the presence of oxygen, precipitation of protein occurs (137–
139). In summary, under the conditions we tried, we were unable to produce 
enough soluble TgElp3 protein to perform the in vitro tRNA modification assay. 
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2.3.7 Global translation is not altered by overexpression of TgElp3 
 The rate of protein synthesis is not uniform along mRNAs; one influential 
factor is the rate of codon-anticodon base pairing, in which the first two codon 
positions interact in a Watson-Crick base pair manner while the third codon 
position can form a non-canonical (wobble) pair. This wobble base pairing is 
heavily influenced by tRNA modifications that can alter translation fidelity and 
efficiency (138, 140). Altered translation rates can globally affect protein levels as 
this was recently observed in S. cerevisiae lacking Elp3/Uba4; the loss 
Elp3/Uba4 resulted in the loss of wobble uridine mcm5 and mcm5s2 tRNA 
modifications and decreased protein levels (141).  Several other studies, 
including one in mammalian cells, have identified Elp3 as an important regulator 
of translation (95, 125, 142, 143).  
The growth defect we observed in HATgElp3OE parasites could be due to 
excessive TgElp3 mediated tRNA modification, which would lead to altered 
translation. Since we have been unable to confirm TgElp3 as a tRNA 
modification enzyme, we decided to assess protein synthesis in the parental 
RHΔhx and HATgElp3OE parasite strains using two independent methods, 
polyribosome profiling and SUrface SEnsing of Translation (SUnSET) analyses.   
 To evaluate the effect of TgElp3 overexpression on global translation we 
performed polyribosome profiling. This technique uses a sucrose gradient to 
separate mRNA associated ribosome complexes. Separation of these complexes 
is based on the number of associated ribosomes: free ribosome (small or large 
ribosome subunit), monosome (one ribosome residing on an mRNA) and 
polysome (multiple ribosomes residing on an mRNA). We treated freshly lysed 
parasites with cycloheximide to block the translocation step in protein synthesis 
essentially “freezing” the ribosomal mRNA complexes. Parasite lysate was then 
subjected to polyribosome fractionation and analyzed by UV spectrometry. No 
overt differences were observed between parental RHΔhx and HATgElp3OE 
parasite strains (Figure 17).  
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Figure 17. Overexpression of Elp3 does not alter global translation.  
Equal amounts of lysate from parental RHΔhx and HATgElp3OE parasite 
strains were separated on a 10 to 50% sucrose gradient and polyribosome 
profiles were generated.  
 
 In addition to polyribosome profiling which provides a snapshot of 
translation at the mRNA level, we performed a second method to assess 
translation at the protein level, SUnSET. This method uses puromycin, a tyrosyl-
tRNA analog that is incorporated into nascent polypeptide chains. Puromycin 
incorporation inhibits further protein synthesis and results in C-terminally labeled 
proteins (144, 145).  
 To determine if SUnSET could be used to assess protein synthesis in 
Toxoplasma, we treated RHΔhx parasites with puromycin before or after 
treatment with the protein synthesis inhibitor cycloheximide. Puromycin 
incorporation into Toxoplasma proteins was assessed by Western blot and IFA; 
minimal detection of puromycin was observed in the untreated parasites 
(control), cycloheximide only treatment (CHX) and treatment with cycloheximide 
followed by puromycin (CHX + Puro). In contrast, strong puromycin incorporation 
was detected in parasites treated with only puromycin (Figure 18). These results 
verify that the SUnSET method works in Toxoplasma and that puromycin 
incorporation is specific to protein synthesis. 
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We applied the SUnSET method to determine if protein synthesis is 
altered in our TgElp3 overexpression parasite strain.  Freshly egressed 
extracellular parasites (parental RHΔhx and HATgElp3OE) were incubated with 
puromycin for 10, 20 and 30 minutes. At each time point, parasites were spun 
down and immediately lysed to halt puromycin incorporation. Puromycin 
incorporation was assessed by Western blot analysis; no overt differences were 
detected between the parental RHΔhx and HATgElp3OE parasite strains (Figure 
18). Since we used intracellular parasites, there is a risk of host cell 
contamination. Therefore, we repeated the experiment using freshly egressed 
parasites which also showed no difference (Figure 18).   
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Figure 18. SUnSET analysis of active protein biosynthesis in Toxoplasma.   
A. Freshly egressed RHΔhx parasites incubated in normal growth medium with 
100 µg/mL cycloheximide (CHX), 10 µg/mL puromycin (Puro) or both 
(CHX+Puro). Western blot analysis of each sample (100 µg) probed with anti-
puromycin. Ponceau staining shows relatively equal loading and transfer. 
Puromycin is incorporated into Toxoplasma proteins (Puro) while 
cycloheximide treatment blocked puromycin incorporation (CHX+Puro); this 
data confirms that SUnSET analysis works in Toxoplasma. B. Freshly 
egressed RHΔhx and HATgElp3OE parasites incubated with 10 µg/mL 
puromycin (Puro) for 10, 20 and 30 minutes. At each time point cells were 
immediately lysed and subjected to SDS-PAGE and Western blotting using 
anti-puromycin antibody. Ponceau staining shows relatively equal loading and 
transfer. A time dependent increase of puromycin incorporation is observed in 
both parasite strains. C. Intracellular RHΔhx and HATgElp3OE parasites 
incubated with 10 µg/mL puromycin for 10 and 20mins. Parasites were 
physically removed from host cells and filtered to remove host cell debris. 
Lysates were immediately prepared and Western blot analysis of each sample 
(100 µg) was probed with anti-puromycin and anti-SAG1 for a loading control.  
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  In addition to Western blot analysis, we also assessed puromycin 
incorporation by IFA analysis. Since the HFF host cells are also actively 
synthesizing proteins, they will also incorporate puromycin and create high 
background levels. Therefore, to more accurately assess puromycin 
incorporation, we performed co-culture experiments where both parental RHΔhx 
and HATgElp3OE parasites were inoculated onto the same coverslip containing 
confluent HFF cells. After 30 hours, puromycin was added and coverslips were 
fixed at 10 and 20 minutes. Puromycin incorporation was similar between 
parental RHΔhx and HATgElp3OE parasites (Figure 19). However, the amount of 
protein biosynthesis as indicated by puromycin incorporation across individual 
parasite vacuoles varied and was independent of parasite strain (Figure 19). This 
variation could be associated with parasite cell cycle, but further studies are 
needed. In summary, using polyribosome profiling and the SUnSET method to 
assess protein synthesis unveiled no differences between the parental RHΔhx 
and HATgElp3OE parasite strains. 
In a S. cerevisiae Elp3/Uba4 knockout strain, the loss of the mcm5s2 tRNA 
modification is associated with drastically decreased protein levels as determined 
by Coomassie blue staining, but protein levels were partially restored with 
overexpression of tRNALys (141). In a subsequent study, ribosome footprint 
profiling identified an accumulation of ribosomes at the GAA and CAA codons in 
a knockout Elp3 yeast strain, suggesting that these codons were translated less 
efficiently by hypomodified tRNAs; however, polyribosome gradient profiles of the 
mcm5s2 deficient strains were indistinguishable from wild-type, suggesting that 
this technique may not be sensitive enough to identify small alterations in global 
protein synthesis (138). Since the initiation step is typically the rate-limiting step 
of eukaryotic translation and tRNA modifications predominantly affect translation 
elongation, these may be missed by global protein synthesis assays (146, 147).  
In addition, the mcm5s2 tRNA modifications may alter protein synthesis of only a 
subset of mRNA transcripts which further limits the ability to detect changes at a 
global level. Future studies are needed to determine if small changes in protein 
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synthesis may be the cause of the significant growth defect identified in the 
HATgElp3OE parasite strains.  
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Figure 19. Protein biosynthesis varies between parasite vacuoles and is 
independent of Elp3 overexpression.  
A. Co-culture of equal numbers of RHΔhx and HATgElp3OE parasites incubated 
with puromycin for 10 and 20 mins at 30 hr post-infection. Coverslips were 
fixed and stained for anti-puromycin (red) to detect protein biosynthesis, anti-
HA to differentiate the HATgElp3OE parasites from the RHΔhx parasites and 
merged with the DNA stain DAPI (blue), scale bar 25 µm. Variation in 
puromycin staining is observed across parasite vacuoles and is independent of 
parasite strain. B. Another example of variation of parasite protein biosynthesis 
as detected by anti-puromycin (red), scale bar 2 µm.  
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2.4 Concluding remarks 
 In these studies, we determined that overexpression of TgElp3 at the 
parasite’s mitochondrion results in a significant replication defect, but 
overexpression of TgElp3 lacking the TMD domain or with a mutant rSAM 
domain is tolerated. These findings signify the importance of TgElp3’s 
localization to the mitochondrion and the functional activity of the rSAM domain. 
In other species, the rSAM domain of Elp3 is responsible for post-transcriptional 
tRNA modifications, specifically the mcm5 and ncm5 wobble uridine modifications. 
These tRNA modifications are thought to alter protein synthesis in a context 
dependent manner, but the exact mechanisms are not well understood (138, 
141). Although we cannot rule out TgElp3 KAT activity, these findings broadened 
our focus from only exploring TgElp3 as a KAT to investigating its potential role 
as a tRNA modification enzyme. Currently, there are no reports on tRNA 
modifications in Toxoplasma.  
Using the in vitro γ-toxin assay in collaboration with Dragony Fu’s lab at 
the University of Rochester we identified the first tRNA modification in 
Toxoplasma, tRNAGlu mcm5s2U35. This wobble uridine modification is predicted 
to change the physical interaction between the anticodon and codon with the 
mcm5 modification preferentially translating –G ending codons while the mcm5s2 
favors –A ending codons (148, 149). In these studies, we were unable to attribute 
the TgElp3OE replication defect to changes in the tRNAGlu mcm5s2U35 
modification. Knowing that the tRNAGlu mcm5s2U35 modification requires a 
second enzyme, Ctu1/Ctu2, and that we do not have a way to directly measure 
the Elp3 specific mcm5 modification, we diverted our efforts to assess protein 
synthesis. Using two independent methods, polyribosome profiling and SUnSET, 
we did not detect differences in TgElp3OE global protein synthesis compared to 
the parental RHΔhx. However, these methods may not be sensitive enough to 
identify small changes in protein synthesis and codon specific translation defects 
may only affect a few genes required for a particular cellular process. More 
studies are needed to confirm that overexpression of TgElp3 does not alter 
translation of a subset of mRNA transcripts.  
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Previous reports on Elp3 are associated with many different biological 
processes specifically its function as either a tRNA modification enzyme and/or a 
lysine acetyltransferase. In Toxoplasma, TgElp3 is anchored to the outer 
mitochondrial membrane with its catalytic domains protruding into the cytosol. 
With this unique location, TgElp3 may possess one or the other, or both 
enzymatic activities. Due to the complete lack of tRNA genes in the mitochondrial 
genome, Toxoplasma must import all tRNAs required for mitochondrial 
translation (17). Several reports suggest that tRNA modifications could regulate 
which tRNAs are imported into the mitochondria and which remain in the cytosol 
(150, 151). For example, in Leishmania tarentolae nuclear encoded tRNAs 
containing the mcm5 modification are found mostly in the mitochondria; in 
contrast, cytosolic tRNAs contain both the mcm5 and s2 modifications (mcm5s2), 
indicating that the cytosol specific 2-thiolaion could play an inhibitory role in 
mitochondrial tRNA import (150). A similar mechanism may be present in 
Toxoplasma, but further studies are needed.  
Since we have shown that TgElp3 can acetylate histone H3 in vitro, it is 
reasonable to consider that TgElp3 is a bona fide lysine acetyltransferase in vivo 
(83). To date, TgElp3 is the only putative lysine acetyltransferase localized to the 
Toxoplasma mitochondrion and with the identification of twenty acetylated 
mitochondrial proteins, it is reasonable to think that these proteins may be 
acetylated by TgElp3 prior to import (83, 125). Given TgElp3’s KAT domain juts 
out into the cytosol, acetylation of cytosolic proteins is also likely. The cytosolic 
protein alpha-tubulin has been identified as a substrate of Elp3 in humans and 
yeast, making it a logical choice to explore as a potential substrate of TgElp3. 
The next chapter investigates TgElp3 as an alpha-tubulin acetyltransferase in 
Toxoplasma.  
 
 
 
 
62 
CHAPTER 3: Tubulin acetylation, a critical PTM important for parasite 
viability, is mediated by TgATAT not TgElp3.  
3.1 Introduction 
 Constructed from tubulin monomers, microtubules are a component of the 
cytoskeleton and are required for a variety of steps in Toxoplasma biology 
including parasite replication (152). Upon invasion, tachyzoites undergo a form of 
asexual division termed endodyogeny in which two daughter parasites assemble 
within the mother parasite (153, 154). This complex process is dependent upon 
the function of two distinct microtubule populations (155, 156). The spindle 
microtubules originate from a microtubule organizing center (MTOC) termed the 
centrosome, and ensure proper chromosome segregation and karyokinesis as 
the parasite completes each round of closed (intranuclear) mitosis (155, 156). 
Progression through mitosis is partnered with expansion of the daughter parasite 
cytoskeleton driven by elongation of the 22-subpellicular microtubules from a 
second MTOC, the apical polar ring, towards the basal end of the parasite. Once 
formed, the subpellicular microtubules are nondynamic, tethered to the cytosolic 
face of the parasite inner membrane complex (IMC), a collection of flattened 
vesicles originating from the ER-Golgi network (157). In addition to replication, 
microtubules play critical roles in a variety of aspects of Toxoplasma biology, 
including parasite motility, host cell attachment, and invasion; consequently, 
microtubules have emerged as attractive targets for therapeutic intervention 
(152). In addition, the mechanisms by which Toxoplasma microtubules are 
regulated is an active area of inquiry. 
 Microtubule functions are regulated by a diverse collection of post-
translational modifications (PTMs) that occur on the α- and β-tubulin subunits 
that make up microtubule polymers (158–161). Most of these tubulin PTMs occur 
on the C-terminal tails that extend out from the surface of the microtubules to 
regulate interactions with effector microtubule associated proteins (MAPs) (162, 
163). By contrast, acetylation of lysine 40 (K40) on α-tubulin is a unique PTM that 
resides within the lumen of microtubules (164, 165).  
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Several studies have implicated Elp3 as the major α-tubulin 
acetyltransferase. In Arabidopsis, tubulin affinity chromatography identified an 
Elp3 homolog (Elongata 3) which can bind to αβ-tubulin heterodimers (166). In 
2009, Elp3 was identified as an α-tubulin acetyltransferase required for radial 
migration and branching of mouse cortical projection neurons; similar neuronal 
migration defects were observed in an α-tubulin (K40A) mutant (81). In the same 
year, Elp3 was identified in a microsatellite-based genetic association study of 
amyotrophic lateral sclerosis (ALS), a progressive motor neuron degeneration 
disease in humans and further mutational studies in Drosophila concluded Elp3 
tubulin acetylation is critically important for the axonal biology of neurons (78, 
93). Mutations in Elongator are present in a second neurologic disease, familial 
dysautonomia (FD) which is thought to be caused by impaired vesicle trafficking 
along microtubules due to defects in tubulin acetylation (89). Furthermore, 
incubation of α-tubulin with a purified recombinant human ELP3 results in 
increased α-tubulin acetylation (81). In summary, several independent studies 
have identified Elp3 as an important factor in neuronal health and mechanistic 
studies implicate Elp3 as an α-tubulin acetyltransferase.  
However, a second enzyme has been identified as a tubulin 
acetyltransferase, Mec17/ATAT (167, 168) which is responsible for K40 
acetylation, a PTM conserved across eukaryotes.  Mec17/ATAT was originally 
identified in the flagella of the unicellular green algae Chlamydomonas reinhardtii 
(169, 170), K40 acetylation was subsequently found to be enriched on long-lived 
microtubules throughout higher eukaryotes (171, 172). Recent studies in C. 
elegans suggest that K40 acetylation stabilizes microtubules by promoting the 
formation of a salt bridge that augments interactions between α-tubulin subunits 
in adjacent protofilaments (173). Despite the mounting evidence supporting a 
role of K40 acetylation in microtubule stability, the biological function of this PTM 
in vivo remains unclear, as evidenced by the variety of phenotypes observed 
across numerous systems when K40 acetylation is manipulated (168, 174–176).  
 Numerous tubulin PTMs, including acetylation of K40, have been 
catalogued in Toxoplasma (55, 177–179), but the functional importance of these 
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modifications on microtubule dynamics and parasite biology remains largely 
undefined. In these studies, we establish the role of α-tubulin K40 acetylation by 
generating point mutants in endogenous α-tubulin and identified the Toxoplasma 
α-tubulin acetyltransferase orthologue (named TgATAT), not TgElp3, as the 
enzyme responsible for acetylating α-tubulin. Together, these approaches reveal 
that K40 acetylation is critical for stabilizing tachyzoite microtubules, which is 
required for daughter cell formation and karyokinesis. The discovery that 
TgATAT-mediated acetylation of α-tubulin is necessary for Toxoplasma 
replication establishes the importance of tubulin PTMs in apicomplexan parasites 
and uncovers a new opportunity for potential therapeutic exploitation. 
 
3.2 Materials and Methods 
3.2.1 Antibodies 
The following primary antibodies were used at the indicated dilutions:  
rabbit anti-T. gondii-β-tubulin (1:2,000; (156)), mouse anti-acetyl-K40-α-tubulin 
(1:2,000; Sigma 6-11-B-1), rabbit anti-acetyl-K40-α-tubulin (1:2,000; EMD 
Millipore ABT241), mouse anti-SAG1 (1:2,000; Genway), rat anti-IMC3 (1:2,000; 
(180)), rat anti-ISP1 (1:1,000; (181)), rabbit anti-Centrin 1 (1:1,000; (182)), 
mouse anti-Atrx1 (1:2,000; 11G8 (183)) and rat anti-HA (1:1,000; Roche). 
Secondary antibodies used for immunoblots include donkey anti-rabbit (1:2,000; 
GE Healthcare), sheep anti-mouse (1:5,000; GE Healthcare), and goat anti-rat 
(1:2,000; GE Healthcare) conjugated to horseradish peroxidase. Fluorophore-
conjugated secondary antibodies (AlexaFluor, ThermoFisher) were used for 
immunofluorescence assays at 1:2,000 dilutions (1:1,000 for TgATATHA). 
 
3.2.2 Parasite culture and transfection 
Toxoplasma parasites were maintained in HFFs with DMEM 
supplemented with 10% heat-inactivated FBS at 37°C and 5% CO2 (113). To 
assess parasite doubling time, purified tachyzoites were allowed to invade HFF 
monolayers in 12-well plates for 2 hours. Extracellular parasites were removed 
and infected monolayers were incubated for an additional 22 hours before being 
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fixed in methanol for staining with Differential Quick Staining Kit (Polysciences, 
Inc). For generation of TgTUBA1 K40 mutants, wild-type RH parasites were 
electroporated with 100 μg of linearized plasmid and selection medium 
containing 2.5 µM oryzalin was added 24 hours following transfection. Similarly, 
TgATATHA parasites were generated by transfection of RH∆hx∆Ku80 parasites 
(102, 103) with 75 µg of linearized plasmid and were selected with medium 
containing 1 µM pyrimethamine. Following 3 passages under drug selection, 
resistant parasites were cloned by limiting dilution in 96-well plates. 
 
3.2.3 Generation of TgTUBA1 K40 mutant parasites 
The plasmid construct described in (184) containing the TgTUBA1 
genomic sequence carrying T239I oryzalin-resistance mutation was used as 
template for site-directed mutagenesis using the QuikChange II Kit (Agilent) to 
introduce K40K silent, K40R and K40Q mutations using the primers 1-6 in 
Appendix B. This construct was then linearized by digestion with NotI-HF and 
HindIII-HF and transfected into RH strain parasites by electroporation as 
described above. Transfected parasites were selected by growth in media 
containing 2.5 µM oryzalin, and surviving parasites were cloned out by limiting 
dilution into 96-well plates. For the generation of V252L strains, T239I was 
restored to T239T and the V252L mutation was introduced using the Q5 Site 
Directed Mutagenesis Kit (New England Biolabs) using primers 7-10, and stable 
clones were selected as described above. Single clones were confirmed by PCR 
amplification of the TgTUBA1 locus from gDNA purified using the DNeasy Blood 
and Tissue Kit (Qiagen) and sequencing with primers 11 and 12. 
 
3.2.4 Endogenous tagging of TgATAT 
Genomic DNA was isolated from RH∆hx∆ku80 parasites and primers 13 
and 14 (Appendix B) were used to amplify ~1.2kb of the TgATAT gene just 
upstream of the stop codon. The In-Fusion HD cloning kit (Clontech) was used to 
clone the amplified TgATAT sequence into the PacI restriction site of 
pLIC.HA3.DHFR (121). Prior to transfection, 75 µg of plasmid DNA was 
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linearized by NcoI and electroporated into RH∆hx∆ku80 parasites. Following 
three passages under 1.0 μM pyrimethamine selection, parasites were cloned by 
limiting dilution, and positive clones were identified by immunoblotting. 
 
3.2.5 Immunoblotting 
Freshly egressed parasites were passed through 3.0 micron filters to 
remove host cell debris and then washed in PBS. Parasites were lysed in RIPA 
buffer supplemented with complete protease inhibitor cocktail (Roche), sonicated 
twice for 10s each using a microtip sonicator, and centrifuged at 21,000 x g for 
10 min at 4ºC to remove insoluble debris. Cleared lysate was subjected to SDS-
PAGE electrophoresis using pre-cast 4-20% Mini-PROTEAN TGX gels (BioRad) 
and resolved proteins were transferred to nitrocellulose membranes using Trans-
blot SD semi-dry transfer system (BioRad). Membranes were blocked in 5% 
milk/TBST, and probed with primary antibodies for 1.5 hours at room temperature 
or overnight at 4°C. Membranes were washed 3x 10 min in TBST and probed 
with secondary antibodies for 45 min at room temperature. Membranes were 
washed again 3x 10 min in TBST and proteins were detected using SuperSignal 
West Femto substrate (ThermoFisher) and imaged on a FluorChem R imager 
(Bio-Techne). 
 
3.2.6 IFAs 
Confluent HFF monolayers grown on coverslips in 24-well plates were 
infected with freshly lysed parasites. For all images of microtubules, cells were 
fixed with cold methanol, washed with PBS, and blocked for 30 min with 3% BSA 
in PBS. For imaging TgATATHA, cells were fixed with 4% paraformaldehyde in 
PBS, blocked for 30 min in 3% BSA/PBS, and permeabilized with PBS with 0.2% 
Triton X-100 (PBS-T) for 10 min. Primary antibodies diluted in 3% BSA/PBS were 
applied for 1.5 hours at room temperature or (for TgATATHA) overnight at 4°C in 
BSA/PBS-T. Coverslips were washed 3x 15 min with PBS and secondary 
antibodies were added in 3% BSA/PBS for 45 min. Following 3x 15 min washes 
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in PBS, coverslips were mounted using Vectashield antifade mounting medium 
(Vector Labs) containing 4′,6-diamidino-2-phenylindole (DAPI) to visualize nuclei.  
 
3.2.7 CRISPR-mediated disruption of TgATAT 
Plasmid described in (24825012) (GFP-Cas9/sgUPRT) was used for site-
directed mutagenesis using the Q5 Kit to mutate the single guide RNA sequence 
to target the TgATAT locus using primers 15 and 16. TgATATHA parasites were 
transfected with 50 µg of purified TgATAT- or UPRT-targeted GFP-Cas9 plasmid 
and 50 µg of 90 bp dsDNA oligos 17 and 18. Transfected populations were used 
to inoculate coverslips and were fixed at timepoints as indicated in figures. 
 
3.3 Results 
3.3.1 K40 acetylation is dispensable only if tubulin is stabilized through 
another mutation 
 Toxoplasma α-tubulin can be acetylated at lysine-40 (K40), but the 
functional significance of this post-translational modification (PTM) has yet to be 
addressed. Three α-tubulin isotypes are present in the Toxoplasma genome: 
TGME49_316400 (TgTUBA1), TGME49_231770 (putative alpha-tubulin I), and 
TGME49_231400 (tubulin/Ftsz family). TgTUBA1 is the only isotype expressed in 
tachyzoites and the only one that contains the conserved K40 residue reported 
as acetylated (177). To address the role of α-tubulin K40 acetylation in 
tachyzoites, we generated three parasite clones with different K40 mutations in 
the endogenous TgTUBA1 genomic locus:  (i) lysine to arginine (K40R), which 
conserves the positive charge of lysine but prevents acetylation, (ii) lysine to 
glutamine (K40Q), which is an acetyl-lysine mimic (185), or (iii) a silent mutation 
as a control (K40K). To select for positive clones harboring mutant K40, our 
construct included a second mutation that confers resistance to the microtubule-
disrupting drug oryzalin (184, 186). Since studies in other species suggest that 
K40 acetylation stabilizes microtubules, we chose to generate oryzalin resistance 
by mutating valine-252 to lysine (V252L), a mutation known to have no effect on 
microtubule stability (187).  
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Figure 20. Ablation of K40 acetylation is not tolerated unless replaced by the 
K40Q acetyl-lysine mimic. Reprinted from reference (188). 
A. Diagram of TgTUBA1 genomic locus aligned with the construct used to 
replace the endogenous locus by double homologous recombination. The 
construct contains the nonstabilizing V252L oryzalin resistance mutation and 
the K40K, K40R, or K40Q mutation. B. IFAs of K40 mutants stained for acetyl-
K40–α-tubulin (red) or β-tubulin (specific to Toxoplasma, green). The K40Q 
mutation results in complete loss of K40 acetylation in the parasite but not its 
host cell. Images were merged with the DNA stain DAPI (blue). Scale bars, 3 
μm. C. Western blot (WB) assay of parental RH and mutant parasites showing 
loss of K40 acetylation in K40Q mutants. The blot was probed with anti-acetyl-
K40–α-tubulin and anti-SAG1 antibodies as a loading control. D. Doubling 
assays performed to assess the growth of parental RH and mutant parasites. 
Replication rates were determined by counting the parasites within 100 random 
vacuoles at 24 h post-infection. Three independent trials were conducted, and 
the average percentage of vacuoles with the indicated number of parasites ± 
the standard error of the mean is shown (no significant difference between 
mean percentages of vacuoles at each stage between strains as determined by 
two-way analysis of variance). 
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We used an allelic replacement strategy to make K40 mutants using the 
non-stabilizing V252L mutation to confer oryzalin resistance (Figure 20). The 
TgTUBA1 gene was amplified from genomic DNA isolated from oryzalin-resistant 
clones and the presence of the expected mutations in each established line was 
confirmed by sequencing. While both K40K and K40Q mutations were readily 
obtained, K40R mutant parasites were never obtained despite seven 
independent attempts. The acetylation status of α-tubulin K40 was assessed 
using both immunofluorescence assays (IFA) and Western blot (Figure 20). 
K40Q mutant parasites show a complete loss of K40 acetylation (as expected, 
the glutamine acetyl-lysine mimic does not cross-react with the anti-K40-acetyl α-
tubulin antibody), but no obvious defects in any microtubule structures, as 
visualized using a Toxoplasma-specific β–tubulin antibody (Figure 20). Parasite 
growth assays further show that replacement of K40 with the glutamine acetyl-
lysine mimic (K40Q) did not affect replication rate (Figure 20). 
Some mutations in the oryzalin pocket stabilize microtubules by promoting 
protofilament interactions and tubulin polymerization (187). Given the reported 
role of K40 acetylation in microtubule stability, we hypothesized that an oryzalin-
resistant mutation in this binding pocket might allow for the generation of K40R 
mutants. We therefore generated constructs containing K40K, K40R, and K40Q 
using the T239I oryzalin binding pocket mutation (Figure 21), chosen for its 
similar levels of drug resistance as V252L (189). Sequencing of the TgTUBA1 
gene confirmed the presence of both mutations in the oryzalin-resistant clones. 
In the T239I oryzalin-resistant background, all K40 mutants including K40R were 
readily obtained. Both K40Q and K40R parasites showed a complete loss of K40 
acetylation as visualized by both IFA and Western blot (Figure 21), yet displayed 
no difference in replication relative to the silent mutation or wild-type (Figure 21). 
Our mutational analyses show that ablation of α-tubulin K40 acetylation is 
only possible when a second, stabilizing mutation is present (e.g., T239I), or 
when K40 is mutated to a residue (glutamine) that mimics an acetylated lysine. 
These results suggest that K40 acetylation is required in tachyzoites and likely 
contributes to the stabilization of microtubules. 
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Figure 21. K40 acetylation is dispensible in the presence of the T239I oryzalin 
resistance mutation. Reprinted from reference (188). 
A. Diagram of the TgTUBA1 genomic locus aligned with the allelic replacement 
construct containing the oryzalin resistance mutation T239I and the K40K, K40R, 
or K40Q mutation. B. IFAs of mutant parasite lines stained for acetyl-K40–α-
tubulin (red) or β-tubulin (green). Images were merged with the DNA stain DAPI 
(blue). Scale bars, 3 μm. C. Western blot (WB) assay of parental RH and 
mutants confirms the loss of K40 acetylation in K40Q and K40R parasites. The 
blots were probed with anti-acetyl-K40–α-tubulin and anti-SAG1 antibodies as a 
loading control. D. Doubling assays performed as described in the legend to Fig. 
1D to assess the growth of parental RH and mutant parasites. 
 
3.3.2 Identification of an acetyltransferase that co-localizes with acetylated 
tubulin during tachyzoite division 
To further characterize the role of α-tubulin K40 acetylation in tachyzoites, 
we sought to identify the enzyme delivering this PTM. In other species, Alpha-
Tubulin AcetylTransferase (ATAT, also known as Mec17) has been implicated as 
the primary enzyme acetylating tubulin (167, 168, 190, 191). A bioinformatics 
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survey of ToxoDB.org v.24 (192) revealed a single gene containing a Mec17-
domain belonging to the Gcn5-related superfamily, TGME49_319600, which we 
will refer to as TgATAT. TgATAT is located on chromosome IV and contains two 
exons encoding a predicted protein of 907 amino acids (Figure 22). We aligned 
the lysine acetyltransferase (KAT) domains of ATAT homologues from several 
representative species using Clustal Omega (192, 193) (Figure 22). Interestingly, 
while the Mec-17 domain is highly conserved, including the key residues critical 
for enzymatic activity (Figure 22), the predicted TgATAT protein is considerably 
larger compared to all previously characterized ATAT/Mec17 proteins (Figure 22) 
(168, 189). TgATAT transcripts are expressed in tachyzoites, peaking in the early 
stages of mitosis, waning during cytokinesis, and remaining at basal levels during 
interphase, suggesting that TgATAT is a cell-cycle regulated protein (194). 
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Figure 22. Comparison of ATAT/Mec-17 homologues. Reprinted from 
reference (188). 
A. Depiction of ATAT protein sequences from T. gondii (TgATAT, 
TGME49_31600), Plasmodium falciparum (PfATAT, PF3D7_0924900), Homo 
sapiens (HsMec17, XP_005249477.1), Tetrahymena thermophila (TtMec17, 
TTHERM_00355780), and C. elegans (CeATAT2, CELE_W06B11.1), with the 
number of amino acids (aa) in parentheses. Gray boxes represent the lysine 
acetyltransferase domain. B. Amino acid sequence alignment of the KAT 
domain of the indicated ATAT homologues with identical residues highlighted 
in black and similar residues highlighted in gray. The asterisk denotes an 
aspartic acid residue previously shown to be important for ATAT activity (189). 
 
 To confirm the unusual size and assess the expression patterns of 
TgATAT, we introduced three C-terminal hemaggluttinin (3xHA) epitope tags at 
the endogenous TgATAT locus using single-crossover homologous 
recombination in the RH∆ku80∆hxgprt parasites (102, 121). TgATATHA resolves 
as a single band migrating at the predicted size of 98 kDa, and the C-terminal 
3xHA tag had no effect on K40 acetylation (Figure 23). IFAs show that TgATATHA 
exhibit cell-cycle regulated expression, with low-levels appearing during S phase 
and mitosis and peak levels occurring during early cytokinesis (Figure 23). In 
agreement with the mRNA expression data (194), TgATATHA protein levels 
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decrease as tachyzoites complete division and then remain undetectable 
throughout interphase (Figure 23). In agreement with other studies (178, 179), 
we observe that α-tubulin K40 acetylation occurs at both spindle and 
subpellicular microtubules during early daughter formation (Figure 23). 
Collectively, these findings suggest that TgATAT is expressed during the early 
stages of tachyzoite replication, when acetylation of nascent microtubule 
structures occurs. These findings strongly support that K40 acetylation is 
mediated by TgATAT and there is little evidence that TgElp3 functions as a 
tubulin acetyltransferase in Toxoplasma.    
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Figure 23. Expression of TgATAT and acetylated α-tubulin during the tachyzoite 
cell cycle. Reprinted from reference (188). 
A. Western blot (WB) assay of lysates from the parental strain (RHΔhxΔku80) 
and parasites containing endogenously HA-tagged TgATAT (TgATATHA). The 
blot was probed with antibodies recognizing the HA epitope or acetyl-K40–α-
tubulin. β-Tubulin was also probed as a loading control. B. IFAs of TgATATHA 
parasites stained for HA (red, TgATATHA) or β-tubulin (green) at the indicated 
stages of the parasite cell cycle. Images were merged with the DNA stain DAPI 
(blue). C. IFAs of RH parasites stained for acetyl-K40–α-tubulin (red) or β-
tubulin (green) at the indicated stages of the parasite cell cycle. Note that K40 
acetylation is present on both spindle microtubules during mitosis and in the 
daughter subpellicular microtubules throughout replication. Scale bar, 3 μm. 
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3.3.3 Disruption of TgATAT leads to loss of α-tubulin K40 acetylation 
To determine the impact of TgATAT on α-tubulin K40 acetylation, we 
attempted to knockout the genomic locus using double homologous 
recombination but could not isolate viable clones, suggesting that TgATAT may 
be essential in tachyzoites. We then employed the CRISPR/Cas9 system 
recently reported for Toxoplasma (195, 196) by transfecting a plasmid encoding 
a GFP-Cas9 fusion and a TgATAT-targeting single guide RNA (sgRNA) into our 
TgATATHA parasites. Along with the GFP-Cas9/sgRNA plasmid, we co-
transfected a dsDNA oligomer containing four stop codons flanked by short 
regions of homology to the TgATAT Cas9 cleavage site to ensure disruption of 
the gene, and the loss of TgATATHA protein was subsequently confirmed by IFA 
(Figure 24). A control transfection was performed using the aforementioned 
dsDNA oligomer and the GFP-Cas9 plasmid containing sequences encoding a 
sgRNA targeting the unrelated and nonessential uracil phosphoribosyltransferase 
(UPRT) gene (196). Transfected parasites were inoculated onto human foreskin 
fibroblasts (HFF) and the infected monolayers were fixed after 20 hours so that 
the expression of GFP-Cas9 could be observed by fluorescence microscopy 
(Figure 24). In parasites transfected with the UPRT targeting construct, we 
observed 13% (30/231) expressing GFP-Cas9; in contrast, GFP-Cas9 
expression was observed at a lower frequency in parasites transfected with 
TgATAT-targeting sgRNA (2.89±0.93% SEM, n=3). Importantly, α-tubulin K40 
acetylation was completely abolished in the majority of the GFP-Cas9 positive 
parasites transfected with the TgATAT-targeting sgRNA (57.8±4.97% SEM, n=3) 
but never diminished in GFP-Cas9 positive parasites transfected with the control 
UPRT-targeting sgRNA (Figure 24). At 40 hours post-transfection, the number of 
GFP-Cas9 positive parasites lacking α-tubulin K40 acetylation increased to 
76.1±2.01% (SEM, n=3) in TgATAT-sgRNA transfected populations. The inability 
to detect α-tubulin K40 acetylation when the TgATAT locus is selectively targeted 
for CRISPR/Cas9-mediated disruption strongly suggests that TgATAT is the 
major α-tubulin K40 acetyltransferase in Toxoplasma and not TgElp3.  
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Figure 24. Selective targeting of GFP-Cas9 to the TgATAT locus eliminates 
K40 acetylation. Reprinted from reference (188).  
A. Diagram showing the site on TgATAT targeted by GFP-Cas9. The 20-bp 
TgATAT sgRNA sequence is shown; it is immediately upstream of the 
protospacer adjacent motif sequence (PAM, red). The dsDNA oligomer used 
for recombination is shown, and in brackets are the numbers of bases of 
homology flanking the PAM site. Underlined is the exogenous sequence 
introduced, including the four stop codons in bold. IFAs of dividing parasites 
expressing GFP-Cas9 confirm that disruption of TgATAT and loss of K40 
acetylation occur only when Cas9 is targeted to the TgATAT locus 
(sgTgATAT). B. IFA of TgATATHA parasites 40 h posttransfection with dsDNA 
oligomers and GFP-Cas9 targeted to either the UPRT (sgUPRT) or the 
TgATAT (sgTgATAT) locus. Scale bar, 3 μm. C. Bar graph showing the 
percentage of GFP-Cas9-positive vacuoles that are acetyl-K40 negative in 
parasites in which GFP-Cas9 was targeted to UPRT (sgUPRT) versus TgATAT 
(sgTgATAT) 20 or 40 h after transfection. Error bars show the standard errors 
of the means (n = 3). 
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3.3.4 Loss of K40 acetylation causes microtubule defects and impairs 
replication.  
GFP-Cas9 expressing parasites transfected with the UPRT targeting 
control retained acetylated α-tubulin and displayed normal microtubule structures 
40 hours post-transfection, as did TgATAT-sgRNA transfectants that lacked 
GFP-Cas9 expression (Figure 25). In contrast, TgATAT-sgRNA transfectants 
expressing GFP-Cas9 that lost α-tubulin acetylation exhibited abnormal 
morphology (Figure 25, phase, compare acetyl-K40 positive parasites in inset i 
with acetyl-K40 negative parasites in inset ii). DAPI-staining revealed that the 
parasites lacking K40 acetylation possessed nuclei that were grossly deformed, 
as if they failed to complete karyokinesis (Figure 25, inset ii, asterisks). TgATAT-
sgRNA transfectants that retained acetylated α-tubulin contain nuclei of uniform 
shape and area (as measured in pixels), whereas parasites lacking acetylated α-
tubulin possess a wide variety of DAPI-staining structures that are abnormal in 
size and shape (Figure 25). Of note, while large nuclei that appeared to have 
undergone genomic duplication were frequently observed, the classic horseshoe 
shape of the nucleus routinely seen during cytokinesis was largely absent in 
parasites lacking K40 acetylation. Further, many of the parasites lacking K40 
acetylation contained daughter parasites that were devoid of nuclear material 
(Figure 25, inset i, arrowheads). Parasites lacking K40 acetylation were also 
observed to possess numerous additional cytoplasmic β-tubulin-containing 
structures, many of which resembled caps of budding daughter cells (Figure 25, 
inset ii, arrows); in these parasites, the mother’s microtubules and cytoskeleton 
fail to undergo recycling to the residual body and instead appear to remain intact 
while the formation of multiple daughter parasites seems to have been initiated. 
Despite this evidence of early daughter bud initiation, proper formation of the 
mature cytoskeleton appears to be impaired upon loss of K40 acetylation, as a 
variety of abnormal parasite sizes and shapes are observed (Figure 25, phase 
and β-tubulin channels). Together, these defects in cytokinesis and cytoskeleton 
formation suggest that K40 acetylation likely impacts both spindle and 
subpellicular microtubule populations. 
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Figure 25. Defects in nuclear division and segregation in parasites lacking α-
tubulin K40 acetylation. Reprinted from reference (188). 
A. TgATATHA parasites were transfected with GFP-Cas9-sgTgATAT and 
imaged at 40 h post-transfection. Shown are transfectants lacking GFP-Cas9 
expression, which display normal replication and have microtubules containing 
K40 acetylation, as visualized with anti-β-tubulin (green) and acetyl-K40–α-
tubulin (red) antibodies, with DAPI co-stain in blue. B. Parasites expressing 
GFP-Cas9 lose K40 acetylation and contain abnormal nuclear morphology 
compared to that of parasites possessing K40 acetylation. Nuclei were 
visualized by DAPI staining (blue). Insets of acetyl-K40-positive (i) and -
negative (ii) parasites are shown and expanded in the lower panels. The DAPI-
stained structures was measured with ImageJ (n = 100 nuclei). Double 
asterisks indicate a significant difference in mean area, as determined by 
unpaired t test with Welch’s correction for unequal variance (P = 0.0085). C. 
Vacuoles containing parasites lacking acetylated microtubules (red) and 
showing aberrant phenotypes detected by staining all of the microtubules 
(green) and DNA (blue) are shown. Inset i shows that parasites lacking K40 
acetylation have defects in microtubule structures and fail to partition nuclear 
material into daughter parasites. Anucleate parasites are marked by 
arrowheads, while the improperly segregated nuclear mass is indicated by the 
asterisk. Inset ii shows parasites containing multiple β-tubulin structures 
resembling daughter cell conoids (arrows). Scale bar, 3 μm. 
 
 To explore these replication defects more closely, we examined early 
steps in Toxoplasma endodyogeny when the duplication of the centrosome and 
subsequent division of the apicoplast occur (197). Control parasites containing 
K40 acetylation have either a single or duplicated centrosome per nucleus 
(Figure 26, arrowhead), as well as a single apicoplast (Figure 26, arrowhead). 
Parasites lacking K40 acetylation can still duplicate centrosomes; however, those 
with defects in nuclear division often had >2 centrosomes per nucleus (Figure 26, 
arrows). Additionally, parasites lacking K40 acetylated α-tubulin often contained 
large, irregular apicoplasts, suggesting a role for acetylated α-tubulin in the 
proper division of this organelle (Figure 26, arrows).  
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Figure 26. Centrosome duplication and apicoplast division in parasites lacking 
K40 acetylation. Reprinted from reference (188). 
A. Duplication of the centrosomes occurs in the presence (top row, arrowhead) 
or absence of K40 α-tubulin acetylation (bottom row, arrowheads), as visualized 
by IFA staining for centrin 1 (red), acetyl-K40–α-tubulin (green), and DNA 
(DAPI, blue). K40-acetylated α-tubulin and GFP-Cas9 (localized to the nucleus) 
were detected in the same channel (green). Note the loss of acetylated α-
tubulin and GFP-Cas9-expressing parasites. Dotted lines encircle individual 
parasites with arrowheads indicating multiple centrosomes. B.IFAs of parasites 
stained for apicoplast membrane protein Atrx1 (red), acetyl-K40–α-tubulin 
(green), DNA (DAPI, blue), and GFP-Cas9 (green, nuclear). Apicoplasts that 
underwent normal division are visible in acetyl-K40-positive parasites (top row, 
arrowhead). Apicoplasts that failed to divide in parasites lacking K40 acetylation 
(bottom row) are indicated by arrows. Scale bars, 3 μm. 
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Centrosome duplication is followed by formation of the daughter bud 
apical complex. As we observed evidence of apical conoid formation in the 
absence of K40 acetylation (Figure 25, arrowheads), we investigated whether 
K40 acetylation was required to recruit the IMC and IMC subcompartment 
proteins (ISPs) to the nascent daughter cytoskeleton. During interphase, ISP1 
localizes to the apical cap of each parasite (Figure 27), and is recruited to the 
apical regions of the daughter buds during bud formation (181). While parasites 
containing acetylated α-tubulin showed two ISP1-labeled apical caps per dividing 
parasite, loss of α-tubulin acetylation resulted in parasites containing multiple 
ISP1 structures per nucleus (Figure 27, arrowhead). In parasites lacking 
acetylated α-tubulin, IFAs staining for IMC3, which localizes to the IMC following 
recruitment of ISP1 to daughter caps, revealed the presence of multiple IMC 
structures forming within a single parasite (Figure 27, arrowheads). Taken 
together, these results suggest that acetylation of α-tubulin at K40 is dispensable 
for initiation of mitosis and the early steps of daughter cell formation, but is 
required for karyokinesis, apicoplast division, and completion of Toxoplasma 
replication. 
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Figure 27. Daughter cytoskeleton completion is impaired upon loss of K40 
acetylation. Reprinted from reference (188). 
A. IFA visualizing ISP1 (red), acetyl-K40–α-tubulin (green), DNA (DAPI, blue), 
and GFP-Cas9 (green, nuclear) in normal parasites (top) versus those lacking 
acetylated α-tubulin (bottom). Dotted lines encircle an individual parasites 
containing excess daughter buds (bottom row, arrowhead), as visualized by 
numerous ISP1-positive apical cap structures. B. IFA stained for IMC3 (red), 
acetyl-K40–α-tubulin (green), DNA (DAPI, blue), and GFP-Cas9 (green, 
nuclear). Arrowheads indicate multiple IMC3-positive structures in parasites 
lacking K40 α-tubulin acetylation, indicative of partially formed daughter cells 
that failed to complete division. Scale bars, 3 μm. 
 
3.4 Discussion 
In this study, we addressed the biological role of α-tubulin K40 acetylation 
in the protozoan pathogen Toxoplasma using two independent genetic 
approaches that ablated either the modifying enzyme or the substrate. Our 
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mutational analyses of TgTUBA1 show that mutation of K40 to glutamine, an 
acetyl-lysine mimic, is tolerated, while mutation to arginine is inviable unless a 
secondary mutation that stabilizes microtubules is made. Additionally, we have 
identified that the KAT responsible for mediating K40-acetylation is TgATAT (not 
TgElp3). Loss of K40 acetylation following CRISPR/Cas9-mediated disruption of 
the TgATAT locus severely impairs nuclear division and parasite replication. 
Interestingly, many of the phenotypes we observed upon the disruption of 
K40 α-tubulin acetylation parallel the effects observed when microtubules are 
destabilized with oryzalin (155, 156, 186, 198, 199). Treatment of intracellular 
parasites with oryzalin prevents completion of the daughter budding process, 
although nuclei size increased and centriole replication occurred (187). Additional 
studies show that destabilization of the spindle microtubules by oryzalin results in 
the formation of anuclear “zoids”, similar to what we observed in parasites 
lacking K40 acetylation (Figure 25) (156). Importantly, EM analysis of oryzalin-
treated parasites showed that numerous daughter conoids form within mother 
parasites when nuclear division failed. This bears a striking resemblance to the 
defects we observed in parasites lacking K40 acetylation, as we detect numerous 
structures resembling daughter caps that stain positive for β-tubulin, ISP1, and 
IMC3 (Figure 25, Figure 27). Early stages of parasite division, including 
replication of genomic DNA, duplication of the centrosomes, and daughter bud 
initiation, remain intact following loss of K40 acetylation, again mirroring what is 
seen in oryzalin-treated parasites. In addition to defects in nuclear division, we 
also see evidence that apicoplast division is impaired in parasites without K40 
acetylation (Figure 26, arrows). This agrees with studies showing that apicoplast 
division is a microtubule-dependent process that occurs temporally with nuclear 
division and is disrupted by oryzalin treatment (200). Together, these results 
suggest that acetylation of α-tubulin at K40 plays an important role in stabilizing 
both the subpellicular and mitotic spindle populations of microtubules in 
Toxoplasma, and that this microtubule stabilization is especially critical for proper 
tachyzoite replication. 
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Our mutational analyses of TgTUBA1 showed that the function of K40 
acetylation can be mimicked by substitution of K40 with glutamine (Figure 20), in 
agreement with findings in both C. elegans and R. norvegicus (167, 201). 
Molecular dynamics simulations provide a plausible explanation for the ability of 
the K40Q substitution to effectively mimic K40 acetylation. In those simulations, 
acetylation of K40 on α-tubulin disrupts an intra-monomeric salt bridge between 
α-tubulin residues K40 and E55, a residue conserved in Toxoplasma α-tubulin. 
This disruption allows for the acetyl-group on K40 to form a new salt bridge with 
H283 (also conserved in Toxoplasma) of an α-tubulin monomer in an adjacent 
protofilament (173). Mutation of K40 to arginine would chemically allow for salt 
bridge formation with the carboxyl-group of E55 while preventing inter-
protofilament salt bridge formation through H283. Conversely, mutation of K40 to 
glutamine would constitutively promote salt bridge formation between the 
glutamine carboxyl group (Q40) with the imidazole group (H283) located on the 
adjacent protofilament. Therefore, our ability to generate parasites expressing 
only Q40 in the non-stabilizing V252L background suggests that salt bridge 
formation between protofilaments is important for microtubule structure and 
stability.  
The ability to generate K40R mutants in the T239I background further 
speaks to the role of K40 acetylation in Toxoplasma microtubule stability. T239I 
resides in the H7 helix of α-tubulin and is within the oryzalin binding pocket (202). 
Mutation of another binding pocket residue (L136F) stabilized microtubules by 
promoting interactions between α-tubulin subunits within the microtubule lattice 
(187). Together, these data suggest that oryzalin-resistance generated by 
mutating binding pocket residues may also lead to increased inter-protofilament 
interactions, which is similar to the proposed mechanism by which K40 
acetylation promotes microtubule stability discussed above. Therefore, it is 
plausible that like L136F, the T239I mutation stabilizes microtubules and 
compensates for the loss of stability when K40 acetylation is nullified. 
To further determine the biological importance of α-tubulin K40 acetylation 
in Toxoplasma, we identified and disrupted the α-tubulin acetyltransferase, 
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TgATAT. Endogenous tagging of the TgATAT locus revealed a cell-cycle 
expression pattern that correlated temporally with enriched regions of α-tubulin 
acetylation during parasite replication. These results agree with a recent report 
noting that α-tubulin K40 acetylation occurs after spindle microtubule assembly in 
early daughter formation (179). TgATAT is considerably larger than all previously 
characterized ATAT/Mec17 proteins, possessing highly divergent sequences 
flaking the conserved Mec17-domain (Figure 22). Further bioinformatic analysis 
revealed that select species within the coccidian subclass of the Apicomplexa 
phylum also possess a large TgATAT homologue, 89 kDa in Neospora caninum 
(NCLIV_010560) and 98 kDa in Hammondia hammondia (HHA_319600). Our 
CRISPR-mediated disruption of TgATAT indicates that it is the primary α-tubulin 
acetyltransferase in Toxoplasma. As TgATAT is essential for parasite replication 
and has divergent features, it may make an attractive potential drug target. 
While mammalian ATAT has been shown to localize to the lumen of the 
microtubule where it exerts its KAT activity (203), the considerably larger size of 
the apicomplexan orthologues may seem to preclude their access to this site. 
However, recent in vitro studies using polymerized microtubules have shown that 
large macromolecules, such as the full-length 6-11B-1 anti-acetyl-K40-α-tubulin 
antibody (~150 kDa), are able to enter the lumen of microtubules (203). Other 
studies have also reported that ATAT/Mec17 can bind to the exterior surface of 
microtubules; if microtubules undergo lateral opening between protofilaments, 
the K40 substrate could be exposed for acetylation (204, 205). Further studies 
are required to address exactly how TgATAT gains access to its substrate. 
Whether TgATAT has additional substrates is also an intriguing question for 
future study. Outside of ATAT/Mec17 itself (206), no other substrates have been 
reported for this family of KATs to date. 
Our analysis of K40 acetylation provides the first detailed look at the 
functional role and importance of tubulin modifications in Toxoplasma biology. 
Given that many other tubulin PTMs have been reported for Toxoplasma (177), it 
is likely that these modifications may also contribute to regulating microtubule 
function in the parasite. While dissecting the biological role of these PTMs in 
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other species is complicated by the expression of multiple α-tubulin isotypes, 
their function in Toxoplasma tachyzoites may be easier to determine as only 
TgTUBA1 is expressed in this stage. The identification and characterization of 
the enzymes responsible for mediating these PTMs provides an exciting new 
field of study for the development of novel therapeutics to treat toxoplasmosis. 
 
3.5 Concluding Remarks 
 Unlike higher eukaryotes, Elp3 in Toxoplasma does not function as an 
alpha-tubulin acetyltransferase. Instead, we identified TgATAT as the enzyme 
responsible for K40 acetylation. Our experimental findings determined that K40 
acetylation is essential for parasite replication, making this an exciting new 
avenue to explore for future drug development. However, we still do not know the 
enzymatic function of TgElp3. Despite strong sequence homology of the KAT 
and rSAM domains of TgElp3 with higher eukaryotes, our data suggests that it 
may function differently in Toxoplasma. Supporting this idea, TgElp3 contains a 
transmembrane domain which is only found in the phylum Apicomplexa and a 
few select species. Seeing that this transmembrane domain is not present in 
higher eukaryotes and that parasite viability is dependent on TgElp3 localization 
to the outer mitochondrial membrane, in the next chapter we explore this 
trafficking mechanism. 
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CHAPTER 4: Targeting of TgElp3 and other tail-anchored proteins to 
subcellular organelles in Toxoplasma gondii 
4.1 Introduction 
In Toxoplasma gondii, selective permeabilization experiments determined 
TgElp3 is positioned at the OMM with the N-terminal domains facing the 
cytoplasm (83). Proteins like TgElp3 with a single TMD positioned within 30 
amino acids of the C-terminus and uniquely positioned with the N-terminal 
domain protruding into the cytosol are classified as tail-anchored (TA) proteins 
(207, 208). Interestingly, only Elp3 homologues identified in the Apicomplexa 
phylum and a few select species possess a C-terminal TMD, suggesting Elp3 
may have functions pre-dating the evolution of the Elongator complex. Moreover, 
localization of TgElp3 to the parasite mitochondrion is essential for Toxoplasma 
viability signifying a possible role specific to this organelle.   
Organellar localization and lipid membrane integration are highly 
dependent on the TA protein TMD sequence (208). Numerous biological 
processes including vesicle-mediated trafficking, protein translocation and the 
regulation of apoptosis are reliant on correct TA protein localization (209–211). 
Due to the notable position of the C-terminal TMD sequence, translation 
termination must occur prior to the exit of the TMD sequence from the ribosome 
(212, 213). Thus, the localization of TA proteins to their target membranes must 
ensue in a post-translational dependent manner (212).  
Post-translational targeting of TA proteins to the ER is well characterized 
in some species, with 4 distinct targeting mechanisms: Hsc70/Hsp40 (214–216), 
TRC40/Asna1/Get1 (217–219), SRP assisted insertion (212, 220) and 
unassisted insertion (221–223). TA proteins residing in the Golgi apparatus first 
insert into the ER and then are trafficked to the Golgi (210). Less well-
characterized is the trafficking and targeting of TA proteins to the mitochondria 
and other organelles. Compared to ER-targeted TA proteins, mitochondrial TA 
proteins tend to possess TMDs that are shorter and moderately hydrophobic 
(207). Additionally, studies in Saccharomyces cerevisiae have shown that low 
levels of ergosterol present in the OMM can strongly influence unassisted TMD 
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integration (224). Most recently, a dibasic targeting motif was identified in many 
OMM-TA targeted proteins in Arabidopsis thaliana (225). Despite the 
identification of several TA trafficking mechanisms, localization to distinct 
subcellular organelles is complex and needs further study. The discovery of TA 
proteins in the early-branching eukaryote Toxoplasma speaks to the antiquity of 
this trafficking system in eukaryotic cells and to date, no detailed studies of TA 
proteins have been performed in protozoa. 
Previous bioinformatics surveys have identified putative TA proteins in 
several species including Saccharomyces cerevisiae (55 TA proteins) (226), 
Arabidopsis thaliana (454 TA proteins) (227), and Homo sapiens (325 TA 
proteins) (228). To identify how TgElp3 localizes to the parasite mitochondrion, 
we followed a similar approach to identify and characterize other potential TA 
proteins in Toxoplasma. In collaboration with Dr. Gustavo Arrizabalaga we 
identified 59 putative TA proteins, 9 of which contained representative features 
we dissected further. The results revealed novel TA proteins trafficking to specific 
subcellular organelles in Toxoplasma, including the parasite ER, mitochondrion 
and Golgi apparatus. Domain-swapping strategies were also employed to gain 
insight into the targeting mechanisms of these Toxoplasma TA proteins, including 
TgElp3. 
 
4.2 Materials and Methods 
4.2.1 Parasite culture and transfection 
For all experiments the starting Toxoplasma strain was RH. Parasites 
were maintained in confluent human foreskin fibroblast (HFF) monolayers with 
Dulbecco’s modified Eagle’s medium supplemented with 1% heat-inactivated 
fetal bovine serum at 37°C and 5% CO2 (113). Wild-type RH strain parasites 
were electroporated with 75μg of plasmid and allowed to infect fresh HFFs; 24 
hours post-transfection, 1μM pyrimethamine was added to select for transgenic 
parasites (100). 
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4.2.2 Bioinformatics analyses 
Annotated Toxoplasma proteins from strain ME49 in release 9.0 of the 
genome database (ToxoDB.org) were downloaded as a single FASTA file. The 
FASTA file was submitted to the TMHMM (version 2.0, 
http://www.cbs.dtu.dk/services/TMHMM/) (229) and DAS 
(http://www.sbc.su.se/~miklos/DAS/) (230) transmembrane prediction sites for 
batch analysis. With both prediction sites default parameters were used. Proteins 
that were predicted to possess a single transmembrane domain were analyzed 
for its position within the protein sequence. Those for which the transmembrane 
domain was followed by only 30 or less amino acids were considered as putative 
TA proteins.  
Total hydrophobicity of each putative TA protein TMD was calculated 
using the Kyte and Doolittle hydrophobicity scale, default parameters were used 
(http://web.expasy.org/protscale/) (231). 
 
4.2.3 Plasmid DNA construction 
4.2.3.1 HA-tagging vectors 
All generated DNA vectors are listed in Appendix E and all primers used 
are listed in Appendix F. To generate constructs for immunolocalization, a 
Toxoplasma expression vector was generated that fuses an N-terminal 
hemagglutinin (HA)-tag to the protein under study. The DHFR 3’ UTR was 
amplified from the pHXGPRT:tub vector using primers F1 and R1 and inserted 
into the Toxoplasma expression vector pDHFR-TS at the HindIII restriction site 
(DHFR 3’UTR-pDHFR-TS) (99, 100). Next, the tubulin promoter-5’UTR-HA-tag 
(TubHA) was amplified from the HATgElp3 plasmid using primers F2 and R2 and 
inserted upstream into the ApaI restriction site of the DHFR 3’UTR-pDHFR-TS 
plasmid (TubHA-EcorV-DHFR 3’UTR-pDHFR-TS) (83, 100). EcoRV restrictions 
sites were inserted into both the TubHA and 3’UTR DHFR PCR fragments to 
generate in-frame restriction sites used for insertion of gene amplicons. RNA was 
extracted from RH∆hxgprt (or Pru∆ku80∆hxgprt for Cytb-5) parasites using the 
RNeasy Plus mini kit (Qiagen; #74134) and cDNA was prepared using the 
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Omniscript RT kit (Qiagen; #205111). Genes were amplified starting with the first 
nucleotide downstream of the start codon through the stop codon from cDNA. All 
primers are listed in Appendix F. PCR amplicons were inserted into the EcorV 
sites of the HA-tagging plasmid (TubHA-EcorV-DHFR 3’UTR-pDHFR-TS) using 
the in-Fusion HD cloning kit (Clontech; #011614). 
 
4.2.3.2 YFP-fusion vectors 
An N-terminal YFP-fusion construct was generated by amplifying the 
tubulin promoter-5’UTR-YFP (TubYFP) using primers F2 and R2-2 (Appendix F) 
from the previously published YFP-C construct (83). This fragment was inserted 
into the ApaI restriction site of the DHFR 3’UTR-pDHFR-TS plasmid described 
above. Similarly, PCR was used to insert in-frame EcorV restriction sites 
downstream of the TubYFP and upstream of the 3’UTR-pDHFR to create the 
YFP-tagging plasmid, TubYFP-EcorV-DHFR3’UTR-pDHFR-TS. DNA fragments 
encoding the tail anchor signal for each gene including ten amino acids upstream 
of the predicted transmembrane domain, the transmembrane domain, and the 
flanking C-terminal sequence were amplified from the HA-tagging constructs 
using primers listed in Appendix F. These fragments were inserted into the EcorV 
restriction sites using the in-Fusion HD cloning kit (Clontech; #011614).  
 
4.2.3.3 Domain-swap vectors 
For constructs in which only the CTS was swapped, PCR amplification 
was performed using primers to insert the designated CTS mutations (See 
Appendices E and F for primers used and their sequences). Constructs 
containing the replacement of the TMD and CTS were created by fusing two 
different gene fragments that were each amplified from the gene-specific HA-
tagging constructs described above. To generate the TMD replacement 
constructs, the cytoplasmic domain and TMD were amplified from the TMD-CTS 
domain swapping plasmids; primers were used to insert the CTS corresponding 
to the cytoplasmic domain. For all domain swapping constructs, amplicons were 
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inserted into the EcorV sites of the TubHA-EcorV-DHFR 3’UTR-pDHFR-TS 
construct using the in-Fusion HD cloning kit (Clontech; #011614). 
 
4.2.4 Immunofluorescence Assays 
Confluent HFF monolayers grown on coverslips in 24-well plates were 
infected with freshly lysed parasites. Infected host cells were fixed with 4% 
paraformaldehyde in PBS, blocked for 30 min in 3% BSA+PBS, and 
permeabilized with 0.2% Triton X-100 (PBS-T) for 10 min. Primary antibodies 
(see below) diluted in 3% BSA-PBS were applied overnight at 4°C. Cultures were 
washed three times for 10 min each with PBS. Secondary antibodies diluted in 
3% BSA-PBS were applied for 1hr at room temperature. Coverslips were washed 
three times for 10 min and 4’,6-Diamidino-2-phenylindole dihydrochloride (DAPI, 
Life Technologies; #D1306) diluted 1:1,000 in PBS was applied for 10 mins at 
room temperature. Following three 10 min washes, coverslips were mounted 
using Vectashield antifade mounting medium (Vector Labs; #H-1000).  
The following primary antibodies were used at the dilutions indicated:  rat 
anti-HA (1:2,000; Roche #11867423001), rabbit anti-HA (1:2,000; Cell Signaling 
Technology #3724), mouse anti-TgF1B-ATPase (1:4,000; (109)), rat anti-
TgSORTLR (1:2,000; (232)) and mouse anti-TgSERCA (1:2,000; (233)). 
Secondary antibodies conjugated to a fluorophore (Alexa Fluor; Thermo Fisher 
#A11005, #A11006, #A11007, #A11034) were used for IFAs at a 1:5,000 dilution. 
 
4.3 Results and Discussion 
4.3.1 Identification of TA membrane proteins in Toxoplasma 
We previously identified TgElp3 as a TA membrane protein in Toxoplasma 
that resides at the outer membrane of the parasite’s single mitochondrion (83). 
We performed a bioinformatics survey to identify other candidate TA proteins in 
the parasite in order to investigate targeting of this unusual protein family in an 
early-branching eukaryote. For this analysis, FASTA sequences for each 
annotated Toxoplasma protein were downloaded from ToxoDB.org v.9.0 (192) 
and analyzed for the presence of a single transmembrane within 30 amino acids 
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of the C-terminus using the prediction servers TMHMM 
(http://www.cbs.dtu.dk/services/TMHMM/) (229) and DAS 
(http://www.sbc.su.se/~miklos/DAS/) (234). Only proteins predicted to have a 
single transmembrane were analyzed using SignalP 
(http://www.cbs.dtu.dk/services/SignalP/) and proteins devoid of a signal 
sequence were included in our list of putative TA proteins (Figure 28, Table 2 
and Appendix D). Of the 57 predicted Toxoplasma TA proteins, nearly half (25 
out of 57) are annotated as hypothetical proteins with unknown function. A few 
proteins (5) appear to be parasite specific, and the remaining 27 proteins contain 
conserved domains that make them likely homologues that have been 
characterized in other species (Appendix D). 
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Figure 28. Identification of putative tail-anchored (TA) proteins in Toxoplasma. 
A. Flow diagram listing the bioinformatics steps performed to identify putative 
TA proteins is shown. The computational tools used and the number of 
proteins retained at each step are listed. B. Average amino acid frequencies 
were calculated for the predicted transmembrane domain (TMD) sequence and 
subsequent C-terminal sequence (CTS). Amino acids are listed in decreasing 
order of hydrophobicity according to the Kyte and Doolittle scale (231). 
Crossed out arrows represent excluded proteins. Plus sign represents addition 
of proteins. Reprinted from reference (119) with permission. 
 
 We also examined the Toxoplasma proteome for homologues of the 
predicted 454 TA proteins in Arabidopsis thaliana (227). Our search identified 57 
Toxoplasma homologues, but only 11 of these proteins possess TA protein 
characteristics; the other 46 protein homologues were eliminated due to the lack 
of TMD (33 proteins), prediction of more than one TMD (10 proteins) or incorrect 
TMD location (3 proteins) (Appendix G). Of the 11, only two putative TA proteins 
were not detected in our original analysis (Appendix D). Together, these two 
independent approaches revealed 59 putative TA proteins in Toxoplasma. 
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 Sequence composition and length for both the TMD and C-terminal 
sequence (CTS) influences TA protein localization in other species (235–239). 
The TMD sequence length among the 59 putative Toxoplasma TA proteins 
varies from 18 to 28 amino acids, with an average length of 22 amino acids 
(Appendix D). We used ProtParam (http://web.expasy.org/protparam) (240) to 
determine whether certain amino acids were enriched in the TMD and CTS 
domains for each Toxoplasma TA protein. Our findings show that the TMD 
contains a bias towards amino acids with hydrophobic side chains, as expected; 
in contrast, there was no clear preference for any particular type of amino acid in 
the CTS (Figure 28), which has an average sequence length of 8 amino acids. 
Collectively, these TMD characteristics are consistent with previously validated 
TA proteins in other species, underscoring the fidelity of our bioinformatics 
approach to identify TA proteins in Toxoplasma. 
 
Table 2. The 9 putative TA proteins selected for experimental validation. 
Reprinted from reference (119) with permission. 
Assigned protein names along with their functional description are listed. 
Protein attributes including the TMD and CTS amino acid sequences along 
with the TMD length and hydrophobicity according to the Kyte and Doolittle 
scale are listed (231). Localization of each TA protein is shown. Abbreviations: 
CTS, C-terminal sequence; ER, endoplasmic reticulum; F1S1, fission 1 protein; 
TA, tail-anchored; KD, Kyte and Doolittle; RBD, RNA-binding domain protein; 
TMD, transmembrane domain; UBC, ubiquitin-conjugating enzyme. 
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4.3.2 Hydrophobicity of the TMDs in Toxoplasma 
Localization of TA proteins is influenced by the hydrophobic properties of 
the TMD. It has been reported that TMD hydrophobicity may have predictive 
value in determining where a TA protein traffics in the cell (213, 228, 241).  In 
general, mitochondrial TA proteins tend to cluster toward lower hydrophobicity 
values compared to ER-localizing TA proteins, and TA proteins that ultimately 
localize to the Golgi apparatus tend to possess TMDs with higher hydrophobicity 
values (228, 241–243). 
We examined the hydrophobicity of the TMDs for each of the predicted 59 
putative TA proteins in Toxoplasma. For each protein, the TMD was analyzed 
using the Kyte and Doolittle (KD) scale (231). This widely used hydrophobicity 
scale uses a numerical value assigned to each amino acid type. A more 
hydrophobic region of amino acids is represented by a more positive numerical 
value (231); in Toxoplasma, TMD hydrophobicity values ranged from 0.434 to 
3.195 with the 3 most hydrophobic TA proteins classified as putative soluble N-
ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins 
(Table 2 and Appendix D). SNARE proteins are involved in vesicle-mediated 
trafficking and are often localized to the Golgi apparatus (244). In HeLa cells, TA 
proteins that ultimately traffic to the Golgi apparatus typically possess TMDs with 
high hydrophobicity values (228), similar to the Toxoplasma putative SNARE 
protein hydrophobicity values, suggesting the KD hydrophobicity scale might 
have predictive value in Toxoplasma. 
 
4.3.3 Localization of Toxoplasma TA proteins to various organelles 
We selected 9 representatives from the putative TA proteins that exhibit 
diverse attributes with respect to TMD length, CTS composition and 
hydrophobicity, for localization studies. Names were assigned to these selected 
proteins based on the descriptive function provided by ToxoDB (Table 2).  
All but two (RNA-binding domain protein (RBD) and radical S-adenosyl-L-
methionine (SAM) domain-containing protein (RlmN)) of the Toxoplasma TA 
proteins selected for experimental validation were homologues of proteins 
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previously localized to various organelles in other species. Ubiquitin-conjugating 
enzyme (UBC) (245, 246) and cytochrome b5 (Cyt-b5) (245, 247–250) are 
putative homologues of known ER TA proteins in other species. We also 
examined 3 predicted SNARE proteins:  R-SNARE1, R-SNARE2, and 
QaSNARE, all of which are expected to traffic to the Golgi apparatus based on 
studies in other species (228, 251). In addition to the previously characterized 
TgElp3 (83), we chose to examine a putative Toxoplasma homologue of 
mitochondrial fission 1 protein (Fis1) as a candidate TA protein targeting the 
parasite’s mitochondrion (83, 226, 252, 253).  
To determine the subcellular localization of each of the 9 selected TA 
proteins in Table 2, we generated a series of constructs to ectopically express 
each protein fused to an HA-tag at the N-terminus. The constructs drive 
expression of the fusion protein using the Toxoplasma tubulin promoter and 
5’UTR (99) (Figure 29). Using these tagging constructs, each of the 9 genes 
were transiently expressed in RH strain parasites and protein localization was 
assessed by immunofluorescence assays (IFAs) that included established 
markers for the parasite ER (TgSERCA, (233)), Golgi apparatus (TgSORTLR, 
(232)), and mitochondrion (TgF1B-ATPase, (108, 109)) (Figure 29).  
As shown in Figure 29 and listed in Table 2, each of the Toxoplasma TA 
protein homologues localized to a single, subcellular organelle. In addition to the 
expected presence of R-SNARE2 at the Golgi apparatus, we observed a strong 
localization of this protein at the plasma membrane along with some vesicle-like 
structures, suggesting this protein may be involved in membrane vesicle 
trafficking. Notably, our studies revealed the localization of two previously 
uncharacterized proteins:  RBD was found at the ER and RlmN at the 
mitochondrion. RBD contains an RNA-binding domain that is likely to be involved 
in stabilizing RNA; its localization at the ER could signify a functional role in 
protein synthesis. Interestingly, RlmN contains a radical SAM domain and is a 
mitochondrial TA protein, like TgElp3 (83). Proteins with a radical SAM domain 
are associated with the delivery of diverse methylation modifications; Elp3 and 
RlmN in particular have been shown to have tRNA methyltransferase activity (84, 
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254, 255). In Escherichia coli, RlmN is responsible for the m2A synthesis at 
purine 37 in tRNA (256) and in Saccharomyces cerevisiae, Elp3 was found to 
modify uridine 34 located in the tRNA wobble position (86). Interestingly, a TMD 
on Elp3 or RlmN homologue is only found in the phylum Apicomplexa and select 
species within the Chromalveolata supergroup; it is not present in E. coli, S. 
cerevisiae, or higher eukaryotes (83). Why these radical SAM domain proteins 
uniquely localize to the mitochondrion through a TA-mediated trafficking 
mechanism, and whether or not RlmN and Elp3 possess tRNA methyltransferase 
activity in Toxoplasma, are important questions for future investigation. 
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Figure 29. Subcellular localization of tail-anchored (TA) proteins. Reprinted 
from reference (119) with permission. 
A. Schematic of constructs introduced into parasites to express HA-tagged 
versions of the putative TA proteins. Cyto-domain: Cytoplasmic region of the 
protein, TMD: transmembrane domain; CTS: C-terminal Sequence. B-D, HA-
tagged full-length proteins stained with α-HA (green). The following markers of 
designated parasite organelles were used for colocalization: B. Endoplasmic 
reticulum (ER) stained with α-TgSERCA (red). C. Golgi apparatus stained with 
α-TgSORTLR (red). D.Mitochondrion stained with α-TgF1B-ATPase (red). E. 
Localization of ectopically expressed yellow fluorescent protein (YFP) fused 
with the TMD (including 10 amino acids upstream) and CTS for each protein. 
YFP-C-terminal fusion proteins are visualized using YFP (green). All images 
merged with the DNA stain DAPI (blue). Scale bar = 2 μm.  
 
4.3.4 TMD and CTS are sufficient to target Toxoplasma TA proteins to the 
proper subcellular organelle 
To begin deciphering the mechanism of TA protein trafficking, we tested 
whether the C-terminal TMD and CTS were sufficient for specific organellar 
targeting. We generated 9 additional constructs engineered to ectopically 
express Yellow Fluorescence Protein (YFP) fused to the TMD (including 10 
amino acids upstream) and CTS of each protein (Figure 29). Following transient 
transfection, the localization of each of the YFP-fusion proteins was assessed by 
IFA. As shown in Figure 29, the full-length, HA-tagged proteins and their 
corresponding YFP-TMD-CTS fusion protein localized to the same organelle. 
These data show that targeting to the proper subcellular organelle requires only 
the TMD and CTS, the signature feature confirming that these are indeed TA 
proteins. 
 
4.3.5 Targeting of TA proteins to the mitochondrion 
Positively charged residues located immediately downstream of the TMD 
in the CTS are critical for targeting TA proteins to the mitochondria in other 
species (211, 241, 257, 258). In accordance, positively charged residues are 
strongly enriched within the CTS region of two of the Toxoplasma TA proteins 
that we found to target the mitochondrion:  RlmN and Elp3 (Table 2, Figure 29). 
In contrast, the 3 amino acids comprising the Fis1 CTS only include one 
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positively charged residue (lysine). To examine the contribution of the CTS to TA 
protein localization, we ectopically expressed each of these 3 TA proteins using 
the previously described HA-tagging construct containing a premature stop 
codon immediately downstream of the TMD (Figure 30). Elp3 and RlmN share a 
similar CTS (RRRR and RRARV, respectively), and its removal ablated 
mitochondrial targeting (Figure 30). However, removal of the CTS from Fis1 
(LSK) did not perturb localization to the parasite’s mitochondrion (Figure 30). 
101 
 
Figure 30. Role of the C-terminal sequence (CTS) in subcellular localization of 
tail-anchored (TA) proteins. Reprinted from reference (119) with permission. 
Immunofluorescence assays (IFAs) of intracellular parasites expressing HA-
tagged TA-proteins containing the transmembrane domain (TMD) sequence 
and lacking the CTS. Parasites were stained with α-HA (green), DNA stain 
DAPI (blue) and either (A) α-TgF1B-ATPase (red) to detect the mitochondrion, 
(B) α-TgSERCA (red) to detect the ER or (C) α-TgSORTLR to detect the Golgi 
apparatus stained with (red). Scale bar = 2 μm. 
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These data suggest that there may be at least two pathways in 
Toxoplasma for targeting mitochondrial TA proteins (225):  one pathway relies on 
the established dibasic targeting motif (-R-R/K/H-X ({X≠E})) found in both Elp3 
and RlmN (225, 250), and a second pathway responsible for the mitochondrial 
localization of Fis1. This is reminiscent of two distinct mechanisms of Fis1 
isoform targeting in Arabidopsis thaliana; Fis1a contains the dibasic motif 
(VAAMSRKK) while Fis1b does not (LRS) (225). The mitochondrial targeting of 
Fis1 varies between species. The S. cerevisiae Fis1 CTS contains the dibasic 
mitochondrial targeting motif (259, 260), but human Fis1 (hFis1) does not contain 
the dibasic motif (SKSKS) (261). Rather than the dibasic motif, the Toxoplasma 
Fis1 CTS (LSK) has an amino acid sequence more similar to that found in hFis1 
and Arabidopsis Fis1b. Some evidence also exists that Fis1 can also target to 
the peroxisome in mammalian cells (262); evidence for membrane-bound 
peroxisomes in Toxoplasma is contradictory (263, 264) and our data indicates 
that Toxoplasma Fis1 is only at the mitochondrion. 
Since the CTS is required for Elp3 localization to the mitochondrion, we 
tested whether the CTS alone could operate as a mitochondrial targeting 
sequence by replacing the RBD CTS (which targets ER) with the Elp3 CTS. 
Replacing the RBD CTS (just two amino acids, EA) with the Elp3 CTS (RRRR) 
was sufficient to mislocalize RBD from the ER to the cytoplasm, but it did not 
target the protein to the mitochondrion (Figure 31). We then replaced both the 
TMD and CTS of RBD with those of Elp3, which was able to redirect RBD from 
the ER to the mitochondrion (Figure 31). To further explore the signal 
contribution of the TMD verses the CTS, we replaced the RBD TMD with the 
similarly hydrophobic Elp3 TMD (RBD TMD: 1.97; Elp3 TMD: 2.04). While the 
fusion protein levels were too low to discern localization with confidence, there 
appears to be little overlap with the mitochondrion (Figure 31). Collectively, these 
studies show that the Elp3 CTS is necessary but not sufficient to target the 
mitochondrion; however, the combination of TMD and CTS are all that is required 
to redirect a heterologous protein to the mitochondrion. 
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Figure 31. C-terminal sequence swap of tail-anchored (TA) proteins alters 
subcellular localization. Reprinted from reference (119) with permission. 
A, Schematic of RNA-binding domain protein (RBD), QaSNARE, and Elp3 with 
sequences of their transmembrane domain (TMD) and C-terminal sequence 
(CTS) shown. B, CTS, TMD-CTS and TMD were swapped between HA-tagged 
TA proteins as depicted in schematic on the left, (i)-(ix) denote specific construct 
designs. Gray shades match those in A to indicate origin of domain. Fusion 
constructs are listed with the gene name, the TMD (bold), and 
CTS (italicized). Immunofluorescence assays (IFAs) showing the localization of 
swapping mutants stained with α-HA (green), α-TgF1B-ATPase (red) and 
merged with DAPI (blue). Scale bar = 2 μm. 
 
4.3.6 Targeting of TA proteins to the ER and Golgi apparatus 
Our findings have uncovered the first TA proteins in phylum Apicomplexa 
that target the ER, as well as those that traffic to the Golgi apparatus. It has been 
established that TA proteins destined for the Golgi apparatus are first inserted 
into the ER and then delivered via vesicular transport, whereas ER TA proteins 
are targeted directly to the ER upon release from the ribosome (210, 265). To 
gain insight into the specificity of these targeting mechanisms in Toxoplasma, we 
performed additional domain swap experiments. To determine if the CTS is 
required for TA protein localization for either RBD (ER) or QaSNARE (Golgi 
apparatus), we used the previously described HA-tagging construct containing a 
premature stop codon immediately downstream of the TMD. Removal of the CTS 
did not alter protein localization for either RBD or QaSNARE, suggesting the 
TMD sequence is sufficient for the targeting of these proteins (Figure 30). 
To further explore protein localization to the ER, we generated fusion 
constructs to identify which sequences are necessary for ER localization (Figure 
31). For these experiments we used the mitochondrial localizing protein TgElp3 
and swapped the TgElp3 CTS, TMD and TMD-CTS sequences with those of 
RBD (ER). Replacement of the TgElp3-TMD with the similarly hydrophobic RBD-
TMD resulted in protein localization to the mitochondrion, while replacement of 
the TgElp3 TMD-CTS with the RBD TMD-CTS or even just the RBD CTS (EA) 
resulted in targeting of TgElp3 to the ER instead of the mitochondrion (Figure 
31). As observed in other species, proteins lacking clear mitochondrial targeting 
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sequences are often inserted into the more permissive ER membrane, which is 
able to accept TMDs of different lengths and sequences (207, 211, 257, 260, 
266–268). In Toxoplasma, replacement of the TgElp3 CTS dibasic motif was 
enough to reroute TgElp3 to the ER, suggesting that without a strong 
mitochondrial targeting sequence the ER is likely the default destination for TA 
protein localization. 
 Given that we were able to mislocalize TgElp3 to the ER by simply 
replacing the CTS with a sequence from RBD, we examined whether it was 
possible to mislocalize TgElp3 to the Golgi apparatus by replacing the CTS from 
QaSNARE (KHT). Replacement of just the CTS of TgElp3 with the CTS of 
QaSNARE resulted in some mislocalization from the mitochondrion, but no clear 
trafficking to the ER or Golgi apparatus (Figure 31). We then swapped the 
TgElp3 TMD and TMD-CTS sequences with those from QaSNARE, which 
resulted in a striking redirection of TgElp3 to the Golgi apparatus (Figure 31). The 
more hydrophobic QaSNARE TMD (2.47 compared to 2.04) may prevent protein 
insertion into the mitochondrial membrane or may act as a robust signal 
sequence overriding the TgElp3 CTS dibasic mitochondrial targeting motif. 
Generally, these data suggest that optimal TA protein targeting in early-
branching eukaryotes like Toxoplasma is determined by both the TMD and CTS 
sequences. 
 
4.4 Concluding Remarks 
Our findings represent the first characterization of TA proteins in the 
phylum Apicomplexa using the early-branching protozoan parasite Toxoplasma 
as a model. Our bioinformatics analysis identified 59 putative TA proteins in the 
Toxoplasma proteome. Nine representatives were chosen for experimental 
analyses, localizing to various subcellular compartments including the parasite 
ER, mitochondrion, or Golgi apparatus. As in other species, at least two 
pathways appear to direct mitochondrial TA protein localization, one of which 
employs an established dibasic targeting motif which is required for Elp3 and 
RlmN mitochondrial localization; removal of this motif results in mislocalization of 
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the TA protein to the ER membrane. TA protein localization to ER (or 
subsequently the Golgi apparatus) appear to be solely dependent on the TMD 
sequence; however, addition of a CTS containing a mitochondrial targeting 
dibasic motif results in TA protein mislocalization, suggesting the dibasic motif 
may prevent membrane integration or signal removal from the ER.  
Based on the experimentally localized Toxoplasma TA proteins described 
here, the Kyte and Doolittle hydrophobicity scale appears to have some 
predictive power, similar to what is observed in other species. Domain swapping 
experiments confirmed that the combination of the TMD and CTS are all that is 
required to redirect a heterologous protein to a destined organelle. Interestingly, 
when only the TMD was swapped to forma a heterologous TMD-CTS sequence, 
localization of fusion proteins varied, indicating protein targeting may occur in a 
context dependent manner. Further mechanistic studies and exploration of 
potential chaperones are required to resolve how the TMD and CTS mediate 
organelle-specific targeting. As in other species, it is likely that Toxoplasma TA 
proteins interact with chaperone proteins, integrate in an unassisted manner, or 
recognize docking proteins present in their target organelle. Based on sequence 
homology analyses of the ToxoDB, putative homologues for components of the 
Hsc70/Hsp40, SRP54, and some members of the GET complex appear to be 
present in Toxoplasma. 
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CHAPTER 5:  Conclusions 
5.1 Summary of Findings 
 Disruption of lysine acetylation is detrimental to Toxoplasma, and previous 
studies identified that the putative lysine acetyltransferase TgElp3 is essential for 
parasite viability. Our laboratory determined that TgElp3 possesses KAT activity 
and its localization to the OMM is essential for parasite viability. However, a key 
question remained unanswered, “What is the function of TgElp3 at the 
mitochondrion?” The work in this thesis describes various investigative 
approaches to determine TgElp3’s enzymatic function and how it localizes to the 
parasite mitochondrion. 
 Using a targeted mutational approach, we were unable to generate viable 
parasites with defective KAT or rSAM domains in TgElp3, suggesting that both of 
these domains are essential for protein function. Moreover, overexpression of 
TgElp3 resulted in a significant replication defect while overexpression of mutant 
rSAM and TMD domains were tolerated. These findings highlight the importance 
of the rSAM domain and further confirm that TgElp3 activity is dependent on its 
localization to the OMM.  
Since studies in other species have determined that the rSAM in Elp3 is 
important for the synthesis of tRNA modifications (mcm5 and ncm5), we 
investigated TgElp3 as a potential tRNA modification enzyme. In collaboration 
with Dragony Fu’s lab at the University of Rochester, we identified the first tRNA 
modification in Toxoplasma, tRNAGlu mcm5s2U35. However, we were unable to 
attribute the TgElp3OE replication defect to changes in the tRNAGlu mcm5s2U35 
modification. Knowing that the mcm5s2 modification requires two independent 
enzymes and that Elp3 has been shown to modify 11 different tRNAs, we cannot 
eliminate the possibility that TgElp3 is a tRNA modification enzyme.  
 Elp3 was initially characterized as a lysine acetyltransferase and several 
studies have implicated α-tubulin as a substrate. Recently, a second α-tubulin 
acetyltransferase (ATAT) was identified in C. elegans. When we genetically 
ablated the Toxoplasma homologue, TgATAT, we observed a complete loss of α-
tubulin acetylation in the parasite. Since there was no detectable α-tubulin 
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acetylation when TgATAT was knocked out and assuming TgElp3 was still 
present, we can conclude that TgElp3 is not the primary α-tubulin 
acetyltransferase in Toxoplasma. In support of these findings, a recent study in 
C. elegans analyzed the lysine codon usage of ATAT and found that there is a 
strong codon bias for –G ending codons (33% AAA/67% AAG) compared to the 
average lysine codon usage preferring –A ending codons (61% AAA/39%AAG); 
the authors speculate that Elongator may regulate the protein expression level of 
ATAT through its elevated AAA codon content, and thus the decrease in α-
tubulin acetylation in Elongator mutants may be through an indirect tRNA 
modification pathway (269).   
 Furthermore, since TgElp3 localization to the OMM is essential for 
parasite viability, we sought to determine the factors required for protein 
trafficking. TgElp3 is classified as a tail-anchored (TA) protein as it contains a 
single TMD positioned within 30 amino acids of the C-terminus. To gain insight 
into how TgElp3 is targeted to the OMM, we used a bioinformatics approach and 
identified an additional 59 putative TA proteins in Toxoplasma. Of these proteins, 
a second rSAM domain containing protein was identified, RlmN. Experiments 
determined that RlmN and TgElp3 share a similar positively charged C-terminal 
sequence motif required for OMM localization. Interestingly, RlmN in Escherichia 
coli has been characterized as a tRNA modification enzyme, but its function in 
Toxoplasma is not known.  
Considering that our mutational studies identified the rSAM domain critical 
for TgElp3 function and we identified a second putative tRNA modification 
enzyme that similarly localizes to the OMM, the data presented in this thesis 
suggest that TgElp3 is likely a tRNA modification enzyme. However, we cannot 
rule out TgElp3’s potential role as a lysine acetyltransferase. Moreover, why this 
enzyme localizes to the parasite’s mitochondrion is puzzling. Therefore future 
experimental studies are needed to determine the molecular function of TgElp3 
and the significance of its localization at the mitochondrion.  
 
109 
5.2 Future Directions  
The data presented in this thesis have broadened our focus from not only 
exploring TgElp3 a KAT but also investigating its potential role as a tRNA 
modification enzyme. In addition to determining the enzymatic function of TgElp3, 
determining why it localizes to the mitochondrion is another important facet of 
parasite biology to explore. Our findings have led to a number of new questions 
to be answered. 
 
5.2.1 Does Elp3 bind tRNA? 
 Immunoprecipitation studies in yeast have determined that Elp3 can bind 
tRNA. We could follow a similar approach to determine if TgElp3 can bind tRNA 
in Toxoplasma. The endogenously tagged (HATgElp3) or overexpressing 
(HATgElp3OE) parasite lines can be subjected to formaldehyde treatment (or ultra 
violet light) to cross-link TgElp3 to tRNA substrates. Using anti-HA conjugated 
beads, TgElp3 can be immunoprecipitated. The immunoprecipitated complex can 
be resolved on a polyacrylamide gel and stained with SYBR gold to detect 
associated tRNAs. To specifically determine which tRNA pulled down with the 
TgElp3-RNA complex, subsequent Northern blot or sequencing analysis could be 
performed.  
 An alternative approach is to perform an in vitro TgElp3-tRNA binding 
assay. In this case, TgElp3 protein is immunoprecipitated and incubated with a 
radio-labeled (or biotin-labeled) tRNA. This RNA-protein complex can be 
assessed as described above.  
  
5.2.2 Does TgElp3 modify tRNA in vitro? 
 An in vitro tRNA modification assay was recently developed by Raven 
Huang at the University of Illinois (84). This assay requires a minimum of 1 mg of 
purified protein. Despite employing multiple approaches we were unable to 
generate enough soluble protein to perform this assay. Recently, there have 
been numerous reports stating radical SAM domain containing proteins are very 
sensitive to oxygen, and thus must be purified within an anaerobic chamber. 
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Since the recombinant protein expression constructs are already made, 
repeating the recombinant protein expression experiments in either the SF21 or 
E. coli cells, and then using an anaerobic chamber for protein purification may 
yield enough soluble recombinant TgElp3 protein to perform the in vitro tRNA 
modification assay.  
 
5.2.3 Does overexpression of tRNALys and/or tRNAGlu rescue the HATgElp3OE 
growth phenotype? 
 Several independent studies show that overexpression of specific tRNAs 
especially tRNALys can overcome Elongator mutant stress phenotypes. There is 
some evidence that stress response genes possess a higher number of lysine –
AA ending codons and therefore disruption of Elongator results in preferential 
translation of –AG ending codons (270). Elongator mutants may not be able to 
translate stress response genes as efficiently resulting in a slow growth 
phenotype. Exactly how overexpression of unmodified tRNALys overcomes the 
Elongator mutant phenotype is not understood. Our HATgElp3OE parasites may 
have the opposite problem in which they have hyper-modified tRNAs that 
promote translation of a subset of genes (potentially stress response genes). 
Overexpression of tRNALys may shift the tRNA pool and promote homeostatic 
translation.  
 
5.2.4 Does overexpression of TgElp3 affect protein synthesis? 
We previously used polyribosome profiling and the SUnSET method to 
assess protein synthesis in our TgElp3 overexpression mutants. Using these 
methods we did not detect any difference in protein synthesis. However, these 
approaches assess translation at a global level and likely miss small changes in 
protein synthesis. Since Elp3 tRNA modifications affect anticodon-codon binding, 
(mcm5 efficiently binding –G and mcm5s2 efficiently binding –A ending codon), 
ribosomal footprint profiling could be used to monitor protein synthesis at higher 
resolution. This method essentially produces a “global snapshot” of all the active 
ribosomes in a cell. Briefly, cycloheximide is applied to “freeze” the ribosomes to 
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mRNA transcripts. RNA not protected by the ribosome is digested, followed by 
purification of the mRNA-ribosome complex using a sucrose gradient. The mRNA 
can be purified, reverse-transcribed and then sequenced. Alignment of the 
sequence reads will determine the translational profile. From these data, the 
ribosome distributions could be determined at the codon level and, through 
comparison with the parental strain, biases in codon frequency could be 
detected.   
To further assess translation regulation, luciferase (renilla vs firefly) or 
fluorescent (CFP vs YFP) reporter constructs containing various stretches of 
cognate codons (e.g. 5 x AAA vs 5 x AAG) could be expressed in the TgElp3 
mutant parasite lines we developed. Following transfection, quantitative 
measurements of protein output will determine if overexpression of TgElp3 alters 
protein synthesis. Depending on the promoter used to express the reporter 
genes, there is a chance for protein saturation. Therefore, ribosomal profiling 
followed by qRT-PCR on the collected fractions could be used as a second 
method to assess translation. Early fractions indicate less ribosome association 
(less translation) while the later fractions contain transcripts highly decorated with 
ribosomes (more translation).  If TgElp3 overexpressing parasites exhibit a 
change in protein synthesis as a result of inefficient anticodon-codon base 
pairing, we would expect to see the reporter construct mRNA enriched in 
different polyribosome fractions compared to the parental strain. A second 
method, ribosomal footprinting, can be used to determine the precise position of 
ribosomes on any given transcript and calculation of the codon occupancy will 
unveil any codon usage biases.  
Additionally, a quantitative proteomics approach could be used to 
determine if overexpression of TgElp3 alters protein levels. The proteins 
identified as differentially expressed between the parental and TgElp3 strains will 
be subjected to codon frequency analysis to determine if there is a codon bias. 
However, any changes detected in protein levels and subsequent codon bias 
could be a result of indirect mechanisms, so additional studies are needed. Since 
our TgElp3 overexpressing parasites have a severe replication defect, analysis of 
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protein expression will also give us insight into the cellular state of these 
parasites.     
 
5.2.5 Does TgElp3 overexpression alter parasite mitochondrial function? 
 We did not detect any obvious mitochondrial abnormalities, however since 
overexpression of TgElp3 is detrimental only when the protein resides at the 
parasite’s mitochondrion, a more detailed analysis of mitochondrial function is 
needed. Mitochondrial membrane potential can be assessed using the 
fluorescent MitoTracker probe or JC-1, a membrane potential dependent cationic 
dye that accumulates in the mitochondria and changes from green to red as it 
accumulates. Moreover, we can assess mitochondrial function by measuring 
mitochondrial respiration, ATP and reactive oxygen species (ROS) to determine 
if TgElp3 overexpression disrupts mitochondrial function. In addition, treating our 
TgElp3 overexpressing parasites with mitochondrial inhibitors such as 
atovaquone, antimycin A and myxothiazol may unveil differences in susceptibility 
or resistance. In addition, perturbing the cellular energy pathways in the parasite 
through alterations in media composition (low or high glucose) and assessing 
parasite growth may also give insight into the function of TgElp3 at the 
mitochondrion. Collectively, these studies will determine if TgElp3 
overexpression alters mitochondrial function.  
 
 
 
 
 
 
 
 
 
113 
APPENDICES 
Appendix A. Constructs and primers used in chapter 2. 
 PROJECT AND CONSTRUCT NAME BACKGROUND 
PARASITE 
STRAIN 
SELECTION 
CASSETTE 
BioID     
TubHX-myc-BirA-HA-TgElp3 RHΔhx HXGPRT 
     
Endogenous Replacement    
HATgElp3 RHΔhx∆ku80 DHFR 
HATgElp3-rSAMmut (C284A) RHΔhx∆ku80 DHFR 
HATgElp3-KATmut(Y715/716A) RHΔhx∆ku80 DHFR 
     
Destabilization Domain    
TubHX-DD-HATgElp3 RHΔhx HXGPRT 
TubHX-DD-HATgElp3-rSAM(C284A) RHΔhx HXGPRT 
TubHX-DD-HATgElp3-KATmut(Y715/716A) RHΔhx HXGPRT 
     
Ectopic Overexpression    
TubHXHATgElp3OE RHΔhx HXGPRT 
TubHATgElp3OE ME49 DHFR 
TubHXHATgElp3-KAT(Y715/716A)OE RHΔhx HXGPRT 
TubHXHATgElp3-KAT(Y716A)OE RHΔhx HXGPRT 
TubHXHATgElp3-KAT(Y715F/Y716F)OE RHΔhx HXGPRT 
TubHXHATgElp3-rSAM(C284A/C287A)OE RHΔhx HXGPRT 
TubHXHATgElp3-
rSAM(C284A/C287A)/KAT(Y716A)OE  
RHΔhx HXGPRT 
TubHXHATgElp3-
rSAM(C284A/C287A)/KAT(Y715F/Y716F)OE 
RHΔhx HXGPRT 
TubHXHATgElp3-ΔTMDOE  RHΔhx HXGPRT 
   
RECOMBINANT PROTEIN EXPRESSION 
CONSTRUCTS 
  
pET19b-10xHIS-EnzymaticElp3ΔTMD Rosetta AMP 
pET30a-EnzymaticElp3ΔTMD Rosetta KAN 
pGEX-4T-1-GST-EnzymaticElp3ΔTMD Rosetta AMP 
6HIS-SUMO-Elp3ΔTMD Rosetta KAN 
6HIS-SUMO-Elp3ΔTMDshort1 Rosetta KAN 
6HIS-SUMO-Elp3ΔTMDshort2 Rosetta KAN 
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Insect Cells   
BacPAK9-10xHIS-EnzymaticElp3ΔTMD SF21 AMP 
BacPAK9-EnzymaticElp3ΔTMD SF21 AMP 
BacPAK9-GST-EnzymaticElp3ΔTMD SF21 AMP 
 
PRIMERS: 
 PRIMER DESCRIPTION PRIMER SEQUENCE 
F1 BirA-Elp3F_step1a GCTCGGTACCAAGCTTGTACCCGTACGACGTCC
C 
R1 BirA-Elp3R_step1a GGATCGATCCACTAGCACGATTGGCAGCATTTTT
TTTGACA 
F2 BirAElp3-tubHX-F ATTCCCTTTTAGATCaccatggaacaaaaactcatctcagaa
gag 
R2 BirAElp3-tubHX-R TGTAGTCCCTAGGATCACGATTGGCAGCATTTTT
TTTGAC 
F3 TubHX-SeqF1 CTTGCGGAAAACTACTCGTTGG 
R3 TubHX-SeqR1 GTCGTCGTCGTCCTTGTAGTC 
F4 Knock-IN-Elp3-Prom CCGCTCTAGAACTAGTACCGTTCTCGAACCAGTG
CTTTCA  
R4 Knock-IN-Elp3-Prom  
gacgtcgtacgggtacatGGTGAAAAGAGAGATAGGTTG
AGAGGGC 
F5 Knock-IN-HA-Elp3 ATGTACCCGTACGACGTCCC  
R5 Knock-IN-HA-Elp3 GGATCGATCCACTAGCACGATTGGCAGCATTTTT
TTTGACA 
F6 Knock-IN-Elp3-
Downstream 
CAGCCTGGCGAAGCTAAAAGATTTGCTGCAGAT
GCAGC  
R6 Knock-IN-Elp3-
Downstream 
CGGTATCGATAAGCTGACTGATTATGTCGGATGC
AAAGTTCC 
F7 TgELP3_rSAMC284A_F  TCTTGCCCTCACAACGCGCATTACTGCCCCAAC 
R7 TgELP3_rSAMC284A_R  GTTGGGGCAGTAATGCGCGTTGTGAGGGCAAGA 
F8 TgElp3-
KAT_Y715/716A_F 
GGTGTCGGTACGCGGGAGGCTGCCCGAAAGAAT
GGGTACG 
R8 TgElp3-
KAT_Y715/716A_R 
CGTACCCATTCTTTCGGGCAGCCTCCCGCGTAC
CGACACC 
F9 pDHFR_SeqF1 GGGATCGATCCACTAGTTCTAGAG 
R9 pDHFR_SeqR1 CCCTCGAGGTCGACGGTA 
F10 K-IN-upstream_F1 CCAAGCATAAGGCTGGAAAA 
R10 K-IN-construct_R1 TCGCGAATAAATTCCTCCTG 
F11 K-IN-construct_F2 TTTCTGACGTTCTCGACGTG 
R11 K-IN-downstream_R2 AAGAAACCCAAGCGCCTTAC 
F12 TubHX_to_pDHFR_Hind
III F 
CGGTATCGATAAGCTTCACGTGGTACGGCTATGA
GCC 
R12 TubHX_to_pDHFR_Hind CAGCCTGGCGAAGCTTCCTGCCGGAACACTTGT
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III R CAACCG 
F13 TgElp3-KAT_Y716A_F TACGCGGGAGgcgtacCGAAAGAATGGGTACG 
R13 TgElp3-KAT_Y716A_R CCCATTCTTTCGGTAcgcCTCCCGCGTACCGAC 
F14 TgElp3_KAT_Y715F/Y7
16F_F 
GTCGGTACGCGGGAGTtcTtCCGAAAGAATGGGT
AC 
R14 TgElp3_KAT_Y715F/Y7
16F_R 
GTACCCATTCTTTCGGTAATACTCCCGCGTACCG
AC 
F15 TgELP3_rSAMC287A_F CACAACGCGCATTACGCGCCCAACGAGCCTGGC 
R15 TgELP3_rSAMC287A_R GCCAGGCTCGTTGGGCGCGTAATGCGCGTTGTG 
F16 TgELP3_ΔTMD_F CCCTCGCTGGCGAACTGACTCTGGCTTGGGGT 
R16 TgELP3_ΔTMD_R ACCCCAAGCCAGAGTCAGTTCGCCAGCGAGGG 
F17 pET19b_EnzymaticElp3-
F 
ACGACGACAAGCATAATCAGCGGAACCGCGT 
R17 pET19b_EnzymaticElp3-
R 
GGATCCTCGAGCATATCATAGTGAGGAAGACCC
GACC 
F18 pET30a_EnzymaticElp3
_F 
AAGGAGATATACATAACCATGCAGCGGAACCG 
R18 pET30a_EnzymaticElp3
_R 
TGCTCGAGTGCGGCCTCATAGTGAGGAAGACCC
GACCG 
F19 pGEX-4T-
1_EnzymaticElp3_F 
ATCCCCGGAATTCCCACAGCGGAACCGCGT 
R19 pGEX-4T-
1_EnzymaticElp3_R 
CGCTCGAGTCGACCCTCATAGTGAGGAAGACCC
GACCG 
F20 6HIS-SUMO-Elp3_F1 tacttccaatccaatATGGAACACACTTCCTCTCCTTCTT
CTTCCT 
F20.1 6HIS-SUMO-Elp3_F2 tacttccaatccaatTCTTCGGACCGGTGTGC 
F20.2 6HIS-SUMO-Elp3_F3 tacttccaatccaatCAGCGGAACCGCGTACT 
R20 6HIS-SUMO-Elp3_R1 ttatccacttccaatTCATGGGTTCGCCAGCG 
F21 BacPak9-
EnzymaticElp3#87_F 
ATAAATACGGATCCCACCATGCAGCGGAACCG 
R21 BacPak9-
EnzymaticElp3#87_R 
CGAGCTCGAATTCCCTCATTCCGTGAATGCGTCC
GG 
F22 GST-EnymaticElp3_F ATAAATACGGATCCCACCATGTCCCCTATACTAG
GTTATTGGA 
R22 GST-EnymaticElp3_R CGAGCTCGAATTCCCTCATAGTGAGGAAGACCC
GACCG 
F23 BacPak9 Seq_F1 AACCATCTCGCAAATAAATA 
R23 BacPak9 Seq_R1 ACGCACAGAATCTAGCGCTT 
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Appendix B. Primers used in chapter 3. 
 
 Primer Name Primer Sequence Used 
TUBA1 
Site-
irected 
1 K40K F GCAGATGCCCTCTGACAAAACCATTGGAGG
TGG 
2 K40K R CCACCTCCAATGGTTTTGTCAGAGGGCATCT
GC 
3 K40R F GCAGATGCCCTCTGACCGCACCATTGGAGG
TGG 
4 K40R R CCACCTCCAATGGTGCGGTCAGAGGGCATC
TGC 
5 K40Q F GCAGATGCCCTCTGACCAGACCATTGGAGG
TGG 
6 K40Q R CCACCTCCAATGGTCTGGTCAGAGGGCATC
TGC 
Oryzalin 
Mutation 
7 I239T F gagagacgcggtcagggaggagatgacctg 
8 I239T R caggtcatctcctccctgaccgcgtctctc 
9 V252L F cgctcaacgtcgacttgactgagttccagac 
10 V252L R gtctggaactcagtcaagtcgacgttgagcg 
TgTUBA1 
Sequenci
ng 
11 TgTUBA1 F ATGAGAGAGGTTATCAGCATC 
12 TgTUBA1 R TTAGTACTCGTCACCATAGCC 
TgATAT 
tagging 
13 TgATAT_F ttccaatccaatttaATTTCTACGTCCTCGAGAGCTG
T 
14 TgATAT_R ccacttccaattttaaaCGACCAGTTGAGGAGAGAC
G 
Deletion 
of HA tag 
in GFP-
Cas9/sgU
PRT 
15 CRISPR HA 
del F 
AGCCTGGGCAGCGGCTCC 
16 CRISPR HA 
del R 
GGCGTCGCCTCCCAGCTG 
TgATAT 
CRISPR 
sgRNA 
17 TgATAT 
sgRNA F 
ctcacccgacGTTTTAGAGCTAGAAATAGCAAG 
18 TgATAT 
sgRNA R 
gcccttgagcAACTTGACATCCCCATTTAC 
TgATAT 
CRISPR 
Oligos 
19 TgATAT Oligo 
F 
tccactccgagctcaagggcctcacccgacAATGATGAAT
GAATGAGATATCagAccgccttccaccggctcctgccga
cgctccagtcg 
20 TgATAT Oligo 
R 
cgactggagcgtcggcaggagccggtggaaggcggTctGA
TATCTCATTCATTCATCATTgtcgggtgaggcccttg
agctcggagtgga 
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Appendix D. Identification of 59 putative TA proteins in Toxoplasma. 
List of the 59 predicted TA proteins in Toxoplasma. Proteins highlighted in grey were used for experimental validation and 
localization. Column (A) lists the gene ID for the ME49 strain (ToxoDB v9.0). Gene product description (column B) with 
names assigned listed in bold parenthesis. The TMD (column C) and CTS (column D) sequences are listed for each of the 
putative TA proteins. Various C-terminal characteristics are listed: TMD length (column E), CTS length (column F) and 
TMD hydrophobicity (column G), KD=Kyte and Doolittle (227). 
GENE ID Product Description TM CTS TMD 
length  
CTS 
length  
KD  
       
TGME49_207150 SAG-related 
sequence SRS49C 
(SAG2D) 
EAETPATPEPSRGEQGVVLGSAFMIAFISC
FALVTGNM 
F 28 1 0.43 
TGME49_326100 dynamin gtpase VYTQYIHSDTVVYMYIYIYIYIY MLIC 23 4 0.62 
TGME49_295472 C2 domain-containing 
protein 
VAYLNLVVGQQTCALIKASTACF CGVLF LVIIA FVVAV IVIAA RMP 23 23 1.10 
TGME49_254030 zinc finger CDGSH-
type domain-
containing protein 
NTPLACVASFAAAFSVGVASTYL HG 23 2 1.24 
TGME49_269130 EGF family domain-
containing protein 
VAMLLICIVHTLLGKTPAGE SPFLP 20 5 1.31 
TGME49_247770 hypothetical protein VSLVYFCWGLILFLYPMAMYARS YATEHGHFPFAPARTDGSRGHG
PLWWFIE 
23 29 1.34 
TGME49_278290 Toxoplasma gondii 
family A protein 
GWSSAGGVGGVSGLLLTMVAALF QVYQLY 23 6 1.37 
TGME49_210255 hypothetical protein LFHYGVIPALFVVGLAYTGELTL DPTSLFQKIVIN 23 12 1.38 
TGME49_261300 hypothetical protein GVFVYMLTYIYIYIYMCIYMDIY L 23 1 1.39 
TGME49_263323 (FIS1) 
tetratricopeptide 
repeat protein 11, 
putative 
LIGSVLLGLAVGGCVWYLTRLWT LSK 23 3 1.43 
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TGME49_236550 hypothetical protein PWPFYIWSFWAFSMVVVPIGLLF QSNYYFSGRILPKVNGNTQLCED
SW 
23 25 1.45 
TGME49_238530 hypothetical protein SSAVRAGLAMSAVVGVVASLLQF A 23 1 1.48 
TGME49_242840 membrane protein AWFVLSGQIMFTFFWSFALYSVI ERWYVNGKIDTFSKWQDRATD 23 21 1.50 
TGME49_220310 hypothetical protein LPPASTAFSCFACVYIFLF REI 19 3 1.64 
TGME49_207170 hypothetical protein VYFPLTAVLVTLGPLYMF SKAFF 18 5 1.64 
TGME49_278370 Toxoplasma gondii 
family A protein 
AWSVAGGISTLSVFLSAAAVTLL PTF 23 3 1.64 
TGME49_246230 hypothetical protein YSYRLLALIVPFLSVAAL P 18 1 1.66 
TGME49_270070 synaptobrevin family 
protein 
LQQYAPLVMMCLFFAILIFWKLF L 23 1 1.68 
TGME49_318160 MSP (Major sperm 
protein) domain-
containing protein 
LWHIPVYIFIGVVIWYFFG RSAEITK 19 7 1.73 
TGME49_209790 (RlmN) radical SAM 
domain-containing 
protein 
AVLAASLAAFAGVAAAGVTHWIL RRARV 23 5 1.79 
TGME49_301355 hypothetical protein YACAHAYICIYIYICVYVLIHIF F 23 1 1.83 
TGME49_231991 hypothetical protein IGCIRLAWIHLGCLLAICSPIFV SGTLGRPM 23 8 1.91 
TGME49_301996 ORF D YIYSQILFFLISSFIFFWIL KQFYLIRFIY 20 10 1.93 
TGME49_223620 golgi SNARE, putative LVWGGMFLTLLFFFFLYRLV HRSREVDDADGSWDALNSEQ 20 20 1.95 
TGME49_260470 heat shock protein 
DNAJ pfj4, putative 
WYWVRVAAVVFLSIWIFVVAFLY PSLLG 23 5 1.96 
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TGME49_212980 (RBD) hypothetical 
protein (RNA binding 
domain-containing 
protein) 
WTLAIVLGFVAYLAAKCFFV EA 20 2 1.97 
TGME49_279360 hypothetical protein SLMMLGALVALFLFFFMPTSPIL PLLFW LHGES PPPAP PVA 23 18 2.00 
TGME49_263810 hypothetical protein AVPTWCVFLLAYSVLAVFGV C 20 1 2.01 
TGME49_305480 (ELP3) elongator 
complex protein ELP3  
PLWLGVVGLGAAAVVTLFASVAV RRRR 23 4 2.04 
TGME49_276110 (Cyt-b5) cytochrome 
b5 family heme/steroid 
binding domain-
containing protein 
GSVGAAALVVLAAAAAVFYILNL S 23 1 2.06 
TGME49_211040 Sec61beta family 
protein 
IGPQTVLILTLCFMASVVLLHIV GKVHQTYGGEN 23 11 2.06 
TGME49_268630 YagE family protein LEWIVIYLICVEVLIDLVWNILI KDILKWV 23 7 2.10 
TGME49_278890 hypothetical protein ATRLFALFYFVLLHFLVFLVLFY LQSRG QADQA GSHQP RYHYY 
LNEHA D 
23 26 2.11 
TGME49_251710 hypothetical protein LILALVIAACVCLSLLWVMRGHA SAVDPGPG 23 8 2.12 
TGME49_214330 DnaJ domain-
containing protein 
VFFPAVAGAVVLAVSCFSLFAAT PT 23 2 2.12 
TGME49_293400 hypothetical protein LLSVALGCGAVTVSIAGLVYVVA TWYEQ PLIRV GETTR ETENR 
REPTT VVA 
23 28 2.17 
TGME49_257520 (R-SNARE2) 
synaptobrevin protein 
LTVMLCIAFAATLAYLIYVVVNL LSDSKK 23 6 2.25 
TGME49_205150 ACR, YagE family 
COG1723 domain-
containing protein 
MTWIIVLLLVAQVVAAAVKYVVL DEP 23 3 2.28 
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TGME49_239640 hypothetical protein ILEGSIVCLTALFFLLLWL M 19 1 2.28 
TGME49_220380 hypothetical protein AIVRSLICYILICASLVLWL RRAVHD 20 6 2.29 
TGME49_205030 hypothetical protein TCYLALFVVVIFIIFYFLYG DEP 20 3 2.40 
TGME49_247930 (Qa-SNARE) SNARE 
domain-containing 
protein 
GRAAQCIVFLVITIFFLLVLLIM KHT 23 3 2.47 
TGME49_275870 tubulin/FtsZ family, 
GTPase domain-
containing protein 
FLFFFSLFFALFVFAFSAFLAGI STNDD DWRER RHDFQ SGRAE 
TREKE MCIR 
23 29 2.48 
TGME49_278670 (UBC) ubiquitin-
conjugating enzyme 
subfamily protein 
VAAADLVLLLLVLASVVLLADLF VNPPK VTMYG SSGAG GKL 23 18 2.57 
TGME49_309420 ferlin family protein GVWMTVAGIIALVIFVMFLL K 20 1 2.62 
TGME49_248100 (R-SNARE1) 
synaptobrevin protein 
YFIVFGMIVVLVIILASFFCGGL TFQTCLRIN 23 9 2.62 
TGME49_246610 hypothetical protein LYCLVAGAVVFVVFVAWV L 18 1 2.66 
TGME49_208010 hypothetical protein FYAMALLLIGCILFVMVMSFILF TPG 23 3 2.67 
TGME49_216680 ankyrin repeat-
containing protein 
LLGFVVVAIIFLLLYFGLELFIA RDSRKRR 23 7 2.69 
TGME49_253360 hypothetical protein FFTRLLLIVILLFLVCFVLSIVY ARYIKRA 23 7 2.75 
TGME49_262980 hypothetical protein AVYVALVCFCMVGPLVIALIMLI SQMLQ 23 5 2.76 
TGME49_306640 hypothetical protein FSQCLCLFIFLFLVIAIVLVCVP R 23 1 2.78 
TGME49_242080 hypothetical protein LILVAIIVFLSLAIVCVLIHRLL RLVRDV 23 6 2.88 
TGME49_278630 tetratricopeptide 
repeat-containing 
protein 
IIVFIVLPVLLLLMVLLGCAHFF ASLASPAPSIHPFADPSHHSEL 23 22 2.88 
TGME49_226600 syntaxin 5, putative LILKVFAILFTFIVFFVFFL S 20 1 2.91 
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TGME49_300290 SNARE domain-
containing protein 
ACLLFTALALLVVLIFLVVA TA 20 1 3.13 
TGME49_300240 syntaxin 6, n-terminal 
protein 
LCLILWLSCIALLLFLLLII T 20 1 3.20 
TGME49_235680  peptidase M16 
inactive domain-
containing protein 
LLLLSSLAALGALIWLSRL RQR 19 3 1.90 
TGME49_276940  ribosome associated 
membrane protein 
RAMP4, putative 
VGPLILALFLFVVVGSAILQIIF SAQRGTIL 23 8 2.57 
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Appendix E. Constructs used in chapter 4.  
A list of all the constructs and the primers used to create each construct. 
Construct Name  Primers Used  
HA-tagging: TubHA-EcorV-DHFR3'UTR-pDHFR-TS F1 & R1; F2 & R2 
 TubHA-RlmN-DHFR3'UTR-pDHFR-TS F3 & R3 
 TubHA-Cyt-b5-DHFR3'UTR-pDHFR-TS F4 & R4 
 TubHA-R-SNARE1-DHFR3'UTR-pDHFR-TS F5 & R5 
 TubHA-R-SNARE2-DHFR3'UTR-pDHFR-TS F6 & R6 
 TubHA-QaSNARE-DHFR3'UTR-pDHFR-TS F7 & R7 
 TubHA-FIS1-DHFR3'UTR-pDHFR-TS F8 & R8 
 TubHA-RBD-DHFR3'UTR-pDHFR-TS F9 & R9 
 TubHA-UBC-DHFR3'UTR-pDHFR-TS F10 & R10 
   
YFP fusion: TubYFP-EcorV-DHFR3'UTR-pDHFR-TS F1 & R1; F2 & R2-2 
 TubYFP-RlmN-DHFR3'UTR-pDHFR-TS F16 & R3 
 TubYFP-Cyt-b5-DHFR3'UTR-pDHFR-TS F14 & R4 
 TubYFP-R-SNARE1-DHFR3'UTR-pDHFR-TS F12 & R5 
 TubYFP-R-SNARE2-DHFR3'UTR-pDHFR-TS F13 & R6 
 TubYFP-QaSNARE-DHFR3'UTR-pDHFR-TS F18 & R7 
 TubYFP-FIS1-DHFR3'UTR-pDHFR-TS F15 & R8 
 TubYFP-RBD-DHFR3'UTR-pDHFR-TS F17 & R9 
 TubYFP-UBC-DHFR3'UTR-pDHFR-TS F19 & R10 
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 TubYFP-Elp3-DHFR3'UTR-pDHFR-TS F11 & R11 
   
∆CTS: TubHA-RlmN∆CTS-DHFR3'UTR-pDHFR-TS F3 & R12 
 TubHA-FIS1∆CTS-DHFR3'UTR-pDHFR-TS F8 & R13 
 TubHA-Elp3∆CTS-DHFR3'UTR-pDHFR-TS F20 & R14 
 TubHA-QaSNARE∆CTS-DHFR3'UTR-pDHFR-TS F7 & R15 
 TubHA-RBD∆CTS-DHFR3'UTR-pDHFR-TS F9 & R16 
   
Domain Swap: TubHA-RBD_RBD TMD_RRRR-DHFR3'UTR-pDHFR-TS F9 & R21 
 TubHA-RBD_Elp3 TMD_RRRR-DHFR3'UTR-pDHFR-TS F9 & R22; F23 & R11 
 TubHA-Elp3_Elp3 TMD_EA-DHFR3'UTR-pDHFR-TS F20 & R17 
 TubHA-Elp3_RBD TMD_EA-DHFR3'UTR-pDHFR-TS F20 & R18; F21 & R9 
 TubHA-Elp3_Elp3 TMD_KHT-DHFR3'UTR-pDHFR-TS F20 & R19; F22 & R11 
 TubHA-Elp3_QaSNARE TMD_KHT-DHFR3'UTR-pDHFR-TS F20 & R20; F22 & R11 
 TubHA-RBD_Elp3 TMD_EA-DHFR3'UTR-pDHFR-TS F9 & R24 
 TubHA-Elp3_RBD TMD_RRRR-DHFR3'UTR-pDHFR-TS F20 & R25 
 TubHA-Elp3_QaSNARE TMD_RRRR-DHFR3'UTR-pDHFR-TS F20 & R26 
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Appendix F. Primers used in chapter 4.  
A list of all primer names, primer numbers as referred to within the text and primer sequences used in this study. 
No.=number 
Construct Design  Primer Name Primer 
No. 
Sequence 
    
    
Tagging Constructs:    
 Step1-EcoV-3'UTR-pDHFR F1 CGGTATCGATAAGCTGATATCCTAGGGACTACAAGGACGAC 
 Step1-EcoV-3'UTR-pDHFR R1 CAGCCTGGCGAAGCTCGCGGCTTATCTAGTTAAGGGAG 
 Step2-TubHA-EcorV-pDHFR F2 CAAAAGCTGGTACCGGGAGAAAAACGCTGTTTGCAGAAAC 
 Step2-TubHA-EcorV-pDHFR R2 TCGACCTCGAGGGGGGATATCCGCGTAGTCCGGGAC 
 Step2-TubYFP-EcorV-pDHFR R2-2 TCGACCTCGAGGGGGGATATCCTTGTACAGCTCGTCCATG 
    
    
Gene Amplificaition:    
 RlmN F3 CCGGACTACGCGGATGCGCGCCGTCCG 
  R3 TGTAGTCCCTAGGATCTACACTCGAGCGCGCC 
 Cyt-b5 F4 CCGGACTACGCGGATTTTCTTCAGGAGATCTGGCCGT 
  R4 TGTAGTCCCTAGGATTCAAGAAAGATTCAGAATGTAGAAGACAGCTG 
 R-SNARE1 F5 CCGGACTACGCGGATTGGGCGGCCCGTG 
  R5 TGTAGTCCCTAGGATTTAGTTGATTCGAAGGCATGTTTGAAATGTAAG 
 R-SNARE2 F6 CCGGACTACGCGGATAAGGGGTCAACGAGCACAG 
  R6 TGTAGTCCCTAGGATCTACTTTTTCGAATTGGAAAGGAGGTTGAC 
 Qa-SNARE F7 CCGGACTACGCGGATGCGGCTACACTAGCAGCG 
  R7 TGTAGTCCCTAGGATTTAGGTGTGTTTCATGATCAGCAGAACG 
 FIS1 F8 CCGGACTACGCGGATGAAGACTCCAACTTCAGTCTCCAAG 
  R8 TGTAGTCCCTAGGATTTATTTTGATAGCGTCCACAAACGCG 
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 RBD F9 CCGGACTACGCGGATGAAGAGCTCTCTCACGCCTCT 
  R9 TGTAGTCCCTAGGATTCACGCTTCGACGAAAAAACATTT 
 UBC F10 CCGGACTACGCGGATCAGGGAGTGAGCAATCCCG 
  R10 TGTAGTCCCTAGGATTCAGAGTTTTCCTCCAGCCCC 
 Elp3 R11 TGTAGTCCCTAGGATTCACCTACGTCTTCTTACAGCCAC 
    
    
TMD Amplification:    
 Elp3-TMD F11 GAGCTGTACAAGGATGGACAATGGAAATCCCCCTCG 
 R-SNARE1-TMD F12 GAGCTGTACAAGGATCAGCACGTCTGGTGGTCG 
 R-SNARE2-TMD F13 GAGCTGTACAAGGATAACCAGTCCATGCGGTGG 
 Cyt-b5-TMD F14 GAGCTGTACAAGGATACTGCGACAAAGGGCGC 
 FIS1-TMD F15 GAGCTGTACAAGGATCTAATCATAGACCGGGCTTCCCA 
 RlmN-TMD F16 GAGCTGTACAAGGATGAAACCGATGTAGAGCTTCAGCG 
 RBD-TMD F17 GAGCTGTACAAGGATGATGAAGGCTTTTTGACGTTCATGAAGA 
 Qa-SNARE-TMD F18 GAGCTGTACAAGGATCTTCGCAAAGCTGAGGAAAATCAGAG 
 UBC-TMD F19 GAGCTGTACAAGGATCAAACCCCTTTCACGAGGGG 
    
    
∆CTS:    
 RlmN∆RRARV R12 TGTAGTCCCTAGGATCTACAAAATCCAGTGAGT 
 FIS1∆LSK R13 TGTAGTCCCTAGGATCTACGTCCACAAACGCGTGAGA 
 Elp3∆RRRR F20 CCGGACTACGCGGATGAACACACTTCCTCTCCTTCTTCTTCCT 
 Elp3∆RRRR R14 TGTAGTCCCTAGGATTCATACAGCCACGGATGCG 
 QaSNARE∆KHT R15 TGTAGTCCCTAGGATTTACATGATCAGCAGAACG 
 RBD∆EA R16 TGTAGTCCCTAGGATTCAGACGAAAAAACATTT 
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Domain Swap:    
 Elp3-EA R17 TGTAGTCCCTAGGATTCACGCTTCTACAGCCACGGATGCGAACAG 
 Elp3-RBD_TMD_frag1 R18 AGAGTCCAGTTCGCCAGCGAGGGG 
 Elp3-RBD_TMD_frag2 F21 GGCGAACTGGACTCTCGCCATCGTCT 
 Elp3-KHT R19 TGTAGTCCCTAGGATTCAGGTGTGTTTTACAGCCACGGATGCGAAC 
 Elp3-SNARE_Frag1 R20 GCGCGTCCGTTCGCCAGCGAGGGG 
 Elp3-SNARE_Frag2 F22 GGCGAACGGACGCGCTGCGC 
 RBD-RRRR R21 TGTAGTCCCTAGGATTCACCTACGTCTTCTGACGAAAAAACATTTCGC 
 RBD-Elp3_Frag1 R22 CAGAGTGGCATCTTCATGAACGTCAAAAAGCCTTCA 
 RBD-Elp3_Frag2 F23 GAAGATGCCACTCTGGCTTGGGGT 
 Elp3-RBD_TMD-RRRR R24 TGTAGTCCCTAGGATTCACCTACGTCTTCTGACGAAAAAACA 
 RBD-Elp3_TMD-EA R25 TGTAGTCCCTAGGATTCACGCTTCTTACAGCCACG 
 Elp3-SNARE TM-RRRR R26 TGTAGTCCCTAGGATTCACCTACGTCTTCTCATGATCAGC 
    
    
Sequencing Primers:    
 Sequencing 1 F24 CTTGCGGAAAACTACTCGTTGG 
 Sequencing 2 R23 GTCGTCGTCGTCCTTGTAGTC 
 Sequencing 3 F26 TTTCTGACGTTCTCGACGTG 
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Appendix G. Comparison of Toxoplasma and Arabidopsis TA proteins. 
List of 59 putative TA proteins in Arabidopsis (Arab.) with the corresponding Toxoplasma (Toxo) homologue. Homologues 
are highlighted in grey. SP: Signal Peptide, TMD: Transmembrane Domain.  
 
Arab. Description Toxo  TM prediction Toxoplasma anotation 
AT5G4
6860.1 
VAM3 (syntaxin 22); SNAP receptor  TGME49_
204060 
1 TM 100 aa 
from C term 
SNARE domain-containing protein 
AT1G7
9450.2 
LEM3 (ligand-effect modulator 3) family protein / CDC50 
family protein   
TGME49_
239540 
1 TM besides C 
term TM  
LEM3 (ligand-effect modulator 3) 
family / CDC50 family protein 
AT4G0
8590.1 
zinc finger (C3HC4-type RING finger) family protein   TGME49_
203510 
2 TMs besides C 
term TM  
zinc finger, C3HC4 type (RING finger) 
domain-containing protein 
AT4G2
4920.1 
protein transport protein SEC61 gamma subunit TGME49_
230380 
2 TMs besides C 
term TM  
protein translocation complex, SEC61 
gamma subunit 
AT3G4
8570.1 
protein transport protein SEC61 gamma subunit TGME49_
230380 
2 TMs besides C 
term TM and SP 
protein translocation complex, SEC61 
gamma subunit 
AT1G0
4760.1 
ATVAMP726 (VESICLE-ASSOCIATED MEMBRANE PROTEIN) 
member of Synaptobrevin -like protein family 
TGME49_
230430 
2 TMs besides C 
term TM and SP 
vesicle-associated membrane 
protein, putative 
AT5G5
0460.1 
protein transport protein SEC61 gamma subunit TGME49_
230380 
3 TM  
AT1G0
8560.1 
SYP111 (syntaxin 111); SNAP receptor, identical to Syntaxin-
related protein KNOLLE  
TGME49_
209820 
3 TMs besides C 
term TM and SP 
syntaxin protein 
AT3G0
3800.1 
SYP131 (syntaxin 131); SNAP receptor TGME49_
209820 
3 TMs besides C 
term TM and SP 
syntaxin protein 
AT5G0
8080.1 
SYP132 (syntaxin 132); SNAP receptor member of SYP13 Gene 
Family 
TGME49_
209820 
3 TMs besides C 
term TM and SP 
syntaxin protein 
AT1G1
1250.1 
SYP125 (syntaxin 125); SNAP receptor member of SYP12 gene 
family  
TGME49_
209820  
3 TMs besides C 
term TM and SP 
syntaxin protein 
AT1G4
3310.1 
triose phosphate/phosphate translocator-related  TGME49_
261070  
5 TM besides C 
term TM 
apicoplast triosephosphate 
translocator APT1 (APT1) 
AT2G3 PGP1/PGPS1/PGS1 (PHOSPHATIDYLGLYCEROLPHOSPHATE TGME49_ 7 TMs besides C CDP-alcohol phosphatidyltransferase 
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9290.1 SYNTHASE 1); CDP-alcohol phosphatidyltransferase 254540 term TM superfamily protein 
AT1G1
9310.1 
zinc finger (C3HC4-type RING finger) family protein   TGME49_
205600 
a possible second 
TM 
zinc finger, C3HC4 type (RING finger) 
domain-containing protein 
AT4G0
3510.1 
RMA1 (Ring finger protein with Membrane Anchor 1); protein 
binding / ubiquitin-protein ligase/ zinc ion binding  
TGME49_
205600 
a possible second 
TM 
zinc finger, C3HC4 type (RING finger) 
domain-containing protein 
AT4G2
8270.1 
zinc finger (C3HC4-type RING finger) family protein  TGME49_
205600 
a possible second 
TM 
zinc finger, C3HC4 type (RING finger) 
domain-containing protein 
AT5G5
0430.1 
UBC33 (UBIQUITIN-CONJUGATING ENZYME 33) TGME49_
251640 
a possible second 
TM 
ubiquitin-conjugating enzyme 
subfamily protein 
AT1G7
2090.1 
radical SAM domain-containing protein / TRAM domain-
containing protein   
TGME49_
273140 
SP and 1 TM in N 
term 
radical SAM methylthiotransferase, 
MiaB/RimO family protein 
AT4G1
1970.1 
YT521-B-like family protein   TGME49_
201200 
SP no TM zinc finger (CCCH type) motif-
containing protein 
AT1G5
1740.1 
SYP81 (SYNTAXIN 81); protein binding member of SYP8 Gene 
Family  
TGME49_
267530 
SP no TM hypothetical protein 
AT3G5
6300.1 
tRNA synthetase class I (C) family protein   TGME49_
299810 
SP no TM cysteine-tRNA synthetase (CysRS) 
AT3G2
2920.1 
peptidyl-prolyl cis-trans isomerase, putative / cyclophilin, 
putative / rotamase 
TGME49_
205700 
TM in center of 
protein 
cyclophilin precursor 
AT4G0
9350.1 
DNAJ heat shock N-terminal domain-containing protein  TGME49_
244350 
TM app. 80 aa 
from C term 
DnaJ domain-containing protein 
AT3G6
0540.1 
Sec61beta family protein  TGME49_
211040 
TA protein Sec61beta family protein 
AT3G2
4350.1 
SYP32 (syntaxin 32); SNAP receptor member of Glycoside 
Hydrolase Family 17 
TGME49_
226600 
TA protein syntaxin 5, putative 
AT5G0
5760.1 
SYP31 (T-SNARE SED 5); SNAP receptor A SNARE protein  TGME49_
226600 
TA protein syntaxin 5, putative 
AT5G3
9510.1 
ATVTI11/ATVTI1A/SGR4/VTI11/VTI1A/ZIG (VESICLE 
TRANSPORT V-SNARE 11); receptor  
TGME49_
242080 
TA protein hypothetical protein 
AT1G2
6670.1 
ATVTI12/VTI12/VTI1B (VESICAL TRANSPORT V-SNARE 12) TGME49_
242080  
TA protein   
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AT5G1
6830.1 
SYP21 (syntaxin 21); SNAP receptor  TGME49_
247930 
TA protein SNARE domain-containing protein 
AT3G0
5710.1 
SYP43 (syntaxin 43); SNAP receptor  TGME49_
247930 
TA protein SNARE domain-containing protein 
AT4G0
2195.1 
SYP42 (SYNTAXIN OF PLANTS 41); SNAP receptor TGME49_
247930 
TA protein SNARE domain-containing protein 
AT5G2
6980.1 
SYP41 (SYNTAXIN OF PLANTS 41); SNAP receptor  TGME49_
247930 
TA protein SNARE domain-containing protein 
AT1G1
1890.1 
SEC22 (secretion 22); transporter member of SEC22 Gene 
Family  
TGME49_
270070  
TA protein synaptobrevin family protein 
AT1G2
6340.1 
B5 #6 (cytochrome b5 family protein #6); heme / transition 
metal ion binding  
TGME49_
276110 
TA protein cytochrome b5 family heme/steroid 
binding domain-containing protein 
AT2G3
2720.1 
B5 #4 (cytochrome b5 family); heme binding / transition 
metal ion binding  
TGME49_
276110 
TA protein cytochrome b5 family heme/steroid 
binding domain-containing protein 
AT5G4
8810.1 
  TGME49_
276110 
TA protein cytochrome b5 family heme/steroid 
binding domain-containing protein 
AT5G5
3560.1 
ATB5-A (Cytochrome b5 A) TGME49_
276110 
TA protein cytochrome b5 family heme/steroid 
binding domain-containing protein 
AT3G1
7000.1 
UBC32 (UBIQUITIN-CONJUGATING ENZYME 32); ubiquitin-
protein ligase   
TGME49_
278670 
TA protein ubiquitin-conjugating enzyme 
subfamily protein 
AT1G2
8490.1 
SYP61 (SYNTAXIN OF PLANTS 61)  TGME49_
300240 
TA protein phosphotransferase enzyme family 
protein 
AT1G0
8820.1 
VAP27-2 (VAMP/SYNAPTOBREVIN-ASSOCIATED PROTEIN 27-
2) 
TGME49_
318160 
TA protein MSP (Major sperm protein) domain-
containing protein 
AT5G4
7180.1 
vesicle-associated membrane family protein / VAMP family 
protein   
TGME49_
318160 
TA protein MSP (Major sperm protein) domain-
containing protein 
AT2G4
5140.1 
vesicle-associated membrane protein, putative / VAMP TGME49_
318160 
TA protein MSP (Major sperm protein) domain-
containing protein 
AT3G6
0600.1 
VAP27-1 (VAMP/SYNAPTOBREVIN-ASSOCIATED PROTEIN 27-
1); 
TGME49_
318160 
TA protein MSP (Major sperm protein) domain-
containing protein 
AT4G0 vesicle-associated membrane family protein / VAMP family TGME49_ TA protein MSP (Major sperm protein) domain-
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0170.1 protein  318160 containing protein 
AT5G5
6730.1 
peptidase M16 family protein / insulinase family protein  TGME49_
235680  
TA protein 
missed 
peptidase M16 inactive domain-
containing protein 
AT1G2
7330.1 
similar to unknown protein (TAIR:AT1G27350.1), domain 
Ribosome associated membrane RAMP4 
TGME49_
276940  
TA protein 
missed 
ribosome associated membrane 
protein RAMP4, putative 
AT3G4
7550.2 
zinc finger (C3HC4-type RING finger) family protein   TGME49_
202840 
No TM FHA domain-containing protein 
AT5G4
2320.1 
carboxypeptidase A   TGME49_
202910 
No TM zinc carboxypeptidase superfamily 
protein 
AT2G2
5470.1 
leucine-rich repeat family protein  similar to leucine-rich 
repeat family protein  
TGME49_
203180 
No TM leucine rich repeat-containing 
protein 
AT3G5
8840.1 
similar to myosin heavy chain-related [Arabidopsis thaliana] 
(TAIR:AT1G06530.1) 
TGME49_
207370 
No TM hypothetical protein 
AT1G1
7280.1 
UBC34 (UBIQUITIN-CONJUGATING ENZYME 34); ubiquitin-
protein ligase   
TGME49_
208570 
No TM ubiquitin conjugating enzyme E2, 
putative 
AT3G6
2190.1 
DNAJ heat shock N-terminal domain-containing protein   TGME49_
214530 
No TM DnaJ domain-containing protein 
AT3G4
5540.1 
zinc finger (C3HC4-type RING finger) family protein   TGME49_
226050 
No TM hypothetical protein 
AT1G3
0230.2 
elongation factor 1-beta / EF-1-beta  TGME49_
226410 
No TM EF-1 guanine nucleotide exchange 
domain-containing protein 
AT5G1
9660.1 
ATS1P/ATSBT6.1/S1P (SITE-1 PROTEASE); endopeptidase/ 
subtilase  
TGME49_
231060 
No TM subtilisin SUB9 (SUB9) 
AT4G3
6690.2 
ATU2AF65A; RNA binding   TGME49_
234520 
No TM U2 snRNP auxilliary factor, large 
subunit, splicing factor subfamily 
protein 
AT2G2
6130.1 
zinc finger (C3HC4-type RING finger) family protein   TGME49_
235980 
No TM ARIADNE family protein 
AT1G0
1450.1 
protein kinase-related  similar to protein kinase family protein TGME49_
237210 
No TM Tyrosine kinase-like (TKL) protein 
AT5G6 ATATH13 (ABC2 homolog 13)  TGME49_ No TM ABC1 family protein 
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4940.1 246600 
AT3G6
3410.1 
VTE3, APG1 | APG1 (ALBINO OR PALE GREEN MUTANT 1); 
methyltransferase  
TGME49_
247920 
No TM methyltransferase domain-
containing protein 
AT5G1
5200.2 
40S ribosomal protein S9 TGME49_
248480 
No TM ribosomal protein RPS9 (RPS9) 
AT3G4
6450.1 
SEC14 cytosolic factor family protein / phosphoglyceride 
transfer family protein  
TGME49_
254390  
No TM CRAL/TRIO domain-containing 
protein 
AT4G3
1980.1 
similar to unknown protein (TAIR:AT5G11290.1) DUF862 and 
DUF247 domains 
TGME49_
256780 
No TM hypothetical protein 
AT5G2
6030.1 
FC1 (FERROCHELATASE 1); ferrochelatase TGME49_
258650 
No TM protoheme ferro-lyase, putative 
AT3G1
3445.2 
TBP1 (TRANSCRIPTION FACTOR IID-1); DNA binding / RNA 
polymerase II transcription factor  
TGME49_
258680 
No TM TATA-box binding protein TBP2 
(TBP2) 
AT3G5
3240.1 
leucine-rich repeat family protein  TGME49_
260480 
No TM leucine rich repeat-containing 
protein 
AT1G7
2416.3 
heat shock protein binding TGME49_
265310 
No TM heat shock protein 40, putative 
AT1G6
5060.2 
4CL3 (4-coumarate:CoA ligase 3) TGME49_
266640 
No TM Acetyl-coenzyme A synthetase 2, 
putative 
AT3G2
1640.1 
TWD1 (TWISTED DWARF 1); FK506 binding / peptidyl-prolyl 
cis-trans isomerase  
TGME49_
283850 
No TM peptidyl-prolyl cis-trans isomerase 
AT3G5
4010.1 
PAS1 (PASTICCINO 1); FK506 binding / peptidyl-prolyl cis-trans 
isomerase   
TGME49_
283850 
No TM peptidyl-prolyl cis-trans isomerase 
AT5G0
1980.1 
zinc finger (C3HC4-type RING finger) family protein  TGME49_
285190 
No TM zinc finger, C3HC4 type (RING finger) 
domain-containing protein 
AT5G2
7540.1 
EMB2473 (EMBRYO DEFECTIVE 2473); GTP binding   TGME49_
289680 
No TM Ras-related protein Rab11 
AT4G0
9760.3 
choline kinase TGME49_
306540 
No TM phosphotransferase enzyme family 
protein 
AT1G7
8260.2 
RNA recognition motif (RRM)-containing protein   TGME49_
310050 
No TM RNA recognition motif-containing 
protein 
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AT3G1
3224.1 
RNA recognition motif (RRM)-containing protein  TGME49_
310050 
No TM RNA recognition motif-containing 
protein 
AT4G0
8140.1 
similar to AtRPN1a/RPN1A (26S proteasome regulatory 
subunit S2 1A) 
TGME49_
313410 
No TM proteasome 26S regulatory subunit 
AT5G2
1990.1 
tetratricopeptide repeat (TPR)-containing protein   TGME49_
314100 
No TM tetratricopeptide repeat-containing 
protein 
AT2G4
1910.1 
protein kinase family protein   TGME49_
316150 
No TM ULK kinase 
AT3G4
9430.2 
SRP34A (SER/ARG-RICH PROTEIN 34A)  TGME49_
319530 
No TM splicing factor SF2 (SF2) 
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program 
Indiana University School of Medicine, Indianapolis 
 
  
 
2012-2017  Volunteer for Graduate Student Recruitment Campus Visits 
Indiana University School of Medicine Biomedical Gateway 
program 
Indiana University School of Medicine, Indianapolis 
 
2015   Elite 50 Application Review Committee 
Graduate and Professional Student Government 
   Indiana University-Purdue University Indianapolis (IUPUI) 
 
2014-2015 Admissions Committee Student Representative  
Indiana University School of Medicine Biomedical Gateway 
program 
Indiana University School of Medicine, Indianapolis 
 
2014-2015  Indiana University School of Medicine Representative 
Graduate and Professional Student Government 
   Indiana University-Purdue University Indianapolis (IUPUI) 
   
2014-2015  Graduate Student President 
Department of Pharmacology and Toxicology  
Indiana University School of Medicine, Indianapolis 
 
2014-2015  Education Grant Review Committee 
Graduate and Professional Student Government 
   Indiana University-Purdue University Indianapolis (IUPUI) 
 
November 2014 Volunteer at the Susan G. Komen Tissue Bank  
Indiana University Simon Cancer Center 
 
August 2014 Participant in the Panel for Women in Science (WIS) - 
Indiana BioMedical Gateway (IBMG) Program Summer 
Research Internship program 
